/**
 * Mechanistic Network Edges
 *
 * Causal relationships with evidence, organized by module.
 * Each edge includes citations, mechanism description, and causal confidence.
 */

import type { MechanisticEdge, RelationType, EdgeType } from './types';

// ============================================================================
// MODULE 1: Insulin/mTOR/Autophagy Axis
// ============================================================================

export const module1Edges: MechanisticEdge[] = [
  {
    id: 'E01.001',
    source: 'insulin_resistance',
    target: 'mtorc1_hyperactive',
    relation: 'increases',
    moduleId: 'M01',
    edgeType: 'INFLUENCE', // SBSF v2.0: Indirect downstream effect
    mechanismLabel: 'insulin_mTORC1_activation',
    mechanismDescription: 'Chronic hyperinsulinemia → sustained PI3K-AKT → TSC1/2 phosphorylation (inhibited) → Rheb-GTP accumulates → mTORC1 disinhibited on lysosomal membrane',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '15750215',
        doi: '10.3233/jad-2005-7107',
        firstAuthor: 'Steen',
        year: 2005,
        title: 'Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\'s disease--is this type 3 diabetes?',
        quote: 'Reduced levels of insulin receptor substrate (IRS) mRNA...increased glycogen synthase kinase-3beta activity',
        methodType: 'cohort',
        methodDetails: 'Human postmortem brain tissue',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
          notes: 'Postmortem AD brain tissue'
        },
      },
    ],
    translationalGap: 'Human postmortem = correlational. No human RCT. Animal interventions support directionality',
  },
  {
    id: 'E01.002',
    source: 'mtorc1_hyperactive',
    target: 'tfeb_phosphorylated',
    relation: 'directlyIncreases',
    moduleId: 'M01',
    edgeType: 'MODULATION', // SBSF v2.0: Rate control (kinase → substrate)
    mechanismLabel: 'mTORC1_TFEB_phosphorylation',
    mechanismDescription: 'mTORC1 directly phosphorylates TFEB at Ser211 and Ser142. pSer211 creates 14-3-3 binding site → cytoplasmic retention. Rapamycin/rapalogs inhibit mTORC1 allosterically via FKBP12.',
    timescale: 'minutes',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '22343943',
        doi: '10.1038/emboj.2012.32',
        firstAuthor: 'Settembre',
        year: 2012,
        title: 'A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB',
        quote: 'Phosphorylation of TFEB by mTORC1 inhibits TFEB activity. Conversely, pharmacological inhibition of mTORC1...activates TFEB by promoting its nuclear translocation',
        methodType: 'in_vitro',
        methodDetails: 'Kinase assay, HEK293/HeLa cell lines, rapamycin intervention',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
          strain: 'HEK293, HeLa'
        },
      },
    ],
    // Rapamycin kinetics: PMID:31324781, PMID:19461842
    quantitative: {
      ic50: 0.1,            // nM - Rapamycin IC50 for mTORC1 (HEK293 cells)
      // Note: IC50 varies 0.1-100 nM depending on cell line and readout
      // Rapamycin is allosteric; mTOR kinase inhibitors (Torin1) IC50 = 2-10 nM
      // TFEB nuclear translocation occurs within 30 min of mTORC1 inhibition
    },
    keyInsight: 'Direct biochemical + intervention reversal establishes causality. Rapamycin IC50 ≈ 0.1 nM.',
  },
  {
    id: 'E01.003',
    source: 'tfeb_phosphorylated',
    target: 'lysosomal_genes_down',
    relation: 'increases',
    moduleId: 'M01',
    edgeType: 'TRANSITION', // SBSF v2.0: State change (TFEB state → gene expression state)
    mechanismLabel: 'TFEB_cytoplasmic_sequestration',
    mechanismDescription: 'pSer211-TFEB binds 14-3-3 → cytoplasmic retention → cannot enter nucleus → CLEAR network genes not transcribed',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '22343943',
        doi: '10.1038/emboj.2012.32',
        firstAuthor: 'Settembre',
        year: 2012,
        title: 'A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB',
        quote: 'The transcriptional response of lysosomal and autophagic genes to either lysosomal dysfunction or pharmacological inhibition of mTORC1 is suppressed in TFEB-/- cells',
        methodType: 'knockout',
        methodDetails: 'TFEB-/- MEFs',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          strain: 'TFEB-/- MEFs'
        },
      },
    ],
  },
  {
    id: 'E01.004',
    source: 'lysosomal_genes_down',
    target: 'lysosome_pool',
    relation: 'decreases',
    moduleId: 'M01',
    edgeType: 'MODULATION', // Gene expression state modulates lysosome biogenesis rate
    mechanismLabel: 'reduced_lysosome_biogenesis',
    mechanismDescription: '↓v-ATPase subunits, ↓LAMP proteins, ↓cathepsins → reduced lysosome biogenesis and functional capacity',
    causalConfidence: 'L4',
    crossModule: 'M01 → M02',
    evidence: [
      {
        pmid: '35654956',
        doi: '10.1038/s41593-022-01084-8',
        firstAuthor: 'Lee',
        year: 2022,
        title: 'Faulty autolysosome acidification in Alzheimer\'s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques',
        quote: 'Autolysosome acidification declines in neurons well before extracellular amyloid deposition, associated with markedly lowered vATPase activity',
        methodType: 'intervention_animal',
        methodDetails: 'Multiple AD mouse models (5xFAD, PS1/APP, 3xTg-AD, PS19, APPNL-G-F) with pH probes',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: '5xFAD, PS1/APP, 3xTg-AD, PS19, APPNL-G-F'
        },
      },
    ],
    keyInsight: 'Lysosome pool depleted when TFEB-driven biogenesis is suppressed',
  },
  {
    id: 'E01.004b',
    source: 'lysosome_pool',
    target: 'lysosomal_dysfunction',
    relation: 'decreases', // Lower lysosome pool = more dysfunction (inverse relationship)
    moduleId: 'M02',
    edgeType: 'INFLUENCE', // Stock level influences dysfunction state (inverse: low stock → high dysfunction)
    mechanismLabel: 'lysosome_depletion_dysfunction',
    mechanismDescription: 'Depleted lysosome pool → insufficient degradation capacity → pH rises >5.5, ↓cathepsin activity, cargo accumulation. NOTE: This is an inverse relationship - low lysosome stock increases dysfunction',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '35654956',
        doi: '10.1038/s41593-022-01084-8',
        firstAuthor: 'Lee',
        year: 2022,
        title: 'Faulty autolysosome acidification in Alzheimer\'s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques',
        quote: 'Autolysosome acidification declines in neurons well before extracellular amyloid deposition, associated with markedly lowered vATPase activity',
        methodType: 'intervention_animal',
        methodDetails: 'Multiple AD mouse models (5xFAD, PS1/APP, 3xTg-AD, PS19, APPNL-G-F) with pH probes',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: '5xFAD, PS1/APP, 3xTg-AD, PS19, APPNL-G-F'
        },
      },
    ],
    keyInsight: 'PANTHOS pattern - autolysosomes fail to acidify, becoming Aβ storage depots',
  },
  {
    id: 'E01.005',
    source: 'mtorc1_hyperactive',
    target: 'ulk1_phosphorylated',
    relation: 'directlyIncreases',
    moduleId: 'M01',
    mechanismLabel: 'mTORC1_ULK1_phosphorylation',
    mechanismDescription: 'mTORC1 phosphorylates ULK1 at Ser757, which blocks the AMPK binding site on ULK1',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '21258367',
        doi: '10.1038/ncb2152',
        firstAuthor: 'Kim',
        year: 2011,
        title: 'AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1',
        quote: 'High mTOR activity prevents Ulk1 activation by phosphorylating Ulk1 Ser 757 and disrupting the interaction between Ulk1 and AMPK',
        methodType: 'in_vitro',
        methodDetails: 'Kinase assay, phospho-specific antibody, rapamycin intervention',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
          strain: 'HEK293'
        },
      },
    ],
  },
  {
    id: 'E01.006',
    source: 'ulk1_phosphorylated',
    target: 'mitophagy_rate_reduced',
    relation: 'increases',
    moduleId: 'M01',
    mechanismLabel: 'ULK1_autophagy_block',
    mechanismDescription: 'ULK1 pSer757 blocks AMPK binding → AMPK cannot phosphorylate/activate ULK1 at Ser317/Ser777 → autophagy/mitophagy initiation blocked',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '21258367',
        doi: '10.1038/ncb2152',
        firstAuthor: 'Kim',
        year: 2011,
        title: 'AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1',
        quote: 'AMPK promotes autophagy by directly activating Ulk1 through phosphorylation of Ser 317 and Ser 777...mTOR...phosphorylating Ulk1 Ser 757 and disrupting the interaction between Ulk1 and AMPK',
        methodType: 'intervention_animal',
        methodDetails: 'Rapamycin intervention + mutant analysis',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E01.007',
    source: 'mitophagy_rate_reduced',
    target: 'damaged_mito_pool',
    relation: 'increases',
    moduleId: 'M01',
    mechanismLabel: 'mass_balance_accumulation',
    mechanismDescription: 'Damage rate exceeds clearance rate → damaged mitochondria accumulate. Stock-flow relationship',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '30742114',
        doi: '10.1038/s41593-018-0332-9',
        firstAuthor: 'Fang',
        year: 2019,
        title: 'Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer\'s disease',
        methodType: 'intervention_animal',
        methodDetails: 'Mitophagy reporters in AD models',
        causalConfidence: 'L4',
      },
      {
        pmid: '38280852',
        doi: '10.1038/s41467-024-45044-1',
        firstAuthor: 'Jimenez-Loygorri',
        year: 2024,
        title: 'Mitophagy curtails cytosolic mtDNA-induced STING signaling',
        methodType: 'intervention_animal',
        methodDetails: 'Urolithin A mitophagy induction',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Mass balance logic: when clearance < damage rate, stock accumulates',
  },
  // S6K1-IRS1 feedback loop edges
  {
    id: 'E01.008',
    source: 'mtorc1_hyperactive',
    target: 's6k1_active',
    relation: 'directlyIncreases',
    moduleId: 'M01',
    mechanismLabel: 'mTORC1_S6K1_phosphorylation',
    mechanismDescription: 'mTORC1 phosphorylates S6K1 at Thr389 (hydrophobic motif), enabling full activation',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '19461840',
        doi: '10.1242/jcs.051011',
        firstAuthor: 'Laplante',
        year: 2009,
        title: 'mTOR signaling at a glance',
        quote: 'mTORC1 promotes protein synthesis by phosphorylating...the p70 ribosomal S6 kinase 1 (S6K1)',
        methodType: 'meta_analysis',
        methodDetails: 'Canonical mTOR signaling review',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'S6K1-pThr389 is standard readout for mTORC1 activity',
  },
  {
    id: 'E01.009',
    source: 's6k1_active',
    target: 'irs1_serine_phosphorylated',
    relation: 'directlyIncreases',
    moduleId: 'M01',
    mechanismLabel: 'S6K1_IRS1_phosphorylation',
    mechanismDescription: 'S6K1 phosphorylates IRS-1 at multiple serine residues: S307, S312, S527, S616, S636/639. Creates 14-3-3 binding sites, promotes degradation',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '16914728',
        doi: '10.1128/MCB.01254-05',
        firstAuthor: 'Shah',
        year: 2006,
        title: 'Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis',
        quote: 'S6K1 phosphorylates IRS1 in vitro on multiple residues...loss- and gain-of-function S6K1 constructs...demonstrate a requirement for the catalytic activity of S6K1',
        methodType: 'in_vitro',
        methodDetails: 'Kinase assay + S6K1 gain/loss-of-function',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
          strain: 'HEK293, TSC1/2-/- MEFs'
        },
      },
    ],
    translationalGap: 'Caveat: Rajan 2013 found S6K1 inhibitor doesn\'t block pS307 in human adipocytes - may be tissue-specific',
  },
  {
    id: 'E01.010',
    source: 'irs1_serine_phosphorylated',
    target: 'insulin_resistance',
    relation: 'increases',
    moduleId: 'M01',
    mechanismLabel: 'IRS1_insulin_signaling_block',
    mechanismDescription: 'IRS-1 serine phosphorylation: (1) reduces tyrosine phosphorylation by insulin receptor, (2) promotes IRS-1 degradation, (3) creates 14-3-3 binding → sequestration',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '28550243',
        doi: '10.3233/JAD-160344',
        firstAuthor: 'Nakamura',
        year: 2017,
        title: 'Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer\'s Disease',
        quote: 'Protein levels of pS616 and pS636/639 IRS-1 significantly decreased following APO treatment...suggesting improved brain insulin resistance',
        methodType: 'intervention_animal',
        methodDetails: 'Apomorphine treatment in 3xTg-AD mice',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: '3xTg-AD'
        },
      },
      {
        pmid: '30463045',
        doi: '10.1016/j.biopha.2018.11.043',
        firstAuthor: 'Rahman',
        year: 2018,
        title: 'Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Aβ peptides in animal model of Alzheimer\'s disease',
        quote: 'Aβ(1-42) ICV injection → elevated IRS-S307 in hippocampus; astaxanthin reverses',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10116',
          commonName: 'rat',
          strain: 'Wistar'
        },
      },
    ],
    keyInsight: 'This edge closes the feedback loop: mTORC1→S6K1→IRS1→insulin_resistance→mTORC1',
  },
  // Additional M01 edges for connecting unconnected nodes
  {
    id: 'E01.020',
    source: 'mtorc1_hyperactive',
    target: 'ampk_phosphorylated',
    relation: 'increases',
    moduleId: 'M01',
    mechanismLabel: 'mTORC1_AMPK_inhibition',
    mechanismDescription: 'mTORC1 via S6K1 phosphorylates AMPK at Ser345, preventing its lysosomal recruitment and full activation',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Dite',
        year: 2017,
        pmid: '28446607',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E01.021',
    source: 'ampk_phosphorylated',
    target: 'ulk1_phosphorylated',
    relation: 'increases',
    moduleId: 'M01',
    mechanismLabel: 'AMPK_autophagy_block',
    mechanismDescription: 'Phospho-inhibited AMPK cannot activate ULK1; ULK1 remains phosphorylated/inhibited by mTORC1',
    causalConfidence: 'L4',
    crossModule: 'M01 → M02',
    evidence: [
      {
        firstAuthor: 'Kim',
        year: 2011,
        pmid: '21205641',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'AMPK-ULK1 axis is critical for autophagy initiation',
  },
  // SIRT1 edges
  {
    id: 'E01.022',
    source: 'sirt1_activity',
    target: 'mtorc1_hyperactive',
    relation: 'decreases',
    moduleId: 'M01',
    mechanismLabel: 'SIRT1_mTORC1_inhibition',
    mechanismDescription: 'SIRT1 activates LKB1 via deacetylation, which activates AMPK at Thr172, leading to TSC2 activation and mTORC1 inhibition',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lan',
        year: 2008,
        pmid: '18687888',
        title: 'SIRT1 Modulation of the Acetylation Status, Cytosolic Localization, and Activity of LKB1',
        quote: 'SIRT1 deacetylates LKB1, promoting its cytoplasmic localization and kinase activity',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'SIRT1 → LKB1 → AMPK → TSC2 → mTORC1 inhibition pathway',
  },
  {
    id: 'E01.023',
    source: 'sirt1_activity',
    target: 'ulk1_phosphorylated',
    relation: 'decreases',
    moduleId: 'M01',
    mechanismLabel: 'SIRT1_autophagy_promotion',
    mechanismDescription: 'SIRT1 promotes autophagy by deacetylating autophagy proteins and activating AMPK-ULK1 axis',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lee',
        year: 2008,
        pmid: '18187620',
        title: 'A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy',
        quote: 'Sirt1 can directly deacetylate essential autophagy proteins, Atg5, Atg7, and LC3',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'SIRT1 promotes autophagy via multiple mechanisms',
  },
];

// ============================================================================
// MODULE 2: Lysosomal Pathology
// ============================================================================

export const module2Edges: MechanisticEdge[] = [
  // Route 1A: LMP Pathway
  {
    id: 'E02.001',
    source: 'lysosomal_dysfunction',
    target: 'cargo_accumulation',
    relation: 'increases',
    moduleId: 'M02',
    mechanismLabel: 'degradation_failure_accumulation',
    mechanismDescription: 'Reduced degradation capacity (↓cathepsins, ↓v-ATPase, high pH) → cargo builds up. Stock-flow: inflow unchanged, outflow reduced',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '35654956',
        doi: '10.1038/s41593-022-01084-8',
        firstAuthor: 'Lee',
        year: 2022,
        title: 'Faulty autolysosome acidification in Alzheimer\'s disease mouse models...',
        quote: 'Build-up of Aβ/APP-βCTF selectively within enlarged de-acidified autolysosomes',
        methodType: 'intervention_animal',
        methodDetails: 'AD mouse models with autophagy reporters',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: '5xFAD, PS1/APP, 3xTg-AD, PS19, APPNL-G-F'
        },
      },
    ],
  },
  {
    id: 'E02.002',
    source: 'cargo_accumulation',
    target: 'lipofuscin',
    relation: 'increases',
    moduleId: 'M02',
    mechanismLabel: 'oxidative_crosslinking',
    mechanismDescription: 'Incomplete degradation of proteins/lipids → oxidation → cross-linking → lipofuscin granules (irreversible)',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '34782457',
        doi: '10.1073/pnas.2100122118',
        firstAuthor: 'Pan',
        year: 2021,
        title: 'Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization',
        quote: 'Lipofuscin granules enclose mixtures of cross-linked proteins and lipids',
        methodType: 'intervention_animal',
        methodDetails: 'Aged mice, RPE cells',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          strain: 'Abca4-/- mice'
        },
      },
    ],
    keyInsight: 'Lipofuscin formation is IRREVERSIBLE - no known degradation pathway',
  },
  {
    id: 'E02.003',
    source: 'lipofuscin',
    target: 'lmp',
    relation: 'directlyIncreases',
    moduleId: 'M02',
    mechanismLabel: 'lipofuscin_membrane_damage',
    mechanismDescription: 'Lipofuscin directly destabilizes lysosomal membrane through physical/oxidative damage → permeabilization',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '34782457',
        doi: '10.1073/pnas.2100122118',
        firstAuthor: 'Pan',
        year: 2021,
        title: 'Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization',
        quote: 'Tendency to cause lysosome swelling that results in rupture...ability to trigger NLRP3 inflammation, a symptom of low-level disruption of lysosomes',
        methodType: 'intervention_animal',
        methodDetails: 'In vitro RPE cells + aged mice',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          strain: 'Abca4-/- mice'
        },
      },
    ],
    keyInsight: 'Also triggers atypical necroptosis (RIPK1/RIPK3/MLKL independent)',
  },
  {
    id: 'E02.004',
    source: 'lmp',
    target: 'cathepsin_b_cytosolic',
    relation: 'directlyIncreases',
    moduleId: 'M02',
    mechanismLabel: 'compartment_breach',
    mechanismDescription: 'Lysosomal membrane permeabilization → cathepsins (including active cathepsin B) leak into cytosol',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '23720375',
        doi: '10.1242/jcs.091181',
        firstAuthor: 'Aits',
        year: 2013,
        title: 'Lysosomal cell death at a glance',
        quote: 'Lysosomal membrane permeabilization and the consequent leakage of the lysosomal content into the cytosol leads to "lysosomal cell death"',
        methodType: 'in_vitro',
        methodDetails: 'Multiple cell types',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E02.005',
    source: 'cathepsin_b_cytosolic',
    target: 'nlrp3_active',
    relation: 'directlyIncreases',
    moduleId: 'M02',
    mechanismLabel: 'cathepsin_NLRP3_activation',
    mechanismDescription: 'Cytosolic cathepsin B promotes NLRP3-ASC complex assembly',
    causalConfidence: 'L5',
    crossModule: 'Output to Module 4 (Inflammasome)',
    evidence: [
      {
        pmid: '18604214',
        doi: '10.1038/ni.1631',
        firstAuthor: 'Hornung',
        year: 2008,
        title: 'Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization',
        quote: 'Inhibition of...cathepsin B activity impaired NALP3 activation',
        methodType: 'knockout',
        methodDetails: 'Cathepsin B-/- mice; CA-074-Me inhibitor',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          strain: 'Ctsb-/-'
        },
      },
    ],
    keyInsight: 'Establishes LMP → cathepsin B → NLRP3 as general danger-sensing mechanism',
  },

  // Route 1B: Incomplete Mitophagy Pathway
  {
    id: 'E02.006',
    source: 'damaged_mito_pool',
    target: 'mitophagosome',
    relation: 'increases',
    moduleId: 'M02',
    mechanismLabel: 'PINK1_Parkin_mitophagy_initiation',
    mechanismDescription: 'PINK1 stabilizes on depolarized mitochondria → Parkin recruited → ubiquitin chains → autophagy receptors → autophagosome formation',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '18227278',
        firstAuthor: 'Narendra',
        year: 2008,
        title: 'Parkin is recruited selectively to impaired mitochondria and promotes their autophagy',
        methodType: 'knockout',
        methodDetails: 'PINK1-/-, Parkin-/- studies',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'This step works normally in AD; the problem is downstream degradation',
  },
  {
    id: 'E02.007',
    source: 'mitophagosome',
    target: 'autolysosome',
    relation: 'increases',
    moduleId: 'M02',
    mechanismLabel: 'autophagosome_lysosome_fusion',
    mechanismDescription: 'Autophagosome fuses with lysosome via SNARE proteins (STX17, SNAP29, VAMP8)',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '31682838',
        doi: '10.1016/j.jmb.2019.10.024',
        firstAuthor: 'Zhao',
        year: 2020,
        title: 'Autophagosome-Lysosome Fusion',
        quote: 'autophagosome-lysosome fusion to generate autolysosomes that degrade the cargo',
        methodType: 'meta_analysis',
        methodDetails: 'Comprehensive review of SNARE-mediated fusion mechanisms',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E02.008',
    source: 'lysosomal_dysfunction',
    target: 'mtdna_undegraded',
    relation: 'increases',
    moduleId: 'M02',
    mechanismLabel: 'DNase_II_pH_failure',
    mechanismDescription: 'DNase II requires pH <5 for activity. Lysosomal pH >5.5 → DNase II inactive → mtDNA persists undegraded in autolysosome',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '22535248',
        doi: '10.1038/nature10992',
        firstAuthor: 'Oka',
        year: 2012,
        title: 'Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure',
        quote: 'Cardiac-specific deletion of lysosomal deoxyribonuclease (DNase) II...caused severe myocarditis and dilated cardiomyopathy...with accumulation of mitochondrial DNA deposits in autolysosomes',
        methodType: 'knockout',
        methodDetails: 'Dnase2a cardiac-specific KO',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          strain: 'Dnase2a cardiac-specific KO'
        },
      },
    ],
    keyInsight: 'LANDMARK PAPER - established mtDNA escape as inflammatory trigger',
  },
  {
    id: 'E02.009',
    source: 'mtdna_undegraded',
    target: 'mtdna_from_lysosome',
    relation: 'increases',
    moduleId: 'M02',
    mechanismLabel: 'mtDNA_lysosomal_escape',
    mechanismDescription: 'Undegraded mtDNA exits through compromised autolysosomal membrane (LMP affects autolysosomes too)',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22535248',
        doi: '10.1038/nature10992',
        firstAuthor: 'Oka',
        year: 2012,
        title: 'Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E02.010',
    source: 'mtdna_from_lysosome',
    target: 'cgas_active',
    relation: 'directlyIncreases',
    moduleId: 'M02',
    mechanismLabel: 'mtDNA_cGAS_sensing',
    mechanismDescription: 'Cytosolic mtDNA (CpG-rich, bacterial-like) sensed by cGAS → 2\'3\'-cGAMP → STING → TBK1 → IRF3 → Type I IFN',
    causalConfidence: 'L3',
    crossModule: 'Output to Module 4 (Inflammasome)',
    evidence: [
      {
        pmid: '37532932',
        doi: '10.1038/s41586-023-06373-1',
        firstAuthor: 'Gulen',
        year: 2023,
        title: 'cGAS-STING drives ageing-related inflammation and neurodegeneration',
        quote: 'Cytosolic DNA released from perturbed mitochondria elicits cGAS activity in old microglia',
        methodType: 'knockout',
        methodDetails: 'STING knockout + cGAS gain-of-function knockin',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
        },
      },
    ],
    keyInsight: 'Brain-specific: STING activation triggers reactive microglial transcriptional states',
  },
];

// ============================================================================
// MODULE 3: Mitochondrial Dysfunction (Route 2)
// ============================================================================

export const module3Edges: MechanisticEdge[] = [
  {
    id: 'E03.001',
    source: 'damaged_mito_pool',
    target: 'mito_ros',
    relation: 'increases',
    moduleId: 'M03',
    mechanismLabel: 'ETC_dysfunction_ROS',
    mechanismDescription: 'Damaged mitochondria have dysfunctional ETC → electron leak at Complex I/III → superoxide production',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '30742114',
        doi: '10.1038/s41593-018-0332-9',
        firstAuthor: 'Fang',
        year: 2019,
        title: 'Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer\'s disease',
        quote: 'Mitochondrial dysfunction and accumulation of damaged mitochondria are common features of aging and age-related neurodegeneration',
        methodType: 'intervention_animal',
        methodDetails: 'AD mouse models with NAD+ precursor intervention',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: 'APP/PS1, 3xTgAD'
        },
      },
    ],
  },
  {
    id: 'E03.002',
    source: 'mito_ros',
    target: 'mtdna_oxidized',
    relation: 'directlyIncreases',
    moduleId: 'M03',
    mechanismLabel: 'ROS_DNA_oxidation',
    mechanismDescription: 'ROS oxidizes guanine bases in mtDNA → 8-oxo-deoxyguanosine. mtDNA vulnerable due to proximity to ETC and lack of histones',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling',
        quote: 'ROS...induce Ox-mtDNA generation',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E03.003',
    source: 'mito_ros',
    target: 'ca_overload',
    relation: 'increases',
    moduleId: 'M03',
    mechanismLabel: 'ROS_calcium_dysregulation',
    mechanismDescription: 'ROS damages Ca²⁺ handling proteins (MCU, NCLX) → impaired Ca²⁺ efflux + sustained MCU-mediated uptake → matrix Ca²⁺ accumulation',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels...',
        quote: 'ROS impairs Ca²⁺ handling, MCU-mediated uptake',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E03.004',
    source: 'ca_overload',
    target: 'mptp_open',
    relation: 'directlyIncreases',
    moduleId: 'M03',
    mechanismLabel: 'calcium_mPTP_trigger',
    mechanismDescription: 'Ca²⁺ binds to mPTP regulatory site (likely CypD) → conformational change → pore opening in inner mitochondrial membrane',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels...',
        quote: 'Diverse NLRP3 inflammasome activators rapidly stimulated uniporter-mediated calcium uptake to open mitochondrial permeability transition pores (mPTP)',
        methodType: 'in_vitro',
        methodDetails: 'Isolated mitochondria + interventions',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'Ca²⁺ is the canonical trigger for mPTP; CsA (CypD inhibitor) blocks it',
  },
  {
    id: 'E03.005',
    source: 'mptp_open',
    target: 'vdac_oligomer',
    relation: 'increases',
    moduleId: 'M03',
    mechanismLabel: 'mPTP_VDAC_coordination',
    mechanismDescription: 'mPTP opening causes inner membrane stress + mtDNA interaction with VDAC → triggers VDAC oligomerization in outer membrane',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels...',
        quote: 'trigger VDAC oligomerization. This occurred independently of mtDNA or reactive oxygen species',
        methodType: 'intervention_animal',
        methodDetails: 'mPTP inhibitors reduce VDAC oligomerization',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'mPTP and VDAC coordinate but are mechanistically independent of mtDNA/ROS per se',
  },
  {
    id: 'E03.006',
    source: 'mtdna_oxidized',
    target: 'ox_mtdna_cytosolic',
    relation: 'increases',
    moduleId: 'M03',
    mechanismLabel: 'FEN1_cleavage_release',
    mechanismDescription: 'FEN1 endonuclease cleaves ox-mtDNA into 500-650 bp fragments; these fragments exit via mPTP/VDAC pores',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels...',
        quote: 'Within mitochondria, Ox-mtDNA was either repaired by DNA glycosylase OGG1 or cleaved by the endonuclease FEN1 to 500-650 bp fragments that exited mitochondria',
        methodType: 'knockout',
        methodDetails: 'FEN1 inhibitor studies',
        causalConfidence: 'L3',
      },
    ],
    therapeuticImplication: 'FEN1 inhibitors suppress IL-1β production and mtDNA release in mice',
  },
  {
    id: 'E03.007',
    source: 'vdac_oligomer',
    target: 'ox_mtdna_cytosolic',
    relation: 'directlyIncreases',
    moduleId: 'M03',
    mechanismLabel: 'VDAC_pore_transport',
    mechanismDescription: 'VDAC oligomers form large pores in outer membrane → allow 500-650 bp ox-mtDNA fragments to exit',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels...',
        quote: 'exited mitochondria via mPTP- and VDAC-dependent channels',
        methodType: 'in_vitro',
        methodDetails: 'VDAC inhibitors (VBIT-4) reduce mtDNA release',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E03.008',
    source: 'ox_mtdna_cytosolic',
    target: 'nlrp3_active',
    relation: 'directlyIncreases',
    moduleId: 'M03',
    mechanismLabel: 'ox_mtDNA_NLRP3_binding',
    mechanismDescription: 'Oxidized mtDNA (8-oxo-dG containing) specifically binds NLRP3 LRR domain and triggers inflammasome assembly. Non-oxidized mtDNA does NOT activate NLRP3',
    causalConfidence: 'L5',
    crossModule: 'Output to Module 4 (Inflammasome)',
    evidence: [
      {
        pmid: '35835107',
        doi: '10.1016/j.immuni.2022.06.007',
        firstAuthor: 'Xian',
        year: 2022,
        title: 'Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels...',
        quote: 'Ox-mtDNA...binds cytosolic NLRP3, thereby triggering inflammasome activation',
        methodType: 'knockout',
        methodDetails: 'OGG1-/- enhances, FEN1-KO abolishes NLRP3 activation',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'CRITICAL: Oxidation state is the molecular switch - ox-mtDNA→NLRP3, non-ox-mtDNA→cGAS',
  },
  {
    id: 'E03.009',
    source: 'mtdna_cytosolic',
    target: 'cgas_active',
    relation: 'directlyIncreases',
    moduleId: 'M03',
    mechanismLabel: 'mtDNA_cGAS_sensing',
    mechanismDescription: 'Cytosolic dsDNA (including non-oxidized mtDNA) is sensed by cGAS → 2\'3\'-cGAMP → STING → TBK1 → IRF3 → Type I IFN',
    causalConfidence: 'L3',
    crossModule: 'Output to Module 4 (Inflammasome)',
    evidence: [
      {
        pmid: '37532932',
        doi: '10.1038/s41586-023-06373-1',
        firstAuthor: 'Gulen',
        year: 2023,
        title: 'cGAS-STING drives ageing-related inflammation and neurodegeneration',
        methodType: 'knockout',
        methodDetails: 'cGAS-/-, STING-/- knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  // Protective edge
  {
    id: 'E03.010',
    source: 'pink1_parkin',
    target: 'mtdna_cytosolic',
    relation: 'decreases',
    moduleId: 'M03',
    mechanismLabel: 'mitophagy_prevents_mtDNA_release',
    mechanismDescription: 'Functional PINK1/Parkin mitophagy clears damaged mitochondria BEFORE mtDNA can escape → prevents mtDNA release',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '33029617',
        doi: '10.1093/brain/awaa246',
        firstAuthor: 'Borsche',
        year: 2020,
        title: 'Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism',
        quote: 'elevated IL6 levels in patients with biallelic PRKN/PINK1 mutations...increased circulating cell-free mtDNA serum levels',
        methodType: 'cohort',
        methodDetails: 'Human PRKN/PINK1 carriers',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
          notes: 'Biallelic PRKN/PINK1 mutation carriers'
        },
      },
      {
        pmid: '38280852',
        doi: '10.1038/s41467-024-45044-1',
        firstAuthor: 'Jimenez-Loygorri',
        year: 2024,
        title: 'Mitophagy curtails cytosolic mtDNA-induced STING signaling',
        quote: 'pharmacological induction of mitophagy with urolithin A attenuates cGAS/STING activation',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'PINK1/Parkin are gatekeepers preventing inflammatory mtDNA release',
    translationalGap: 'Note: Original Sliter 2018 source RETRACTED July 2025; mechanism validated by independent sources',
  },
];

// ============================================================================
// MODULE 4: Inflammasome & Cytokines
// ============================================================================

export const module4Edges: MechanisticEdge[] = [
  {
    id: 'E04.001',
    source: 'nlrp3_active',
    target: 'caspase1_active',
    relation: 'directlyIncreases',
    moduleId: 'M04',
    mechanismLabel: 'inflammasome_caspase1_recruitment',
    mechanismDescription: 'NLRP3 recruits ASC → ASC oligomerizes → recruits pro-caspase-1 → caspase-1 auto-activates',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '23254930',
        doi: '10.1038/nature11729',
        firstAuthor: 'Heneka',
        year: 2013,
        title: 'NLRP3 is activated in Alzheimer\'s disease and contributes to pathology in APP/PS1 mice',
        quote: 'Nlrp3(-/-) or Casp1(-/-) mice...demonstrated reduced brain caspase-1 and interleukin-1β activation',
        methodType: 'knockout',
        methodDetails: 'NLRP3-/- and Caspase-1-/- crossed with APP/PS1',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: 'APP/PS1; Nlrp3-/-; Casp1-/-'
        },
      },
    ],
    keyInsight: 'LANDMARK PAPER - First demonstration that NLRP3-/- protects from AD pathology',
  },
  {
    id: 'E04.002',
    source: 'caspase1_active',
    target: 'il1b',
    relation: 'directlyIncreases',
    moduleId: 'M04',
    mechanismLabel: 'IL1B_cleavage',
    mechanismDescription: 'Caspase-1 cleaves pro-IL-1β (31 kDa) to mature IL-1β (17 kDa)',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '31036653',
        doi: '10.3390/ijms20112611',
        firstAuthor: 'Swanson',
        year: 2019,
        title: 'The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation',
        quote: 'The NLRP3 inflammasome is a critical component of the innate immune system that mediates caspase-1 activation and the secretion of proinflammatory cytokines IL-1β/IL-18',
        methodType: 'meta_analysis',
        methodDetails: 'Comprehensive review of NLRP3/caspase-1/IL-1β axis',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E04.003',
    source: 'cgas_active',
    target: 'sting_active',
    relation: 'directlyIncreases',
    moduleId: 'M04',
    mechanismLabel: 'cGAMP_STING_activation',
    mechanismDescription: 'cGAS produces 2\'3\'-cGAMP → binds STING → STING translocates to Golgi → phosphorylated',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '37532932',
        doi: '10.1038/s41586-023-06373-1',
        firstAuthor: 'Gulen',
        year: 2023,
        title: 'cGAS-STING drives ageing-related inflammation and neurodegeneration',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E04.004',
    source: 'sting_active',
    target: 'type_i_ifn',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'STING_IFN_induction',
    mechanismDescription: 'STING → TBK1 → IRF3 phosphorylation → IRF3 dimerization → nuclear translocation → IFN-α/β transcription',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '37532932',
        doi: '10.1038/s41586-023-06373-1',
        firstAuthor: 'Gulen',
        year: 2023,
        title: 'cGAS-STING drives ageing-related inflammation and neurodegeneration',
        quote: 'Blockade of STING suppresses the inflammatory phenotypes of senescent human cells and tissues',
        methodType: 'knockout',
        methodDetails: 'STING-/- abolishes IFN response',
        causalConfidence: 'L3',
      },
    ],
  },
  // NLRP3 → tau hyperphosphorylation pathway
  {
    id: 'E04.005',
    source: 'nlrp3_active',
    target: 'gsk3b_active',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'NLRP3_GSK3B_activation',
    mechanismDescription: 'NLRP3 signaling activates GSK-3β (tau kinase)',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '31748742',
        doi: '10.1038/s41586-019-1769-z',
        firstAuthor: 'Ising',
        year: 2019,
        title: 'NLRP3 inflammasome activation drives tau pathology',
        quote: 'Loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases',
        methodType: 'knockout',
        methodDetails: 'Nlrp3-/- in Tau22 and injection models',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          model: 'Tau22, injection models'
        },
      },
    ],
    keyInsight: 'LANDMARK PAPER - NLRP3 → tau hyperphosphorylation',
  },
  {
    id: 'E04.006',
    source: 'nlrp3_active',
    target: 'pp2a_activity',
    relation: 'decreases',
    moduleId: 'M04',
    mechanismLabel: 'NLRP3_PP2A_inhibition',
    mechanismDescription: 'NLRP3 signaling inhibits PP2A (major tau phosphatase)',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '31748742',
        doi: '10.1038/s41586-019-1769-z',
        firstAuthor: 'Ising',
        year: 2019,
        title: 'NLRP3 inflammasome activation drives tau pathology',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E04.007',
    source: 'gsk3b_active',
    target: 'tau_hyperphosphorylated',
    relation: 'directlyIncreases',
    moduleId: 'M04',
    mechanismLabel: 'GSK3B_tau_phosphorylation',
    mechanismDescription: 'GSK-3β phosphorylates tau at multiple pathological sites: pSer199, pSer202/Thr205 (AT8), pThr231, pSer396/Ser404 (PHF-1). Priming at Ser-404 enables phosphorylation cascade. Lithium inhibits GSK-3β competitively vs Mg²⁺.',
    timescale: 'minutes',
    causalConfidence: 'L5',
    crossModule: 'Output to Module 7 (Tau)',
    evidence: [
      {
        pmid: '26631930',
        doi: '10.1038/nrn.2015.1',
        firstAuthor: 'Wang',
        year: 2016,
        title: 'Tau in physiology and pathology',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    // Kinetic parameters: Lithium IC50 from PMID:8622901, PMID:7568149
    // GSK-3β requires priming phosphorylation for efficient tau modification
    quantitative: {
      // Lithium IC50 = 1-2 mM (competitive inhibitor vs Mg²⁺)
      // Therapeutic range: 0.5-1.5 mM (overlaps with IC50)
      // Note: GSK3β is the principal tau kinase; inhibition reduces p-tau at Ser396, Ser404
      foldChange: 0.5,      // ~50% reduction in tau phosphorylation at therapeutic lithium levels
      direction: 'decrease',
    },
    keyInsight: 'GSK-3β is the principal tau kinase; lithium IC50 ≈ 1-2 mM overlaps therapeutic range',
  },
  {
    id: 'E04.008',
    source: 'pp2a_activity',
    target: 'tau_hyperphosphorylated',
    relation: 'decreases',
    moduleId: 'M04',
    mechanismLabel: 'PP2A_tau_dephosphorylation',
    mechanismDescription: 'PP2A is the major tau phosphatase; reduced activity → phospho-tau accumulates',
    causalConfidence: 'L5',
    crossModule: 'Output to Module 7 (Tau)',
    evidence: [
      {
        pmid: '26631930',
        doi: '10.1038/nrn.2015.1',
        firstAuthor: 'Wang',
        year: 2016,
        title: 'Tau in physiology and pathology',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  // Feedback loops (Aβ and tau → NLRP3)
  {
    id: 'E04.009',
    source: 'abeta_oligomers',
    target: 'nlrp3_active',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'Abeta_NLRP3_activation',
    mechanismDescription: 'Aβ oligomers are phagocytosed by microglia → lysosomal rupture → NLRP3 activation',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '23254930',
        doi: '10.1038/nature11729',
        firstAuthor: 'Heneka',
        year: 2013,
        title: 'NLRP3 is activated in Alzheimer\'s disease and contributes to pathology in APP/PS1 mice',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E04.010',
    source: 'tau_aggregated',
    target: 'nlrp3_active',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'tau_NLRP3_activation',
    mechanismDescription: 'Tau aggregates also activate NLRP3 (creates feedforward loop)',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 7 (Tau) - creates feedback loop',
    evidence: [
      {
        pmid: '31748742',
        doi: '10.1038/s41586-019-1769-z',
        firstAuthor: 'Ising',
        year: 2019,
        title: 'NLRP3 inflammasome activation drives tau pathology',
        quote: 'Tau activated the NLRP3 inflammasome',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Creates self-amplifying tau pathology loop',
  },
  // Additional M04 edges for connecting unconnected nodes
  {
    id: 'E04.011',
    source: 'caspase1_active',
    target: 'il18',
    relation: 'directlyIncreases',
    moduleId: 'M04',
    mechanismLabel: 'IL18_maturation',
    mechanismDescription: 'Caspase-1 cleaves pro-IL-18 to mature IL-18; IL-18 promotes IFN-γ and enhances neuroinflammation',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Dinarello',
        year: 2009,
        pmid: '19703986',
        methodType: 'meta_analysis',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E04.012',
    source: 'il18',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'IL18_neuroinflammation',
    mechanismDescription: 'IL-18 induces IFN-γ production and amplifies inflammatory cascades; elevated in AD brain and CSF',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Ojala',
        year: 2009,
        pmid: '19121329',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E04.013',
    source: 'neuroinflammation',
    target: 'isg_expression',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'IFN_ISG_induction',
    mechanismDescription: 'Type I interferon signaling (from STING, mtDNA) induces interferon-stimulated genes; ISG signature elevated in AD microglia',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Roy',
        year: 2020,
        pmid: '32589960',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Type I IFN signature links mtDNA release to microglial dysfunction',
  },
  {
    id: 'E04.014',
    source: 'isg_expression',
    target: 'microglia_activated',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'ISG_microglia',
    mechanismDescription: 'ISGs drive microglial activation and proinflammatory phenotype; IRM (interferon-responsive microglia) are distinct subtype',
    causalConfidence: 'L4',
    crossModule: 'M04 → M05',
    evidence: [
      {
        firstAuthor: 'Sala Frigerio',
        year: 2019,
        pmid: '31118249',
        methodType: 'transcriptomics',
        causalConfidence: 'L4',
      },
    ],
  },
];

// ============================================================================
// MODULE 5: Microglial Phenotypes
// ============================================================================

export const module5Edges: MechanisticEdge[] = [
  {
    id: 'E05.001',
    source: 'neuroinflammation',
    target: 'microglia_activated',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'inflammation_microglia_activation',
    mechanismDescription: 'Cytokines and DAMPs activate microglia from homeostatic state',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '33318676',
        doi: '10.1038/s41582-020-00435-y',
        firstAuthor: 'Leng',
        year: 2021,
        title: 'Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?',
        quote: 'the discovery of increased inflammatory markers in AD patients and identification of AD risk genes associated with innate immune functions suggest neuroinflammation has a prominent role in AD pathogenesis',
        methodType: 'meta_analysis',
        methodDetails: 'Nature Reviews Neurology comprehensive review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E05.002',
    source: 'microglia_activated',
    target: 'nf_kb_active',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'activation_NFkB',
    mechanismDescription: 'Microglial activation triggers NF-κB nuclear translocation',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '36875627',
        doi: '10.3389/fimmu.2023.1117172',
        firstAuthor: 'Wang',
        year: 2023,
        title: 'The effects of microglia-associated neuroinflammation on Alzheimer\'s disease',
        quote: 'NF-κB activation stimulates BACE1 expression and Aβ processing',
        methodType: 'meta_analysis',
        methodDetails: 'Frontiers in Immunology comprehensive review',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E05.003',
    source: 'nf_kb_active',
    target: 'hif1a_stabilized',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'NFkB_HIF1A_stabilization',
    mechanismDescription: 'NF-κB signaling stabilizes HIF-1α under normoxia',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '27801979',
        doi: '10.1016/j.cmet.2016.10.007',
        firstAuthor: 'Tannahill',
        year: 2016,
        title: 'HIF1α and metabolic reprogramming in inflammation',
        quote: 'succinate buildup...competitive inhibition of Prolyl Hydroxylase Domain (PHD) enzymes...stabilization of HIF-1α',
        methodType: 'meta_analysis',
        methodDetails: 'Cell Metabolism review on inflammatory metabolic reprogramming',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E05.004',
    source: 'hif1a_stabilized',
    target: 'glycolytic_switch',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'HIF1A_glycolysis',
    mechanismDescription: 'HIF-1α → PKM2 dimer → aerobic glycolysis (Warburg effect)',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '39302180',
        doi: '10.3390/cells13181535',
        firstAuthor: 'Gopalkrishna',
        year: 2024,
        title: 'Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases',
        quote: 'activation of mTOR triggers the expression of HIF1α...heightened activity of crucial glycolytic enzymes, including GLUT1, HK2, and PDK1',
        methodType: 'meta_analysis',
        methodDetails: 'Comprehensive review on microglial metabolic reprogramming',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E05.005',
    source: 'glycolytic_switch',
    target: 'srebp1_active',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'glycolysis_SREBP1',
    mechanismDescription: 'Glycolytic intermediates activate SREBP1 lipogenic program',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '31959936',
        doi: '10.1038/s41593-019-0566-1',
        firstAuthor: 'Marschallinger',
        year: 2020,
        title: 'Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E05.006',
    source: 'srebp1_active',
    target: 'lipid_droplets',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'SREBP1_lipogenesis',
    mechanismDescription: 'SREBP1 drives lipid synthesis → lipid droplet formation',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '31959936',
        doi: '10.1038/s41593-019-0566-1',
        firstAuthor: 'Marschallinger',
        year: 2020,
        title: 'Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E05.007',
    source: 'lipid_droplets',
    target: 'ldam',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'LD_LDAM_phenotype',
    mechanismDescription: 'Lipid droplet accumulation defines LDAM phenotype',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '31959936',
        doi: '10.1038/s41593-019-0566-1',
        firstAuthor: 'Marschallinger',
        year: 2020,
        title: 'Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain',
        quote: 'LDAM...are defective in phagocytosis, produce high levels of reactive oxygen species and secrete proinflammatory cytokines',
        methodType: 'in_vitro',
        methodDetails: 'scRNA-seq + functional assays + CRISPR screen',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'LANDMARK PAPER - Discovery of LDAM phenotype',
  },
  {
    id: 'E05.008',
    source: 'ldam',
    target: 'phagocytosis_impaired',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'LDAM_phagocytosis_failure',
    mechanismDescription: 'LDAM phenotype characterized by defective phagocytosis',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '31959936',
        doi: '10.1038/s41593-019-0566-1',
        firstAuthor: 'Marschallinger',
        year: 2020,
        title: 'Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain',
        quote: 'LDAM...are defective in phagocytosis',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    therapeuticImplication: 'DGAT2 inhibitors may restore microglial function',
  },
  {
    id: 'E05.009',
    source: 'ldam',
    target: 'c1q',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'LDAM_C1q_production',
    mechanismDescription: 'LDAM microglia produce C1q',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 8 (Complement)',
    evidence: [
      {
        pmid: '31959936',
        doi: '10.1038/s41593-019-0566-1',
        firstAuthor: 'Marschallinger',
        year: 2020,
        title: 'Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  // A1 astrocyte induction
  {
    id: 'E05.010',
    source: 'microglia_activated',
    target: 'il1a',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'microglia_IL1A',
    mechanismDescription: 'Activated microglia produce IL-1α',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E05.011',
    source: 'microglia_activated',
    target: 'tnf',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'microglia_TNF',
    mechanismDescription: 'Activated microglia produce TNF-α',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E05.012',
    source: 'il1a',
    target: 'a1_astrocytes',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'IL1A_A1_induction',
    mechanismDescription: 'IL-1α required for A1 astrocyte induction (with TNF + C1q)',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        quote: 'Activated microglia induce A1 astrocytes by secreting Il-1α, TNF and C1q',
        methodType: 'knockout',
        methodDetails: 'Triple knockout (Il1a-/-;Tnf-/-;C1qa-/-)',
        causalConfidence: 'L3',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
          strain: 'Il1a-/-;Tnf-/-;C1qa-/-'
        },
      },
    ],
    keyInsight: 'LANDMARK PAPER - IL-1α + TNF + C1q are NECESSARY and SUFFICIENT for A1 induction',
  },
  {
    id: 'E05.013',
    source: 'tnf',
    target: 'a1_astrocytes',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'TNF_A1_induction',
    mechanismDescription: 'TNF required for A1 astrocyte induction (with IL-1α + C1q)',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E05.014',
    source: 'c1q',
    target: 'a1_astrocytes',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'C1q_A1_induction',
    mechanismDescription: 'C1q required for A1 astrocyte induction (with IL-1α + TNF)',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        quote: 'A1 astrocytes lose the ability to promote neuronal survival...and induce the death of neurons and oligodendrocytes',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'A1 astrocytes abundant in AD, PD, HD, ALS, MS',
  },
];

// ============================================================================
// CROSS-MODULE CONNECTIONS: Key Missing Edges
// ============================================================================

export const crossModuleEdges: MechanisticEdge[] = [
  // IL-1β → neuroinflammation (M04 → M05)
  {
    id: 'E_CM.001',
    source: 'il1b',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'IL1B_neuroinflammation',
    mechanismDescription: 'IL-1β is a major driver of neuroinflammation; activates microglia and astrocytes',
    causalConfidence: 'L4',
    crossModule: 'M04 → M05',
    evidence: [
      {
        pmid: '33318676',
        doi: '10.1038/s41582-020-00435-y',
        firstAuthor: 'Leng',
        year: 2021,
        title: 'Neuroinflammation and microglial activation in Alzheimer disease',
        methodType: 'meta_analysis',
        causalConfidence: 'L4',
      },
    ],
  },
  // Type I IFN → neuroinflammation (M04 → M05)
  {
    id: 'E_CM.002',
    source: 'type_i_ifn',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M04',
    mechanismLabel: 'IFN_neuroinflammation',
    mechanismDescription: 'Type I interferons drive ISG expression and neuroinflammatory state',
    causalConfidence: 'L3',
    crossModule: 'M04 → M05',
    evidence: [
      {
        pmid: '37532932',
        doi: '10.1038/s41586-023-06373-1',
        firstAuthor: 'Gulen',
        year: 2023,
        title: 'cGAS-STING drives ageing-related inflammation and neurodegeneration',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  // A1 astrocytes → neuronal dysfunction (M05 → M07)
  {
    id: 'E_CM.003',
    source: 'a1_astrocytes',
    target: 'neuronal_dysfunction',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'A1_neurotoxicity',
    mechanismDescription: 'A1 astrocytes lose ability to promote neuronal survival and actively induce neuronal death',
    causalConfidence: 'L3',
    crossModule: 'M05 → M07',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        quote: 'A1 astrocytes lose the ability to promote neuronal survival...and induce the death of neurons and oligodendrocytes',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  // NF-κB → BACE1 upregulation (M05 → M06)
  {
    id: 'E_CM.004',
    source: 'nf_kb_active',
    target: 'bace1_upregulated',
    relation: 'increases',
    moduleId: 'M05',
    mechanismLabel: 'NFkB_BACE1_transcription',
    mechanismDescription: 'NF-κB binds BACE1 promoter → transcriptional upregulation → increased Aβ production',
    causalConfidence: 'L4',
    crossModule: 'M05 → M06',
    evidence: [
      {
        pmid: '36875627',
        doi: '10.3389/fimmu.2023.1117172',
        firstAuthor: 'Wang',
        year: 2023,
        title: 'The effects of microglia-associated neuroinflammation on Alzheimer\'s disease',
        quote: 'NF-κB activation stimulates BACE1 expression and Aβ processing',
        methodType: 'meta_analysis',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Links neuroinflammation to amyloid production',
  },
  // Ferroptosis → neuronal count (M09 → BOUNDARY)
  {
    id: 'E_CM.005',
    source: 'ferroptosis',
    target: 'neuronal_count',
    relation: 'decreases',
    moduleId: 'M09',
    mechanismLabel: 'ferroptosis_neuronal_death',
    mechanismDescription: 'Ferroptotic cell death reduces neuronal population',
    causalConfidence: 'L4',
    crossModule: 'M09 → BOUNDARY',
    evidence: [
      {
        pmid: '22632970',
        doi: '10.1016/j.cell.2012.03.042',
        firstAuthor: 'Dixon',
        year: 2012,
        title: 'Ferroptosis: an iron-dependent form of nonapoptotic cell death',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  // Neuronal dysfunction → cognitive score (M07 → BOUNDARY)
  {
    id: 'E_CM.006',
    source: 'neuronal_dysfunction',
    target: 'cognitive_score',
    relation: 'decreases',
    moduleId: 'M07',
    mechanismLabel: 'dysfunction_cognition',
    mechanismDescription: 'Neuronal dysfunction impairs synaptic transmission and cognitive function',
    causalConfidence: 'L6',
    crossModule: 'M07 → BOUNDARY',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  // Tau misfolded → tau aggregated (M07 internal - missing explicit edge)
  {
    id: 'E_CM.007',
    source: 'tau_misfolded',
    target: 'tau_aggregated',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'tau_aggregation_cascade',
    mechanismDescription: 'Misfolded tau forms PHF seeds that template further aggregation',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '26631930',
        doi: '10.1038/nrn.2015.1',
        firstAuthor: 'Wang',
        year: 2016,
        title: 'Tau in physiology and pathology',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  // LTP inhibition → cognitive score (M06 → BOUNDARY)
  {
    id: 'E_CM.008',
    source: 'ltp_inhibition',
    target: 'cognitive_score',
    relation: 'decreases',
    moduleId: 'M06',
    mechanismLabel: 'LTP_memory_impairment',
    mechanismDescription: 'LTP is cellular substrate for learning/memory; inhibition directly impairs cognition',
    causalConfidence: 'L4',
    crossModule: 'M06 → BOUNDARY',
    evidence: [
      {
        pmid: '19029886',
        doi: '10.1038/nature07761',
        firstAuthor: 'Lauren',
        year: 2009,
        title: 'Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // BBB breakdown → neuroinflammation (M12 → M05)
  {
    id: 'E_CM.009',
    source: 'bbb_breakdown',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'BBB_peripheral_infiltration',
    mechanismDescription: 'BBB breakdown allows peripheral immune cell infiltration and plasma protein leakage → neuroinflammation',
    causalConfidence: 'L4',
    crossModule: 'M12 → M05',
    evidence: [
      {
        pmid: '22696567',
        doi: '10.1038/nature11087',
        firstAuthor: 'Bell',
        year: 2012,
        title: 'Apolipoprotein E controls cerebrovascular integrity via cyclophilin A',
        methodType: 'knockout',
        causalConfidence: 'L4',
      },
    ],
  },
  // APOE4 → Aβ clearance reduced (M10 → M06)
  {
    id: 'E_CM.010',
    source: 'apoe_lipidation_reduced',
    target: 'abeta_clearance',
    relation: 'decreases',
    moduleId: 'M10',
    mechanismLabel: 'APOE4_clearance_impairment',
    mechanismDescription: 'Hypolipidated APOE4 is less effective at promoting Aβ clearance via LRP1 and BBB transport',
    causalConfidence: 'L4',
    crossModule: 'M10 → M06',
    evidence: [
      {
        pmid: '21725313',
        firstAuthor: 'Castellano',
        year: 2011,
        title: 'Human apoE isoforms differentially regulate brain amyloid-β peptide clearance',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // Additional cross-module edges for BOUNDARY nodes
  {
    id: 'E_CM.011',
    source: 'neuronal_dysfunction',
    target: 'mortality',
    relation: 'increases',
    moduleId: 'BOUNDARY',
    mechanismLabel: 'dysfunction_mortality',
    mechanismDescription: 'Progressive neuronal dysfunction leads to death; AD reduces life expectancy by 4-8 years after diagnosis',
    causalConfidence: 'L6',
    crossModule: 'M07 → BOUNDARY',
    evidence: [
      {
        firstAuthor: 'Todd',
        year: 2013,
        pmid: '23574434',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E_CM.012',
    source: 'tau_aggregated',
    target: 'brain_volume',
    relation: 'decreases',
    moduleId: 'BOUNDARY',
    mechanismLabel: 'tau_atrophy',
    mechanismDescription: 'Tau pathology correlates with regional brain atrophy better than amyloid; neuronal loss → volume loss',
    causalConfidence: 'L6',
    crossModule: 'M07 → BOUNDARY',
    evidence: [
      {
        firstAuthor: 'Jack',
        year: 2019,
        pmid: '30617323',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Brain volume loss correlates with tau, not amyloid',
  },
  {
    id: 'E_CM.013',
    source: 'brain_volume',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'BOUNDARY',
    mechanismLabel: 'volume_cognition',
    mechanismDescription: 'Regional brain volumes correlate with cognitive function; hippocampal volume predicts memory',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Jack',
        year: 2010,
        pmid: '20399717',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E_CM.014',
    source: 'abeta_oligomers',
    target: 'csf_biomarkers',
    relation: 'regulates',
    moduleId: 'BOUNDARY',
    mechanismLabel: 'abeta_CSF',
    mechanismDescription: 'CSF Aβ42 decreases as brain Aβ accumulates (sequestered into plaques); CSF Aβ42/40 ratio is diagnostic',
    causalConfidence: 'L6',
    crossModule: 'M06 → BOUNDARY',
    evidence: [
      {
        firstAuthor: 'Hansson',
        year: 2019,
        pmid: '31127821',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E_CM.015',
    source: 'tau_hyperphosphorylated',
    target: 'csf_biomarkers',
    relation: 'increases',
    moduleId: 'BOUNDARY',
    mechanismLabel: 'ptau_CSF',
    mechanismDescription: 'CSF p-tau181, p-tau217, p-tau231 are elevated in AD; reflect neuronal tau pathology',
    causalConfidence: 'L6',
    crossModule: 'M07 → BOUNDARY',
    evidence: [
      {
        firstAuthor: 'Hansson',
        year: 2019,
        pmid: '31127821',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'p-tau is most specific CSF biomarker for AD',
  },
  {
    id: 'E_CM.016',
    source: 'csf_biomarkers',
    target: 'clinical_benefit',
    relation: 'regulates',
    moduleId: 'BOUNDARY',
    mechanismLabel: 'biomarker_monitoring',
    mechanismDescription: 'CSF biomarkers used for diagnosis and monitoring; biomarker changes may precede/predict clinical outcomes',
    causalConfidence: 'L6',
    crossModule: 'BOUNDARY → M15',
    evidence: [
      {
        firstAuthor: 'Jack',
        year: 2018,
        pmid: '29653606',
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
  },
];

// ============================================================================
// MODULE 6: Amyloid Processing
// ============================================================================

export const module6Edges: MechanisticEdge[] = [
  {
    id: 'E06.001',
    source: 'bace1_upregulated',
    target: 'app_betactf',
    relation: 'directlyIncreases',
    moduleId: 'M06',
    mechanismLabel: 'BACE1_APP_cleavage',
    mechanismDescription: 'BACE1 cleaves APP at β-site → releases sAPPβ and membrane-bound β-CTF (C99)',
    timescale: 'minutes',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Vassar',
        year: 1999,
        title: 'Beta-secretase cleavage of Alzheimer\'s amyloid precursor protein',
        pmid: '10531052',
        doi: '10.1126/science.286.5440.735',
        methodType: 'knockout',
        methodDetails: 'BACE1-/- eliminates Aβ production',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    // Kinetic parameters from PMID:18177262, PMID:21604208
    quantitative: {
      km: 18.3,             // μM - Michaelis constant for APP substrate
      kcat: 0.133,          // s⁻¹ (8.0 min⁻¹) - catalytic rate constant
      // Note: kcat/Km = 1.3-4.5 mM⁻¹s⁻¹; relatively low catalytic efficiency (~50 M⁻¹s⁻¹)
      // Swedish mutation (KM→NL) increases kcat ~10-fold, making BACE1 more efficient
    },
    keyInsight: 'BACE1 is rate-limiting for Aβ production; validated therapeutic target',
  },
  {
    id: 'E06.002',
    source: 'app_betactf',
    target: 'abeta_monomers',
    relation: 'directlyIncreases',
    moduleId: 'M06',
    mechanismLabel: 'gamma_secretase_cleavage',
    mechanismDescription: 'γ-secretase cleaves β-CTF → releases Aβ peptides (Aβ40, Aβ42, Aβ43)',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'De Strooper',
        year: 1998,
        title: 'Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein',
        pmid: '9461215',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E06.003',
    source: 'abeta_monomers',
    target: 'abeta_oligomers',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'oligomerization',
    mechanismDescription: 'Aβ monomers aggregate into soluble oligomers (dimers, trimers, Aβ*56). Oligomers are the TOXIC species. Aβ CNS half-life ~9h (age 30: 3.8h → age 80: 9.4h), synthesis 7.6%/h, clearance 8.3%/h.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '16838177',
        doi: '10.1038/nature04533',
        firstAuthor: 'Lesne',
        year: 2006,
        title: 'A specific amyloid-β protein assembly in the brain impairs memory',
        quote: 'Aβ*56 impairs memory independently of plaques or neuronal loss',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'Tg2576' },
      },
      {
        pmid: '26221020',
        doi: '10.1002/ana.24489',
        firstAuthor: 'Patterson',
        year: 2015,
        title: 'Age and Amyloid Effects on Human CNS Amyloid-Beta Kinetics',
        quote: 'Aβ turnover rate was highly correlated with age, showing a remarkable 2.5-fold longer Aβ half-life (from 3.8 hours at 30 years to 9.4 hours at 80 years)',
        methodType: 'cohort',
        methodDetails: 'SILK stable isotope labeling kinetics in human CSF',
        causalConfidence: 'L5',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    // Aβ kinetics from SILK studies: PMID:26221020, PMID:28756332
    quantitative: {
      // CNS Aβ half-life: 3.8h (age 30) → 9.4h (age 80), average ~9h
      // Synthesis rate: 7.6%/h, Clearance rate: 8.3%/h
      // Plasma half-life: ~3h (faster than CSF)
      foldChange: 2.5,      // Age 30→80 = 2.5× longer half-life
      direction: 'increase',
    },
    translationalGap: 'NOTE: Lesne 2006 has image manipulation concerns; oligomer toxicity supported by independent studies',
  },
  {
    id: 'E06.004',
    source: 'abeta_oligomers',
    target: 'abeta_plaques',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'plaque_deposition',
    mechanismDescription: 'Oligomers seed fibril formation → amyloid plaques. Plaques may be PROTECTIVE sequestration of toxic oligomers',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        title: 'Standard amyloid literature',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Paradox: plaques correlate poorly with cognition; oligomers correlate better',
  },
  {
    id: 'E06.005',
    source: 'abeta_oligomers',
    target: 'ltp_inhibition',
    relation: 'directlyIncreases',
    moduleId: 'M06',
    mechanismLabel: 'synaptic_toxicity',
    mechanismDescription: 'Aβ oligomers bind PrPc/mGluR5 → block LTP, enhance LTD → synaptic dysfunction',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '19029886',
        doi: '10.1038/nature07761',
        firstAuthor: 'Lauren',
        year: 2009,
        title: 'Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E06.006',
    source: 'phagocytosis_impaired',
    target: 'abeta_clearance',
    relation: 'decreases',
    moduleId: 'M06',
    edgeType: 'MODULATION', // Phagocytosis regulates the clearance rate
    mechanismLabel: 'LDAM_clearance_failure',
    mechanismDescription: 'Impaired microglial phagocytosis (from LDAM phenotype) reduces Aβ clearance rate',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 5 (LDAM)',
    evidence: [
      {
        pmid: '31959936',
        firstAuthor: 'Marschallinger',
        year: 2020,
        title: 'Lipid-droplet-accumulating microglia represent a dysfunctional state in the aging brain',
        quote: 'LDAM...are defective in phagocytosis',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'LDAM impairs microglial Aβ clearance capacity',
  },
  {
    id: 'E06.007',
    source: 'lysosomal_dysfunction',
    target: 'abeta_monomers',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'PANTHOS_pathway',
    mechanismDescription: 'Lysosomal de-acidification → autolysosomes become Aβ production sites (PANTHOS). Aβ produced INSIDE neurons, not just secreted',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 2 (Lysosomal)',
    evidence: [
      {
        pmid: '35654956',
        doi: '10.1038/s41593-022-01084-8',
        firstAuthor: 'Lee',
        year: 2022,
        title: 'Faulty autolysosome acidification...induces autophagic build-up of Aβ in neurons, yielding senile plaques',
        quote: 'Build-up of Aβ/APP-βCTF selectively within enlarged de-acidified autolysosomes',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'PARADIGM SHIFT: Aβ is produced in dysfunctional autolysosomes, not just at plasma membrane',
  },
  // Additional M06 edges for connecting unconnected nodes
  {
    id: 'E06.008',
    source: 'app_processing_amyloidogenic',
    target: 'app_betactf',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'amyloidogenic_pathway',
    mechanismDescription: 'Amyloidogenic processing of APP by BACE1 produces β-CTF (C99) substrate for γ-secretase',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Haass',
        year: 2012,
        pmid: '22871125',
        methodType: 'review',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E06.009',
    source: 'bace1_upregulated',
    target: 'app_processing_amyloidogenic',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'BACE1_amyloidogenic',
    mechanismDescription: 'BACE1 upregulation shifts APP processing toward amyloidogenic pathway vs. non-amyloidogenic α-secretase cleavage',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Vassar',
        year: 2014,
        pmid: '25009269',
        methodType: 'review',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E06.010',
    source: 'app_processing_amyloidogenic',
    target: 'abeta_production',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'abeta_generation',
    mechanismDescription: 'Amyloidogenic processing pathway generates Aβ peptides through sequential BACE1 and γ-secretase cleavage',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Selkoe',
        year: 2001,
        pmid: '11588246',
        methodType: 'review',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E06.011',
    source: 'abeta_production',
    target: 'abeta_monomers',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'monomer_release',
    mechanismDescription: 'Aβ production rate determines steady-state monomer concentration; monomers aggregate into toxic oligomers',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Selkoe',
        year: 2001,
        pmid: '11588246',
        methodType: 'review',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E06.012',
    source: 'trem2_surface',
    target: 'plaque_compaction',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'protective_compaction',
    mechanismDescription: 'TREM2-positive microglia compact plaques into dense cores, reducing toxicity by sequestering oligomers',
    causalConfidence: 'L4',
    crossModule: 'M11 → M06',
    evidence: [
      {
        firstAuthor: 'Yuan',
        year: 2016,
        pmid: '27613435',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Plaque compaction is PROTECTIVE; loss of TREM2 leads to diffuse, more toxic plaques',
  },
  {
    id: 'E06.013',
    source: 'plaque_compaction',
    target: 'plaque_barrier_function',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'barrier_formation',
    mechanismDescription: 'Compacted plaques form physical barrier that limits diffusion of toxic Aβ oligomers to surrounding neuropil',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Condello',
        year: 2015,
        pmid: '25497191',
        methodType: 'imaging',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E06.014',
    source: 'abeta_oligomers',
    target: 'synaptic_abeta_binding',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'synaptic_toxicity_binding',
    mechanismDescription: 'Aβ oligomers bind synaptic receptors (PrPc, mGluR5, NMDAR) triggering excitotoxicity and LTP inhibition',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lauren',
        year: 2009,
        pmid: '19029886',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E06.015',
    source: 'synaptic_abeta_binding',
    target: 'ltp_inhibition',
    relation: 'increases',
    moduleId: 'M06',
    mechanismLabel: 'LTP_blockade',
    mechanismDescription: 'Aβ binding to PrPc/mGluR5 complex activates Fyn kinase → NMDAR overactivation → LTP blocked, LTD enhanced',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Um',
        year: 2012,
        pmid: '22622579',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
  },
];

// ============================================================================
// MODULE 7: Tau Pathology & Transsulfuration
// ============================================================================

export const module7Edges: MechanisticEdge[] = [
  // 7A: Tau pathology
  {
    id: 'E07.001',
    source: 'tau_hyperphosphorylated',
    target: 'tau_misfolded',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'phospho_tau_conformational_change',
    mechanismDescription: 'Hyperphosphorylation promotes tau detachment from microtubules and conformational changes exposing aggregation-prone regions. Wild-type tau t½ ~16h; phosphomimetic tau t½ >24h; autophagy is primary clearance pathway.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '26631930',
        doi: '10.1038/nrn.2015.1',
        firstAuthor: 'Wang',
        year: 2016,
        title: 'Tau in physiology and pathology',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
      {
        pmid: '32586946',
        doi: '10.1038/s41467-020-16984-1',
        firstAuthor: 'Silva',
        year: 2020,
        title: 'Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons',
        quote: 'mTOR inhibitors followed by washout leads to a prolonged reduction of tau levels for 12 days',
        methodType: 'intervention_cells',
        methodDetails: 'iPSC-derived neurons, mTOR inhibitors',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human', strain: 'iPSC-neurons' },
      },
    ],
    // Tau turnover: PMID:22817709, PMID:32586946
    quantitative: {
      // Wild-type tau half-life: ~16h in MEFs, ~60h in HT22 cells
      // Phosphomimetic tau: >24h (slower degradation)
      // Autophagy inhibition: minimal degradation after 24h
      foldChange: 1.5,      // ~50% longer half-life for phospho-tau vs WT
      direction: 'increase',
    },
    keyInsight: 'Phosphorylation extends tau half-life; autophagy is primary clearance route',
  },
  {
    id: 'E07.002',
    source: 'tau_misfolded',
    target: 'tau_aggregated',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'tau_aggregation',
    mechanismDescription: 'Misfolded tau forms paired helical filaments (PHF) → neurofibrillary tangles (NFT)',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '26631930',
        firstAuthor: 'Wang',
        year: 2016,
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.003',
    source: 'tau_aggregated',
    target: 'tau_seeding',
    relation: 'directlyIncreases',
    moduleId: 'M07',
    mechanismLabel: 'prion_like_spreading',
    mechanismDescription: 'Aggregated tau acts as seed, templating misfolding of normal tau in connected neurons',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '23898162',
        doi: '10.1016/j.cell.2013.07.033',
        firstAuthor: 'Sanders',
        year: 2014,
        title: 'Distinct tau prion strains propagate in cells and mice',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Tau spreading follows neural connectivity (Braak staging)',
  },
  {
    id: 'E07.004',
    source: 'tau_aggregated',
    target: 'neuronal_dysfunction',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'tau_toxicity',
    mechanismDescription: 'Tau aggregates disrupt axonal transport, impair proteostasis, cause synaptic dysfunction',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // 7B: Transsulfuration pathway (CSE/H2S)
  {
    id: 'E07.005',
    source: 'cse_enzyme',
    target: 'h2s_production',
    relation: 'directlyIncreases',
    moduleId: 'M07',
    mechanismLabel: 'H2S_production',
    mechanismDescription: 'CSE catalyzes cysteine → H₂S + pyruvate. CSE is the primary H₂S synthase in brain',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '19027017',
        firstAuthor: 'Abe',
        year: 2008,
        title: 'The possible role of hydrogen sulfide as an endogenous neuromodulator',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.006',
    source: 'h2s_production',
    target: 'gsk3b_active',
    relation: 'decreases',
    moduleId: 'M07',
    mechanismLabel: 'H2S_GSK3B_sulfhydration',
    mechanismDescription: 'H₂S sulfhydrates GSK3β at Cys218 → inhibits kinase activity → reduces tau phosphorylation',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '25065588',
        doi: '10.1016/j.bbamcr.2014.07.003',
        firstAuthor: 'Giovinazzo',
        year: 2014,
        title: 'Hydrogen sulfide is neuroprotective in Alzheimer\'s disease by sulfhydrating GSK3β and inhibiting tau hyperphosphorylation',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'CSE loss → ↓H₂S → GSK3β hyperactive → tau pathology',
  },
  {
    id: 'E07.007',
    source: 'cse_enzyme',
    target: 'glutathione_gsh',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'cysteine_GSH_synthesis',
    mechanismDescription: 'CSE provides cysteine via transsulfuration; cysteine is rate-limiting for glutathione (GSH) synthesis',
    causalConfidence: 'L5',
    crossModule: 'Output to Module 9 (Ferroptosis - GPX4 requires GSH)',
    evidence: [
      {
        firstAuthor: 'Sbodio',
        year: 2019,
        pmid: '30455430',
        title: 'Regulators of the transsulfuration pathway',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'Links transsulfuration to ferroptosis protection',
  },
  {
    id: 'E07.008',
    source: 'aging',
    target: 'cse_enzyme',
    relation: 'decreases',
    moduleId: 'M07',
    mechanismLabel: 'age_CSE_decline',
    mechanismDescription: 'CSE expression/activity declines with age → H₂S and cysteine depletion',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '39420891',
        doi: '10.1073/pnas.2528478122',
        firstAuthor: 'Chakraborty',
        year: 2025,
        title: 'The transsulfuration pathway metabolite hydrogen sulfide regulates brain iron metabolism',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  // Additional M07 edges for connecting unconnected nodes
  {
    id: 'E07.009',
    source: 'neuroinflammation',
    target: 'p38_mapk_active',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'inflammation_p38_activation',
    mechanismDescription: 'IL-1β and TNF-α from neuroinflammation activate p38 MAPK, a tau kinase',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Sun',
        year: 2003,
        pmid: '12524457',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E07.010',
    source: 'p38_mapk_active',
    target: 'tau_hyperphosphorylated',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'p38_tau_phosphorylation',
    mechanismDescription: 'p38 MAPK directly phosphorylates tau at multiple AD-relevant epitopes (Ser396, Ser404)',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Reynolds',
        year: 2000,
        pmid: '10866716',
        methodType: 'biochemistry',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E07.011',
    source: 'abeta_oligomers',
    target: 'pp2a_inhibited',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'abeta_PP2A_inhibition',
    mechanismDescription: 'Aβ oligomers inhibit PP2A via SET/I2PP2A upregulation; PP2A is the major tau phosphatase (>70%)',
    causalConfidence: 'L4',
    crossModule: 'M06 → M07',
    evidence: [
      {
        firstAuthor: 'Sontag',
        year: 2004,
        pmid: '14986299',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E07.012',
    source: 'pp2a_inhibited',
    target: 'tau_hyperphosphorylated',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'PP2A_tau_accumulation',
    mechanismDescription: 'Reduced PP2A activity allows hyperphosphorylated tau to accumulate',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Liu',
        year: 2005,
        pmid: '16219789',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'PP2A activity reduced ~50% in AD brain',
  },
  {
    id: 'E07.013',
    source: 'tau_aggregated',
    target: 'tau_aggregated_phf',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'PHF_formation',
    mechanismDescription: 'Aggregated tau assembles into paired helical filaments (PHF) as canonical aggregation product',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Fitzpatrick',
        year: 2017,
        pmid: '28678778',
        doi: '10.1038/nature23002',
        title: 'Cryo-EM structures of tau filaments from Alzheimer disease brain',
        methodType: 'cryo_em',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.014',
    source: 'tau_aggregated_phf',
    target: 'nft_formation',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'NFT_maturation',
    mechanismDescription: 'PHF bundles accumulate into neurofibrillary tangles (NFT); Braak staging correlates with cognitive decline',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Braak',
        year: 1991,
        pmid: '1759558',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'NFT burden correlates with cognitive decline better than Aβ',
  },
  {
    id: 'E07.015',
    source: 'nft_formation',
    target: 'neuronal_dysfunction',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'NFT_toxicity',
    mechanismDescription: 'NFT-bearing neurons show impaired function; tau pathology more closely correlates with dementia than amyloid',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Nelson',
        year: 2012,
        pmid: '22539990',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E07.016',
    source: 'tau_aggregated',
    target: 'tau_exosomal_release',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'exosomal_spreading',
    mechanismDescription: 'Tau is released via exosomes; exosomal tau is more aggregation-prone and seeds misfolding in recipient cells',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Wang',
        year: 2017,
        pmid: '28800352',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E07.017',
    source: 'tau_exosomal_release',
    target: 'tau_seeding',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'exosome_seeding',
    mechanismDescription: 'Exosome-delivered tau seeds misfolding in connected neurons; mediates Braak-like spreading',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Asai',
        year: 2015,
        pmid: '26390242',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // Transsulfuration pathway connections
  {
    id: 'E07.018',
    source: 'homocysteine',
    target: 'cbs_enzyme',
    relation: 'substrateof',
    moduleId: 'M07',
    mechanismLabel: 'CBS_substrate',
    mechanismDescription: 'Homocysteine is substrate for CBS (cystathionine β-synthase); elevated homocysteine is AD risk factor',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Seshadri',
        year: 2002,
        pmid: '11844848',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Hyperhomocysteinemia nearly doubles AD risk',
  },
  {
    id: 'E07.019',
    source: 'cbs_enzyme',
    target: 'cystathionine',
    relation: 'directlyIncreases',
    moduleId: 'M07',
    mechanismLabel: 'CBS_product',
    mechanismDescription: 'CBS converts homocysteine + serine → cystathionine (first step of transsulfuration)',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.020',
    source: 'cystathionine',
    target: 'cse_enzyme',
    relation: 'substrateof',
    moduleId: 'M07',
    mechanismLabel: 'CSE_substrate',
    mechanismDescription: 'Cystathionine is substrate for CSE (cystathionine γ-lyase)',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.021',
    source: 'cse_enzyme',
    target: 'cysteine',
    relation: 'directlyIncreases',
    moduleId: 'M07',
    mechanismLabel: 'CSE_cysteine_product',
    mechanismDescription: 'CSE cleaves cystathionine → cysteine + α-ketobutyrate + NH₃',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.022',
    source: 'cysteine',
    target: 'glutathione_gsh',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'cysteine_GSH',
    mechanismDescription: 'Cysteine is rate-limiting substrate for glutathione (GSH) synthesis',
    causalConfidence: 'L5',
    crossModule: 'Output to M09 (Ferroptosis - GPX4 requires GSH)',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E07.023',
    source: 'h2s_production',
    target: 'sulfhydration',
    relation: 'directlyIncreases',
    moduleId: 'M07',
    mechanismLabel: 'H2S_PTM',
    mechanismDescription: 'H₂S mediates protein S-sulfhydration (persulfidation), a post-translational modification affecting ~20% of proteins',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Mustafa',
        year: 2009,
        pmid: '19864462',
        methodType: 'biochemistry',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E07.024',
    source: 'sulfhydration',
    target: 'gsk3beta_sulfhydrated',
    relation: 'increases',
    moduleId: 'M07',
    mechanismLabel: 'GSK3B_sulfhydration',
    mechanismDescription: 'Sulfhydration of GSK3β at Cys218 inhibits its kinase activity',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Sen',
        year: 2012,
        pmid: '22729161',
        methodType: 'biochemistry',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E07.025',
    source: 'gsk3beta_sulfhydrated',
    target: 'gsk3b_active',
    relation: 'decreases',
    moduleId: 'M07',
    mechanismLabel: 'GSK3B_inactivation',
    mechanismDescription: 'Sulfhydrated GSK3β is inactive → reduced tau phosphorylation at Ser396, Ser404',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Sen',
        year: 2012,
        pmid: '22729161',
        methodType: 'biochemistry',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Links H₂S decline to tau hyperphosphorylation in aging',
  },

  // ============================================================================
  // Hyperactivity-Tau Initiation Cascade (IgLON5 Model - Askin/Wegmann 2024)
  // Key paradigm shift: Neuronal hyperactivity INITIATES tau pathology
  // ============================================================================
  {
    id: 'E07.026',
    source: 'iglon5_autoantibodies',
    target: 'neuronal_hyperactivity',
    relation: 'increases',
    moduleId: 'M07',
    edgeType: 'MODULATION',
    mechanismLabel: 'AAB_ion_channel_hyperactivity',
    mechanismDescription: 'Anti-IgLON5 autoantibodies bind IgLON5 → surface clustering + KCNA2 (Kv1.2) co-clustering → altered ion channel function → increased neuronal firing rate. Proven by Ca imaging and MEA in primary neurons. In vivo (mouse ICV): 33% astrocytosis, 100% microgliosis.',
    timescale: 'hours',
    causalConfidence: 'L3',
    evidence: [
      {
        doi: '10.1101/2024.03.10.584272',
        firstAuthor: 'Askin',
        year: 2024,
        title: 'Disease-associated anti-IgLON5 autoantibodies cause neuronal hyperactivity leading to tau pathology',
        quote: 'AABs caused neuronal hyperactivity that was necessary and sufficient for tau changes',
        methodType: 'intervention_cells',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'PARADIGM: Autoantibodies can initiate tau pathology via neuronal hyperactivity',
  },
  {
    id: 'E07.027',
    source: 'neuronal_hyperactivity',
    target: 'tau_missorting',
    relation: 'increases',
    moduleId: 'M07',
    edgeType: 'TRANSITION',
    mechanismLabel: 'hyperactivity_tau_mislocalization',
    mechanismDescription: 'Neuronal hyperactivity causes tau to mislocalize from axon to somatodendritic compartment. CRITICAL: Dampening activity with TTX or CNQX PREVENTED tau missorting, proving hyperactivity is UPSTREAM, not downstream, of tau pathology. Mechanism: Activity-dependent Ca influx may trigger tau release from microtubules.',
    timescale: 'hours',
    causalConfidence: 'L3',
    evidence: [
      {
        doi: '10.1101/2024.03.10.584272',
        firstAuthor: 'Askin',
        year: 2024,
        title: 'Anti-IgLON5 autoantibodies cause neuronal hyperactivity leading to tau pathology',
        quote: 'Dampening neuronal activity with TTX or CNQX PREVENTED tau changes',
        methodType: 'intervention_cells',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'CAUSAL PROOF: Activity precedes tau changes; blocking activity prevents tau pathology',
  },
  {
    id: 'E07.028',
    source: 'tau_missorting',
    target: 'tau_hyperphosphorylated',
    relation: 'increases',
    moduleId: 'M07',
    edgeType: 'TRANSITION',
    mechanismLabel: 'missorting_hyperphosphorylation',
    mechanismDescription: 'Somatodendritic tau is exposed to kinases concentrated in soma (GSK3β, p38-MAPK). IgLON5 model shows AT8, PHF-1 epitope phosphorylation (pSer396/404) follows missorting. Temporal sequence: hyperactivity → missorting → hyperphosphorylation → aggregation.',
    timescale: 'hours',
    causalConfidence: 'L4',
    crossModule: 'M07 → M04 (tau to inflammasome cascade)',
    evidence: [
      {
        doi: '10.1101/2024.03.10.584272',
        firstAuthor: 'Askin',
        year: 2024,
        title: 'Anti-IgLON5 autoantibodies cause neuronal hyperactivity leading to tau pathology',
        quote: 'Tau hyperphosphorylation at AT8 and PHF-1 epitopes followed missorting',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Missorting exposes axonal tau to somatic kinases, enabling pathological phosphorylation',
  },
];

// ============================================================================
// MODULE 8: Complement-Mediated Synapse Elimination
// ============================================================================

export const module8Edges: MechanisticEdge[] = [
  {
    id: 'E08.001',
    source: 'aging',
    target: 'c1q',
    relation: 'increases',
    moduleId: 'M08',
    mechanismLabel: 'age_C1q_upregulation',
    mechanismDescription: 'C1q increases ~300-fold in aged brain (primarily from microglia). Reactivation of developmental pruning pathway',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '23946404',
        doi: '10.1523/JNEUROSCI.1333-13.2013',
        firstAuthor: 'Stephan',
        year: 2013,
        title: 'A dramatic increase of C1q protein in the CNS during normal aging',
        quote: 'C1q is increased up to 300-fold in some regions of the aged mouse and human brain',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'LANDMARK: C1q upregulation is universal feature of brain aging',
  },
  {
    id: 'E08.002',
    source: 'c1q',
    target: 'c3_opsonization',
    relation: 'directlyIncreases',
    moduleId: 'M08',
    mechanismLabel: 'complement_cascade_initiation',
    mechanismDescription: 'C1q binds synapses → activates C1r/C1s → cleaves C4 → cleaves C2 → cleaves C3 → deposits iC3b',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '18083105',
        doi: '10.1016/j.cell.2007.10.036',
        firstAuthor: 'Stevens',
        year: 2007,
        title: 'The classical complement cascade mediates CNS synapse elimination',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'DISCOVERY: Complement cascade mediates developmental synapse elimination (Stevens 2007)',
  },
  {
    id: 'E08.003',
    source: 'c3_opsonization',
    target: 'cr3_mediated_pruning',
    relation: 'increases',
    moduleId: 'M08',
    mechanismLabel: 'C3_iC3b_opsonization',
    mechanismDescription: 'C3 cleavage deposits iC3b on synapses → recognized by microglial CR3 (CD11b/CD18)',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '22632727',
        doi: '10.1016/j.neuron.2012.03.026',
        firstAuthor: 'Schafer',
        year: 2012,
        title: 'Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner',
        quote: 'CR3, the receptor for complement component C3, is required for microglia-mediated synapse elimination',
        methodType: 'knockout',
        methodDetails: 'CR3-/- mice have impaired synapse elimination',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E08.004',
    source: 'cr3_mediated_pruning',
    target: 'synapse_elimination',
    relation: 'directlyIncreases',
    moduleId: 'M08',
    mechanismLabel: 'CR3_phagocytosis_trigger',
    mechanismDescription: 'CR3 binding to iC3b-tagged synapses triggers microglial phagocytosis → synapse elimination',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '22632727',
        firstAuthor: 'Schafer',
        year: 2012,
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E08.005',
    source: 'synapse_elimination',
    target: 'synapses',
    relation: 'decreases',
    moduleId: 'M08',
    mechanismLabel: 'synapse_loss',
    mechanismDescription: 'Excessive synapse engulfment → synapse loss → circuit dysfunction',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '27033548',
        doi: '10.1126/science.aad8373',
        firstAuthor: 'Hong',
        year: 2016,
        title: 'Complement and microglia mediate early synapse loss in Alzheimer mouse models',
        quote: 'Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic microglia, as well as the extent of early synapse loss',
        methodType: 'knockout',
        methodDetails: 'C1q-/-, C3-/-, CR3-/- all prevent synapse loss',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'J20 APP' },
      },
    ],
    keyInsight: 'LANDMARK: Complement-mediated synapse loss occurs BEFORE plaques (Hong 2016)',
  },
  {
    id: 'E08.006',
    source: 'synapses',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'M08',
    mechanismLabel: 'synapse_cognition_correlation',
    mechanismDescription: 'Synapse density is STRONGEST anatomical correlate of cognitive function - better than plaques or tangles',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '23946404',
        firstAuthor: 'Stephan',
        year: 2013,
        quote: 'aged C1q-deficient mice exhibited significantly less cognitive and memory decline',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'C1q-/- mice protected from age-related cognitive decline',
  },
  {
    id: 'E08.007',
    source: 'abeta_oligomers',
    target: 'c1q',
    relation: 'increases',
    moduleId: 'M08',
    mechanismLabel: 'Abeta_C1q_induction',
    mechanismDescription: 'Aβ oligomers induce C1q expression/deposition on synapses',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '27033548',
        firstAuthor: 'Hong',
        year: 2016,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // Additional M08 edges for connecting C1q_elevated
  {
    id: 'E08.008',
    source: 'aging',
    target: 'c1q_elevated',
    relation: 'increases',
    moduleId: 'M08',
    mechanismLabel: 'aging_C1q_elevation',
    mechanismDescription: 'Aging causes dramatic C1q elevation (~300-fold); C1q_elevated captures sustained high levels beyond normal aging',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '23946404',
        firstAuthor: 'Stephan',
        year: 2013,
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E08.009',
    source: 'c1q_elevated',
    target: 'c3_opsonization',
    relation: 'increases',
    moduleId: 'M08',
    mechanismLabel: 'elevated_C1q_cascade',
    mechanismDescription: 'Sustained elevated C1q drives excessive complement cascade activation and synapse tagging',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '27033548',
        firstAuthor: 'Hong',
        year: 2016,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'C1q elevation is therapeutic target for synapse preservation',
  },
  // ----------------------------------------------------------------------------
  // BDNF and Dendritic Spine Edges
  // ----------------------------------------------------------------------------
  {
    id: 'E08.010',
    source: 'abeta_oligomers',
    target: 'bdnf',
    relation: 'decreases',
    moduleId: 'M08',
    edgeType: 'INFLUENCE',
    crossModule: 'M06 → M08',
    mechanismLabel: 'abeta_bdnf_reduction',
    mechanismDescription:
      'Aβ oligomers reduce BDNF expression and secretion. Involves CREB inhibition and impaired TrkB signaling. Contributes to synaptic dysfunction.',
    timescale: 'days',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '19403830',
        firstAuthor: 'Peng',
        year: 2009,
        title: 'Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer disease',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E08.011',
    source: 'bdnf',
    target: 'synaptic_plasticity',
    relation: 'increases',
    moduleId: 'M08',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'bdnf_synaptic_plasticity',
    mechanismDescription:
      'BDNF is essential for LTP, spine formation, and neuronal survival. Signals via TrkB receptor → MAPK/ERK, PI3K/Akt, PLCγ pathways. Master regulator of synaptic plasticity.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '20364143',
        firstAuthor: 'Cunha',
        year: 2010,
        title: 'A simple role for BDNF in learning and memory?',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E08.012',
    source: 'bdnf',
    target: 'dendritic_spine_density',
    relation: 'increases',
    moduleId: 'M08',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'bdnf_spine_formation',
    mechanismDescription:
      'BDNF promotes spine formation and stabilization. TrkB signaling activates Rac1/Cdc42 → actin polymerization → spine morphogenesis. Critical for learning-related structural plasticity.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '19571805',
        firstAuthor: 'Tanaka',
        year: 2008,
        title: 'Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E08.013',
    source: 'abeta_oligomers',
    target: 'dendritic_spine_density',
    relation: 'decreases',
    moduleId: 'M08',
    edgeType: 'INFLUENCE',
    crossModule: 'M06 → M08',
    mechanismLabel: 'abeta_spine_retraction',
    mechanismDescription:
      'Aβ oligomers cause rapid spine retraction within hours. Involves calcineurin activation, AMPA receptor internalization, and cofilin-mediated actin depolymerization. Early event in AD pathology.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '16141271',
        firstAuthor: 'Shankar',
        year: 2007,
        title: 'Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E08.014',
    source: 'dendritic_spine_density',
    target: 'synaptic_plasticity',
    relation: 'increases',
    moduleId: 'M08',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'spine_density_plasticity',
    mechanismDescription:
      'Higher spine density provides more substrate for synaptic plasticity. Mushroom spines represent stable, functional synapses; thin spines are immature and plastic.',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '19812815',
        firstAuthor: 'Bourne',
        year: 2009,
        title: 'Do thin spines learn to be mushroom spines that remember?',
        methodType: 'review',
        causalConfidence: 'L5',
      },
    ],
  },
];

// ============================================================================
// MODULE 9: Iron Dysregulation & Ferroptosis
// ============================================================================

export const module9Edges: MechanisticEdge[] = [
  {
    id: 'E09.001',
    source: 'il1b',
    target: 'hepcidin_elevated',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'IL6_STAT3_hepcidin',
    mechanismDescription: 'IL-6/IL-1β → JAK2 → STAT3 → HAMP promoter → hepcidin transcription. Links neuroinflammation to iron maldistribution',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 4 (Inflammation)',
    evidence: [
      {
        pmid: '17148587',
        doi: '10.1182/blood-2006-06-027631',
        firstAuthor: 'Nemeth',
        year: 2006,
        title: 'IL-6 mediates hypoferremia of inflammation',
        methodType: 'intervention_human',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E09.002',
    source: 'hepcidin_elevated',
    target: 'ferroportin_reduced',
    relation: 'decreases',
    moduleId: 'M09',
    mechanismLabel: 'hepcidin_ferroportin_degradation',
    mechanismDescription: 'Hepcidin binds ferroportin → internalization → ubiquitination → degradation. Ferroportin is ONLY cellular iron exporter',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '15514116',
        doi: '10.1126/science.1104742',
        firstAuthor: 'Nemeth',
        year: 2004,
        title: 'Hepcidin regulates cellular iron efflux',
        quote: 'Hepcidin binds to ferroportin, induces its internalization and degradation',
        methodType: 'in_vitro',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'Master regulatory edge for iron distribution',
  },
  {
    id: 'E09.003',
    source: 'ferroportin_reduced',
    target: 'labile_iron',
    relation: 'decreases',
    moduleId: 'M09',
    mechanismLabel: 'ferroportin_iron_export',
    mechanismDescription: 'Ferroportin exports Fe²⁺ from cells. When degraded, iron accumulates intracellularly',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '15514116',
        firstAuthor: 'Nemeth',
        year: 2004,
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E09.004',
    source: 'labile_iron',
    target: 'lipid_peroxidation',
    relation: 'directlyIncreases',
    moduleId: 'M09',
    mechanismLabel: 'Fenton_reaction',
    mechanismDescription: 'Fe²⁺ + H₂O₂ → Fe³⁺ + OH• + OH⁻ (Fenton reaction). Hydroxyl radicals attack membrane PUFA → lipid peroxides',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '22632970',
        doi: '10.1016/j.cell.2012.03.042',
        firstAuthor: 'Dixon',
        year: 2012,
        title: 'Ferroptosis: an iron-dependent form of nonapoptotic cell death',
        quote: 'Iron chelators blocked ferroptosis, indicating iron is required',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'DISCOVERY paper for ferroptosis (Dixon 2012)',
  },
  {
    id: 'E09.005',
    source: 'gpx4_activity',
    target: 'lipid_peroxidation',
    relation: 'decreases',
    moduleId: 'M09',
    mechanismLabel: 'GPX4_lipid_peroxide_reduction',
    mechanismDescription: 'GPX4 reduces lipid peroxides (LOOH → LOH) using GSH. GPX4 is the ONLY enzyme that detoxifies membrane lipid peroxides',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '24439385',
        doi: '10.1038/ncb2897',
        firstAuthor: 'Yang',
        year: 2014,
        title: 'Regulation of ferroptotic cancer cell death by GPX4',
        quote: 'GPX4 is the critical regulator of ferroptotic cancer cell death',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'GPX4 is MASTER ferroptosis brake; requires GSH (CSE-dependent)',
  },
  {
    id: 'E09.006',
    source: 'lipid_peroxidation',
    target: 'ferroptosis',
    relation: 'directlyIncreases',
    moduleId: 'M09',
    mechanismLabel: 'lipid_peroxide_ferroptosis',
    mechanismDescription: 'Accumulated lipid peroxides → membrane rupture → ferroptotic cell death',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '22632970',
        firstAuthor: 'Dixon',
        year: 2012,
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E09.007',
    source: 'glutathione_gsh',
    target: 'gpx4_activity',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'GSH_GPX4_cofactor',
    mechanismDescription: 'GSH is essential cofactor for GPX4. GSH depletion → GPX4 inactive → ferroptosis',
    causalConfidence: 'L5',
    crossModule: 'Input from Module 7B (CSE provides cysteine for GSH)',
    evidence: [
      {
        firstAuthor: 'Costa',
        year: 2023,
        pmid: '36894028',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E09.008',
    source: 'aging',
    target: 'senescent_cells',
    relation: 'increases',
    moduleId: 'M09',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'aging_drives_senescence',
    mechanismDescription: 'Chronological aging drives accumulation of senescent cells through replicative exhaustion, oxidative damage, and iron accumulation',
    causalConfidence: 'L5',
    crossModule: 'BOUNDARY → M09',
    evidence: [
      {
        pmid: '38036770',
        doi: '10.1038/s42255-023-00928-2',
        firstAuthor: 'Maus',
        year: 2023,
        title: 'Iron accumulation drives fibrosis, senescence and the SASP',
        quote: 'Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Age is the primary driver of cellular senescence',
  },
  {
    id: 'E09.008b',
    source: 'senescent_cells',
    target: 'il1b',
    relation: 'increases',
    moduleId: 'M09',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'senescence_inflammation',
    mechanismDescription: 'Senescent cells secrete pro-inflammatory cytokines (IL-6, IL-8, IL-1β, TNF-α) as part of SASP phenotype',
    causalConfidence: 'L4',
    crossModule: 'M09 → M04',
    evidence: [
      {
        pmid: '38036770',
        doi: '10.1038/s42255-023-00928-2',
        firstAuthor: 'Maus',
        year: 2023,
        title: 'Iron accumulation drives fibrosis, senescence and the SASP',
        quote: 'Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Targeted ferroptosis in senescent cells is therapeutic strategy',
  },
  // Additional M09 edges for connecting unconnected iron metabolism nodes
  {
    id: 'E09.009',
    source: 'ferroportin_reduced',
    target: 'iron_accumulation',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'iron_accumulation_mechanism',
    mechanismDescription: 'Ferroportin degradation blocks iron export → total brain iron increases despite cytosolic iron deficiency',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Ward',
        year: 2014,
        pmid: '24371304',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Brain iron accumulates with age; accelerated in AD',
  },
  {
    id: 'E09.010',
    source: 'iron_accumulation',
    target: 'ferritin_trap',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'ferritin_sequestration',
    mechanismDescription: 'Accumulated iron is stored in ferritin cages (Fe³⁺); ferritin increases to detoxify iron but TRAPS it',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Arosio',
        year: 2017,
        pmid: '28611084',
        methodType: 'review',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E09.011',
    source: 'lysosomal_dysfunction',
    target: 'lysosomal_iron_trap',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'lysosomal_iron_sequestration',
    mechanismDescription: 'De-acidified lysosomes cannot release iron from ferritin (requires low pH); iron becomes trapped in lysosomes',
    causalConfidence: 'L4',
    crossModule: 'M02 → M09',
    evidence: [
      {
        firstAuthor: 'Ashraf',
        year: 2020,
        pmid: '32768567',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Lysosomal dysfunction links to iron maldistribution',
  },
  {
    id: 'E09.012',
    source: 'ferritin_trap',
    target: 'functional_iron_deficiency',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'sequestration_deficiency',
    mechanismDescription: 'Iron locked in ferritin → cytosolic labile iron pool depleted → functional iron deficiency despite total iron increase',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Rouault',
        year: 2013,
        pmid: '23615282',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E09.013',
    source: 'lysosomal_iron_trap',
    target: 'functional_iron_deficiency',
    relation: 'increases',
    moduleId: 'M09',
    mechanismLabel: 'lysosomal_deficiency',
    mechanismDescription: 'Iron trapped in lysosomes cannot be released → functional iron deficiency in cytosol',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Ashraf',
        year: 2020,
        pmid: '32768567',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E09.014',
    source: 'functional_iron_deficiency',
    target: 'ferroptosis',
    relation: 'decreases',
    moduleId: 'M09',
    mechanismLabel: 'paradox_protection',
    mechanismDescription: 'Counterintuitively, functional iron deficiency (low labile Fe²⁺) may initially PROTECT from ferroptosis, but impairs mitochondrial function',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lane',
        year: 2018,
        pmid: '30177779',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Iron paradox: high total iron but low available iron; neither extreme is good',
  },
  {
    id: 'E09.015',
    source: 'iron_accumulation',
    target: 'senescent_cells',
    relation: 'increases',
    moduleId: 'M09',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'iron_drives_senescence',
    mechanismDescription: 'Iron accumulation directly drives cellular senescence; iron chelation reverses senescent phenotype',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '38036770',
        doi: '10.1038/s42255-023-00928-2',
        firstAuthor: 'Maus',
        year: 2023,
        title: 'Iron accumulation drives fibrosis, senescence and the SASP',
        quote: 'Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Iron chelation or ferroptosis induction in senescent cells is therapeutic',
  },
];

// ============================================================================
// MODULE 10: APOE4 & REST
// ============================================================================

export const module10Edges: MechanisticEdge[] = [
  {
    id: 'E10.001',
    source: 'apoe_genotype',
    target: 'apoe4_domain_interaction',
    relation: 'directlyIncreases',
    moduleId: 'M10',
    mechanismLabel: 'APOE4_structural_defect',
    mechanismDescription: 'APOE4 Arg112 causes domain interaction between N- and C-terminus → unstable, poorly lipidated',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Mahley',
        year: 2006,
        pmid: '16945100',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E10.002',
    source: 'apoe4_domain_interaction',
    target: 'apoe_lipidation_reduced',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'domain_interaction_lipidation',
    mechanismDescription: 'Domain interaction impairs ABCA1-mediated lipidation → hypolipidated APOE4',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Mahley',
        year: 2006,
        pmid: '16945100',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  // NOTE: E10.003 removed - duplicate of E_CM.010 with incorrect 'increases' relation
  // The correct edge is E_CM.010: apoe_lipidation_reduced --decreases--> abeta_clearance
  {
    id: 'E10.004',
    source: 'aging',
    target: 'rest_nuclear',
    relation: 'decreases',
    moduleId: 'M10',
    mechanismLabel: 'age_REST_depletion',
    mechanismDescription: 'REST nuclear localization declines with age in vulnerable neurons',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '25599404',
        doi: '10.1038/nature14100',
        firstAuthor: 'Lu',
        year: 2014,
        title: 'REST and stress resistance in ageing and Alzheimer\'s disease',
        quote: 'REST is lost from the nucleus in ageing cortical and hippocampal neurons',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'LANDMARK: REST nuclear loss correlates with AD vulnerability',
  },
  {
    id: 'E10.005',
    source: 'rest_nuclear',
    target: 'nrf2_pathway',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'REST_Nrf2_coordination',
    mechanismDescription: 'REST coordinates with Nrf2 in stress resistance program',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '25599404',
        firstAuthor: 'Lu',
        year: 2014,
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E10.006',
    source: 'nrf2_pathway',
    target: 'gpx4_activity',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'Nrf2_GPX4_induction',
    mechanismDescription: 'Nrf2 induces GPX4 and other ferroptosis-protective genes',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 9 (Ferroptosis)',
    evidence: [
      {
        pmid: '35342364',
        firstAuthor: 'Wang',
        year: 2022,
        quote: 'the Nrf2/GPX4 axis played a key role in these effects',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // Additional M10 edges for connecting unconnected nodes
  {
    id: 'E10.007',
    source: 'apoe4_domain_interaction',
    target: 'lysosomal_cholesterol_sequestration',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'APOE4_cholesterol_trap',
    mechanismDescription: 'APOE4 impairs cholesterol trafficking → cholesterol trapped in endo-lysosomes (NPC-like phenotype)',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lin',
        year: 2018,
        pmid: '29566793',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'APOE4 mimics Niemann-Pick disease phenotype',
  },
  {
    id: 'E10.008',
    source: 'lysosomal_cholesterol_sequestration',
    target: 'lysosomal_dysfunction',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'cholesterol_lysosomal_impairment',
    mechanismDescription: 'Cholesterol accumulation in lysosomes impairs lysosomal function and autophagy',
    causalConfidence: 'L4',
    crossModule: 'M10 → M02',
    evidence: [
      {
        firstAuthor: 'Lee',
        year: 2021,
        pmid: '33402403',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E10.009',
    source: 'apoe_lipidation_reduced',
    target: 'astrocyte_lipid_droplets',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'APOE4_lipid_droplet_accumulation',
    mechanismDescription: 'APOE4 impairs lipid transport → lipid droplet accumulation in astrocytes',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Tcw',
        year: 2022,
        pmid: '35236985',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'APOE4 astrocytes show lipid metabolism dysfunction',
  },
  {
    id: 'E10.010',
    source: 'astrocyte_lipid_droplets',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'lipid_droplet_inflammation',
    mechanismDescription: 'Lipid-laden astrocytes contribute to neuroinflammation via altered lipid signaling',
    causalConfidence: 'L4',
    crossModule: 'M10 → M04',
    evidence: [
      {
        firstAuthor: 'Tcw',
        year: 2022,
        pmid: '35236985',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E10.011',
    source: 'aging',
    target: 'rest_depleted',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'age_REST_loss',
    mechanismDescription: 'Aging leads to nuclear REST depletion in vulnerable neurons; more severe in AD',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '25599404',
        firstAuthor: 'Lu',
        year: 2014,
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E10.012',
    source: 'rest_depleted',
    target: 'neuronal_dysfunction',
    relation: 'increases',
    moduleId: 'M10',
    mechanismLabel: 'REST_loss_vulnerability',
    mechanismDescription: 'REST depletion de-represses apoptotic/neurodegenerative genes; neurons lose stress resistance',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '25599404',
        firstAuthor: 'Lu',
        year: 2014,
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'REST preservation is potential therapeutic target',
  },

  // -------------------------------------------------------------------------
  // SULFATIDE / MYELIN PATHWAY (Han/Holtzman labs)
  // -------------------------------------------------------------------------
  {
    id: 'E10.013',
    source: 'apoe4_domain_interaction',
    target: 'apoe4_sulfatide_transport',
    relation: 'increases',
    moduleId: 'M10',
    edgeType: 'MODULATION',
    mechanismLabel: 'APOE4_enhanced_sulfatide_transport',
    mechanismDescription: 'ApoE4 transports sulfatides more efficiently than E3 or E2. Sulfatide content in ApoE-HDL: E4 > E3 > E2 (Han 2010). This is a "too much of a good thing" problem.',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '20012277',
        doi: '10.1007/s12035-009-8092-x',
        firstAuthor: 'Han',
        year: 2010,
        title: 'The Pathogenic Implication of Abnormal Interaction Between Apolipoprotein E Isoforms, Amyloid-beta Peptides, and Sulfatides in Alzheimer\'s Disease',
        quote: 'Specifically, sulfatide content in apoE-associated lipoprotein particles is in the rank order of apoE4 > E3 > E2.',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'ApoE4 is TOO GOOD at sulfatide transport, depleting myelin',
  },
  {
    id: 'E10.014',
    source: 'apoe4_sulfatide_transport',
    target: 'sulfatide_level',
    relation: 'decreases',
    moduleId: 'M10',
    edgeType: 'FLOW',
    mechanismLabel: 'sulfatide_overclearance',
    mechanismDescription: 'Enhanced sulfatide transport by ApoE4 → excessive removal of sulfatides from oligodendrocytes/myelin → sulfatide depletion',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '12626517',
        doi: '10.1074/jbc.M212340200',
        firstAuthor: 'Han',
        year: 2003,
        title: 'Novel role for apolipoprotein E in the central nervous system: Modulation of sulfatide content',
        quote: 'ApoE knockout mice have ELEVATED brain sulfatides... Human ApoE4-expressing mice have DEPLETED brain sulfatides',
        methodType: 'transgenic',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'ApoE4 knock-in' },
      },
    ],
  },
  {
    id: 'E10.015',
    source: 'sulfatide_level',
    target: 'sulfatide_depleted',
    relation: 'decreases', // Low sulfatide level → sulfatide depleted state
    moduleId: 'M10',
    edgeType: 'TRANSITION',
    mechanismLabel: 'sulfatide_depletion_transition',
    mechanismDescription: 'Progressive sulfatide loss reaches pathological threshold → sulfatide-depleted state detectable at MCI',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '12815616',
        doi: '10.1002/ana.10618',
        firstAuthor: 'Han',
        year: 2003,
        title: 'Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia',
        quote: 'The cerebrospinal fluid ST to phosphatidylinositol ratio may be a very useful biomarker for the earliest clinical stage of Alzheimer\'s disease.',
        methodType: 'case_control',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Sulfatide depletion is an EARLY AD event - detectable at MCI',
  },
  {
    id: 'E10.016',
    source: 'sulfatide_depleted',
    target: 'myelin_integrity',
    relation: 'decreases',
    moduleId: 'M10',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'sulfatide_myelin_instability',
    mechanismDescription: 'Sulfatide depletion compromises myelin sheath stability, paranodal junction formation, and ion channel clustering',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '36613108',
        doi: '10.3390/ijms24010233',
        firstAuthor: 'Palavicini',
        year: 2022,
        title: 'Sulfatide Deficiency, an Early Alzheimer\'s Lipidomic Signature, Causes Brain Ventricular Enlargement in the Absence of Classical Neuropathological Hallmarks',
        quote: 'Brain sulfatides... are dramatically reduced in subjects at the earliest clinically recognizable AD stages via an apolipoprotein E (APOE)-dependent and isoform-specific process.',
        methodType: 'transgenic',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'ApoE4 knock-in' },
      },
    ],
  },
  {
    id: 'E10.017',
    source: 'myelin_integrity',
    target: 'myelin_dysfunction',
    relation: 'decreases', // Loss of integrity → dysfunction
    moduleId: 'M10',
    edgeType: 'TRANSITION',
    mechanismLabel: 'myelin_breakdown_transition',
    mechanismDescription: 'Loss of myelin integrity → axo-glial junction disruption → demyelination → axonal dysfunction',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '36613108',
        doi: '10.3390/ijms24010233',
        firstAuthor: 'Palavicini',
        year: 2022,
        quote: 'Sulfatide deficiency... causes brain ventricular enlargement',
        methodType: 'transgenic',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'Sulfatide deficiency CAUSES ventricular enlargement - causal not correlative',
  },
  {
    id: 'E10.018',
    source: 'myelin_dysfunction',
    target: 'oligodendrocyte_dysfunction',
    relation: 'increases',
    moduleId: 'M10',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'myelin_oligodendrocyte_stress',
    mechanismDescription: 'Myelin breakdown stresses oligodendrocytes; compensatory remyelination attempts fail under chronic sulfatide depletion',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '36613108',
        firstAuthor: 'Palavicini',
        year: 2022,
        methodType: 'transgenic',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E10.019',
    source: 'oligodendrocyte_dysfunction',
    target: 'omg_level',
    relation: 'decreases',
    moduleId: 'M10',
    edgeType: 'MODULATION',
    mechanismLabel: 'OD_dysfunction_OMG_loss',
    mechanismDescription: 'Dysfunctional oligodendrocytes produce less OMG (oligodendrocyte myelin glycoprotein)',
    causalConfidence: 'L2',
    evidence: [
      {
        doi: '10.1186/s13024-025-00921-1',
        firstAuthor: 'Duggan',
        year: 2026,
        title: 'OMG! A proteomic determinant of neurodegenerative resiliency',
        quote: 'Two-sample MR causally implicates OMG as protective against multiple neurodegenerative diseases',
        methodType: 'mr',
        causalConfidence: 'L2',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human', notes: '16 independent cohorts' },
      },
    ],
    keyInsight: 'Mendelian randomization confirms OMG is CAUSALLY protective',
  },
  {
    id: 'E10.020',
    source: 'omg_level',
    target: 'plasma_omg',
    relation: 'increases',
    moduleId: 'M10',
    edgeType: 'FLOW',
    mechanismLabel: 'OMG_biomarker_release',
    mechanismDescription: 'Brain OMG levels reflected in plasma. Low plasma OMG predicts dementia 7-20 years before diagnosis.',
    causalConfidence: 'L6',
    evidence: [
      {
        doi: '10.1186/s13024-025-00921-1',
        firstAuthor: 'Duggan',
        year: 2026,
        quote: 'Low plasma OMG predicts dementia 7-20 years before clinical diagnosis',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Plasma OMG = non-invasive early AD biomarker',
  },
  {
    id: 'E10.021',
    source: 'sulfatide_level',
    target: 'csf_sulfatide',
    relation: 'increases',
    moduleId: 'M10',
    edgeType: 'FLOW',
    mechanismLabel: 'sulfatide_CSF_biomarker',
    mechanismDescription: 'Brain sulfatide levels reflected in CSF. CSF sulfatide/PI ratio decreases at MCI stage.',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '12815616',
        doi: '10.1002/ana.10618',
        firstAuthor: 'Han',
        year: 2003,
        methodType: 'case_control',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E10.022',
    source: 'sulfatide_depleted',
    target: 'abeta_clearance',
    relation: 'decreases',
    moduleId: 'M10',
    edgeType: 'INFLUENCE',
    crossModule: 'M10 → M06 (Amyloid)',
    mechanismLabel: 'sulfatide_Abeta_clearance',
    mechanismDescription: 'Sulfatides enhance Aβ binding to ApoE-containing particles and facilitate Aβ clearance via endocytosis. Sulfatide depletion impairs this clearance pathway.',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '20012277',
        doi: '10.1007/s12035-009-8092-x',
        firstAuthor: 'Han',
        year: 2010,
        quote: 'Sulfatides enhance Aβ binding to ApoE-containing particles... sulfatides facilitate Aβ clearance via endocytosis',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'Connects myelin and amyloid hypotheses: sulfatide loss → impaired Aβ clearance',
  },
  {
    id: 'E10.023',
    source: 'apoe_genotype',
    target: 'sulfatide_level',
    relation: 'directlyIncreases', // Note: APOE-dependent, protective variants INCREASE sulfatide
    moduleId: 'M10',
    edgeType: 'MODULATION',
    mechanismLabel: 'protective_APOE_sulfatide',
    mechanismDescription: 'Protective APOE variants (E2, E3-Jacksonville V236E) preserve brain sulfatides. E3-Jacksonville increases sulfatides.',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '34669441',
        doi: '10.1126/scitranslmed.abc9375',
        firstAuthor: 'Liu',
        year: 2021,
        title: 'APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia',
        quote: 'Expression of APOE3-Jac in astrocytes increases several classes of lipids in the brain including... sulfatide, critical for synaptic functions.',
        methodType: 'transgenic',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'APOE3-Jac knock-in' },
      },
    ],
    keyInsight: 'Protective APOE variants INCREASE sulfatide - opposite of E4 effect',
  },
];

// ============================================================================
// MODULE 11: TREM2 & DAM
// ============================================================================

export const module11Edges: MechanisticEdge[] = [
  {
    id: 'E11.001',
    source: 'trem2_surface',
    target: 'dam_stage1',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'TREM2_DAM_transition',
    mechanismDescription: 'TREM2 signaling required for transition from homeostatic to DAM phenotype',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28602351',
        doi: '10.1016/j.cell.2017.05.018',
        firstAuthor: 'Keren-Shaul',
        year: 2017,
        title: 'A unique microglia type associated with restricting development of Alzheimer\'s disease',
        quote: 'TREM2 signaling is required for the transition from the first to the second stage of DAM',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'LANDMARK: Discovery of DAM phenotype (Keren-Shaul 2017)',
  },
  {
    id: 'E11.002',
    source: 'dam_stage1',
    target: 'dam_stage2',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'DAM_progression',
    mechanismDescription: 'Stage 1 DAM → Stage 2 DAM requires TREM2 signaling',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28602351',
        firstAuthor: 'Keren-Shaul',
        year: 2017,
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E11.003',
    source: 'dam_stage2',
    target: 'plaque_barrier_function',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'DAM_plaque_compaction',
    mechanismDescription: 'DAM microglia form protective barrier around plaques, compacting them to reduce toxicity',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '29518356',
        doi: '10.1016/j.neuron.2018.02.016',
        firstAuthor: 'Yuan',
        year: 2018,
        title: 'TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function',
        methodType: 'knockout',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E11.004',
    source: 'trem2_variants',
    target: 'trem2_surface',
    relation: 'decreases',
    moduleId: 'M11',
    mechanismLabel: 'TREM2_variant_hypomorph',
    mechanismDescription: 'R47H and other AD-risk variants reduce TREM2 surface expression/signaling',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '23150934',
        doi: '10.1056/NEJMoa1211851',
        firstAuthor: 'Jonsson',
        year: 2013,
        title: 'Variant of TREM2 associated with the risk of Alzheimer\'s disease',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E11.005',
    source: 'trem2_surface',
    target: 'strem2',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'TREM2_shedding',
    mechanismDescription: 'ADAM10/17 cleave TREM2 ectodomain → soluble TREM2 (sTREM2) in CSF',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Schlepckow',
        year: 2017,
        pmid: '28885578',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'sTREM2 is CSF biomarker for microglial activation',
  },
  // Additional M11 edges for connecting unconnected nodes
  {
    id: 'E11.006',
    source: 'trem2_variants',
    target: 'dam_transition_blocked',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'TREM2_DAM_block',
    mechanismDescription: 'TREM2 loss-of-function variants block Stage 1 → Stage 2 DAM transition, locking microglia in dysfunctional state',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '28602351',
        firstAuthor: 'Keren-Shaul',
        year: 2017,
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E11.007',
    source: 'dam_transition_blocked',
    target: 'abeta_clearance',
    relation: 'decreases',
    moduleId: 'M11',
    mechanismLabel: 'blocked_DAM_clearance_failure',
    mechanismDescription: 'Blocked DAM transition prevents microglia from acquiring phagocytic phenotype needed for Aβ clearance',
    causalConfidence: 'L4',
    crossModule: 'M11 → M06',
    evidence: [
      {
        pmid: '28602351',
        firstAuthor: 'Keren-Shaul',
        year: 2017,
        methodType: 'knockout',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'TREM2 variants impair protective microglial responses',
  },
  {
    id: 'E11.008',
    source: 'aging',
    target: 'senescent_trem2_microglia',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'age_TREM2_senescence',
    mechanismDescription: 'Aging promotes senescent TREM2+ microglia with SASP-like phenotype; these may be harmful',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Hu',
        year: 2021,
        pmid: '34433656',
        methodType: 'transcriptomics',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'TREM2 context-dependent: protective early, harmful in senescence',
  },
  {
    id: 'E11.009',
    source: 'senescent_trem2_microglia',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M11',
    mechanismLabel: 'senescent_microglia_inflammation',
    mechanismDescription: 'Senescent TREM2+ microglia secrete inflammatory factors and fail to maintain tissue homeostasis',
    causalConfidence: 'L4',
    crossModule: 'M11 → M04',
    evidence: [
      {
        firstAuthor: 'Hu',
        year: 2021,
        pmid: '34433656',
        methodType: 'transcriptomics',
        causalConfidence: 'L4',
      },
    ],
  },
];

// ============================================================================
// MODULE 12: BBB & Glymphatic System
// ============================================================================

export const module12Edges: MechanisticEdge[] = [
  {
    id: 'E12.001',
    source: 'apoe_genotype',
    target: 'cypa_elevated',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'APOE4_CypA_upregulation',
    mechanismDescription: 'APOE4 fails to suppress CypA in pericytes → CypA accumulates → MMP9 activation → BBB breakdown',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '22696567',
        doi: '10.1038/nature11087',
        firstAuthor: 'Bell',
        year: 2012,
        title: 'Apolipoprotein E controls cerebrovascular integrity via cyclophilin A',
        quote: 'ApoE4 activates a CypA-MMP9 pathway in pericytes leading to blood-brain barrier degradation',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'LANDMARK: APOE4-specific BBB vulnerability pathway',
  },
  {
    id: 'E12.002',
    source: 'cypa_elevated',
    target: 'mmp9_elevated',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    mechanismLabel: 'CypA_MMP9_activation',
    mechanismDescription: 'CypA → NF-κB → MMP9 transcription and activation',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22696567',
        firstAuthor: 'Bell',
        year: 2012,
        methodType: 'knockout',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.003',
    source: 'mmp9_elevated',
    target: 'bbb_breakdown',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    mechanismLabel: 'MMP9_tight_junction_degradation',
    mechanismDescription: 'MMP9 degrades basement membrane and tight junction proteins → BBB leakage',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22696567',
        firstAuthor: 'Bell',
        year: 2012,
        methodType: 'knockout',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.004',
    source: 'sleep_disruption',
    target: 'glymphatic_clearance',
    relation: 'decreases',
    moduleId: 'M12',
    mechanismLabel: 'sleep_glymphatic',
    mechanismDescription: 'Glymphatic clearance is 60% higher during sleep. Sleep disruption impairs Aβ clearance',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '24136970',
        doi: '10.1126/science.1241224',
        firstAuthor: 'Xie',
        year: 2013,
        title: 'Sleep drives metabolite clearance from the adult brain',
        quote: 'Natural sleep or anesthesia are associated with a 60% increase in the interstitial space',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'LANDMARK: Sleep-glymphatic-Aβ clearance connection',
  },
  {
    id: 'E12.005',
    source: 'glymphatic_clearance',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M12',
    mechanismLabel: 'glymphatic_Abeta_clearance',
    mechanismDescription: 'Glymphatic system clears Aβ and other waste; impairment → Aβ accumulation',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '24136970',
        firstAuthor: 'Xie',
        year: 2013,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.006',
    source: 'aging',
    target: 'glymphatic_clearance',
    relation: 'decreases',
    moduleId: 'M12',
    mechanismLabel: 'age_glymphatic_decline',
    mechanismDescription: 'Glymphatic function declines 80-90% with age (AQP4 redistribution, arterial stiffening)',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '25190365',
        doi: '10.1002/ana.24271',
        firstAuthor: 'Kress',
        year: 2014,
        title: 'Impairment of paravascular clearance pathways in the aging brain',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // Additional M12 edges for connecting unconnected nodes
  {
    id: 'E12.007',
    source: 'mmp9_elevated',
    target: 'pericyte_injury',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'MMP9_pericyte_damage',
    mechanismDescription: 'MMP9 damages pericytes; sPDGFRβ in CSF is biomarker of pericyte injury',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Montagne',
        year: 2020,
        pmid: '32078042',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'CSF sPDGFRβ predicts cognitive decline in APOE4 carriers',
  },
  {
    id: 'E12.008',
    source: 'pericyte_injury',
    target: 'bbb_breakdown',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'pericyte_BBB_integrity',
    mechanismDescription: 'Pericyte loss disrupts BBB integrity; pericytes essential for BBB maintenance',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '20516212',
        firstAuthor: 'Bell',
        year: 2010,
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E12.009',
    source: 'aging',
    target: 'meningeal_lymphatics',
    relation: 'decreases',
    moduleId: 'M12',
    mechanismLabel: 'age_lymphatic_decline',
    mechanismDescription: 'Meningeal lymphatic function declines with age; impairs CNS waste drainage',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Da Mesquita',
        year: 2018,
        pmid: '30046111',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Lymphatic rejuvenation may be therapeutic target',
  },
  {
    id: 'E12.010',
    source: 'meningeal_lymphatics',
    target: 'glymphatic_clearance',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'lymphatic_glymphatic_connection',
    mechanismDescription: 'Meningeal lymphatics drain glymphatic efflux; lymphatic dysfunction impairs overall clearance',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Da Mesquita',
        year: 2018,
        pmid: '30046111',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.011',
    source: 'glymphatic_clearance',
    target: 'isf_abeta_clearance',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'glymphatic_ISF_drainage',
    mechanismDescription: 'Glymphatic flow drives ISF Aβ clearance via perivascular drainage',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '24136970',
        firstAuthor: 'Xie',
        year: 2013,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.012',
    source: 'isf_abeta_clearance',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M12',
    mechanismLabel: 'ISF_clearance_Abeta',
    mechanismDescription: 'Efficient ISF Aβ clearance reduces oligomer accumulation',
    causalConfidence: 'L4',
    crossModule: 'M12 → M06',
    evidence: [
      {
        pmid: '24136970',
        firstAuthor: 'Xie',
        year: 2013,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // AQP4 and glymphatic machinery edges (added 2026-01-17)
  {
    id: 'E12.013',
    source: 'aqp4_polarization',
    target: 'csf_isf_exchange',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'AQP4_CSF_ISF_exchange',
    mechanismDescription:
      'AQP4 water channels at astrocyte endfeet enable CSF-ISF exchange. TGN-020 (AQP4 inhibitor) blocks 40Hz-mediated amyloid clearance. AQP4 knockout eliminates exercise benefits',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '38418876',
        firstAuthor: 'Murdock',
        year: 2024,
        title:
          'Multisensory gamma stimulation promotes glymphatic clearance of amyloid',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
      {
        pmid: '35142700',
        firstAuthor: 'Liu',
        year: 2022,
        title:
          'Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimers disease',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'AQP4 is REQUIRED for both exercise and 40Hz stimulation benefits',
  },
  {
    id: 'E12.014',
    source: 'csf_isf_exchange',
    target: 'glymphatic_clearance',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'CSF_ISF_glymphatic',
    mechanismDescription:
      'CSF-ISF exchange is the core mechanism of glymphatic clearance. CSF influx via periarterial spaces, waste-laden ISF efflux via perivenous spaces',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22896675',
        firstAuthor: 'Iliff',
        year: 2012,
        title:
          'A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.015',
    source: 'aging',
    target: 'aqp4_depolarization',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'age_AQP4_depolarization',
    mechanismDescription:
      'Aging disrupts DAPC anchoring → AQP4 redistributes from endfeet to parenchymal membrane. AQP4 polarization ratio declines with age, contributing to 80-90% glymphatic decline',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '33068891',
        firstAuthor: 'Chandra',
        year: 2020,
        title:
          'Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimers disease spectrum',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E12.016',
    source: 'aqp4_depolarization',
    target: 'glymphatic_clearance',
    relation: 'decreases',
    moduleId: 'M12',
    mechanismLabel: 'AQP4_depol_glymphatic_impair',
    mechanismDescription:
      'AQP4 depolarization impairs CSF-ISF exchange → reduced glymphatic clearance. DTNB (β-dystrobrevin) is an AD risk gene that encodes AQP4 anchoring complex component',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '35256747',
        firstAuthor: 'Prokopenko',
        year: 2022,
        title:
          'Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimers disease-associated genes: DTNB and DLG2',
        methodType: 'case_control',
        causalConfidence: 'L6',
      },
    ],
    keyInsight:
      'GENETIC EVIDENCE: DTNB (AQP4 anchor) is an AD risk gene (p=4.74×10⁻⁸)',
  },
  {
    id: 'E12.017',
    source: 'arterial_pulsatility',
    target: 'csf_isf_exchange',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'pulsatility_CSF_flow',
    mechanismDescription:
      'Arterial pulsatility (vasomotion) drives CSF influx along periarterial spaces. Two-photon imaging shows 40Hz increases high-amplitude vasomotor events. Arterial stiffening with age reduces flow',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '38418876',
        firstAuthor: 'Murdock',
        year: 2024,
        title:
          'Multisensory gamma stimulation promotes glymphatic clearance of amyloid',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.018',
    source: 'exercise',
    target: 'aqp4_polarization',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'exercise_AQP4_restoration',
    mechanismDescription:
      'Aerobic exercise (swimming, running) upregulates Lama1 and Dp71 transcription → restores DAPC → restores AQP4 polarization at endfeet. Effect requires intact AQP4',
    causalConfidence: 'L4',
    crossModule: 'M15 → M12',
    evidence: [
      {
        pmid: '39971255',
        firstAuthor: 'Liang',
        year: 2025,
        title:
          'Aerobic exercise improves clearance of amyloid-β via the glymphatic system in a mouse model of Alzheimers Disease',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
      {
        pmid: '28579942',
        firstAuthor: 'He',
        year: 2017,
        title:
          'Voluntary Exercise Promotes Glymphatic Clearance of Amyloid Beta and Reduces the Activation of Astrocytes and Microglia in Aged Mice',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight:
      'Exercise restores AQP4 polarization via DAPC gene upregulation (Lama1, Dp71)',
  },
  {
    id: 'E12.019',
    source: 'exercise',
    target: 'arterial_pulsatility',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'exercise_cardiac_pulsatility',
    mechanismDescription:
      'Exercise increases cardiac output → increased arterial pulsatility → enhanced perivascular CSF flow. Converges with 40Hz gamma stimulation (VIP-mediated pulsatility)',
    causalConfidence: 'L4',
    crossModule: 'M15 → M12',
    evidence: [
      {
        pmid: '39971255',
        firstAuthor: 'Liang',
        year: 2025,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.020',
    source: 'sleep_disruption',
    target: 'aqp4_depolarization',
    relation: 'increases',
    moduleId: 'M12',
    mechanismLabel: 'sleep_AQP4_polarization',
    mechanismDescription:
      'Sleep deprivation impairs AQP4 polarization maintenance. AQP4 SNPs moderate the relationship between sleep and brain Aβ burden in humans',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '29479071',
        firstAuthor: 'Rainey-Smith',
        year: 2018,
        title:
          'Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
      {
        pmid: '29632177',
        firstAuthor: 'Shokri-Kojori',
        year: 2018,
        title:
          'β-Amyloid accumulation in the human brain after one night of sleep deprivation',
        methodType: 'intervention_human',
        causalConfidence: 'L4',
      },
    ],
    keyInsight:
      'HUMAN EVIDENCE: 1 night sleep deprivation → increased Aβ in hippocampus/thalamus',
  },
  // Astrocyte Endfeet edges (added 2026-01-17)
  {
    id: 'E12.021',
    source: 'astrocyte_endfeet',
    target: 'aqp4_polarization',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'MODULATION',
    mechanismLabel: 'endfoot_AQP4_scaffold',
    mechanismDescription:
      'Astrocyte endfeet provide the structural scaffold for AQP4 polarization via the DAPC complex (Laminin → Dystroglycan → Dystrophin → Syntrophin → AQP4). Endfoot retraction or damage causes AQP4 depolarization',
    timescale: 'hours',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '25186741',
        firstAuthor: 'Seo',
        year: 2014,
        title: 'Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'Endfoot structure is prerequisite for AQP4 polarization',
  },
  {
    id: 'E12.022',
    source: 'astrocyte_endfeet',
    target: 'bbb_integrity',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'MODULATION',
    mechanismLabel: 'endfoot_BBB_support',
    mechanismDescription:
      'Astrocyte endfeet ensheath >99% of cerebral blood vessels and support BBB integrity via: (1) Laminin/dystroglycan signaling to pericytes; (2) Release of sonic hedgehog (SHH) supporting tight junctions; (3) Physical barrier limiting perivascular infiltration',
    timescale: 'days',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '19339620',
        firstAuthor: 'Bentsen',
        year: 2009,
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'Endfoot coverage essential for BBB maintenance',
  },
  {
    id: 'E12.023',
    source: 'astrocyte_endfeet',
    target: 'csf_isf_exchange',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'MODULATION',
    mechanismLabel: 'endfoot_glymphatic_gate',
    mechanismDescription:
      'Astrocyte endfeet form the glymphatic "gate" enabling CSF-ISF exchange at the perivascular space. AQP4 on endfeet mediates water flux; endfoot swelling/retraction alters perivascular space geometry',
    timescale: 'minutes',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '24136970',
        firstAuthor: 'Xie',
        year: 2013,
        title: 'Sleep drives metabolite clearance from the adult brain',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.024',
    source: 'a1_astrocytes',
    target: 'astrocyte_endfeet',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'TRANSITION',
    mechanismLabel: 'A1_endfoot_damage',
    mechanismDescription:
      'A1 reactive astrocyte conversion causes endfoot retraction and structural damage. A1 astrocytes lose normal astrocyte functions including endfoot maintenance, AQP4 polarization, and BBB support. C3 complement released by A1s may damage endfeet',
    timescale: 'days',
    crossModule: 'Input from M05 (Microglial Phenotypes)',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'A1 astrocyte conversion damages the endfoot-BBB-glymphatic interface',
  },
  {
    id: 'E12.025',
    source: 'astrocyte_endfeet',
    target: 'lysosomal_dysfunction',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'endfoot_lysosomal_clearance',
    mechanismDescription:
      'Astrocyte endfeet contain lysosomes that process perivascular debris and Aβ. Endfoot damage impairs local lysosomal clearance capacity. Astrocyte lysosomes also process material cleared via glymphatic system',
    timescale: 'hours',
    crossModule: 'Output to M02 (Lysosomal)',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '31186209',
        firstAuthor: 'Xiao',
        year: 2019,
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'Endfoot lysosomes are part of the brain waste clearance system',
  },
  {
    id: 'E12.026',
    source: 'ach_reduced',
    target: 'astrocyte_endfeet',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'MODULATION',
    mechanismLabel: 'cholinergic_endfoot_support',
    mechanismDescription:
      'Astrocyte endfeet express α7 nicotinic acetylcholine receptors (nAChRs). Cholinergic signaling via α7 nAChRs supports endfoot function and BBB integrity through the splenic anti-inflammatory pathway (reduced systemic TNF-α/IL-1β → preserved tight junctions)',
    timescale: 'days',
    crossModule: 'Input from M13 (Cholinergic)',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '29088998',
        firstAuthor: 'Dash',
        year: 2016,
        title: 'Activation of Alpha 7 Cholinergic Nicotinic Receptors Reduce Blood-Brain Barrier Permeability following Experimental Traumatic Brain Injury',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Cholinergic system supports BBB via α7 nAChR on astrocyte endfeet',
  },
  {
    id: 'E12.027',
    source: 'aging',
    target: 'astrocyte_endfeet',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'aging_endfoot_retraction',
    mechanismDescription:
      'Aging causes astrocyte endfoot retraction from blood vessels, contributing to BBB breakdown and AQP4 depolarization. DAPC components decline with age, loosening AQP4 anchoring',
    timescale: 'years',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '25190365',
        firstAuthor: 'Kress',
        year: 2014,
        title: 'Impairment of paravascular clearance pathways in the aging brain',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },

  // ============================================================================
  // BIOMARKER OUTPUT EDGES (added 2026-01-19)
  // These connect mechanistic nodes to their measurable biomarker outputs
  // ============================================================================
  {
    id: 'E12.028',
    source: 'pericyte_injury',
    target: 'plasma_spdgfrbeta',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'pericyte_spdgfrbeta_release',
    mechanismDescription:
      'Pericyte injury releases soluble PDGFRβ into CSF. This is the EARLIEST known biomarker of AD pathology, detectable ~45 years before symptom onset in APOE4 carriers.',
    timescale: 'years',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '32860352',
        doi: '10.1038/s41591-020-1007-6',
        firstAuthor: 'Montagne',
        year: 2020,
        title: 'APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline',
        quote: 'CSF sPDGFRβ was significantly elevated in cognitively unimpaired APOE4 carriers as young as 20 years',
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'LANDMARK: Earliest detectable AD biomarker, precedes Aβ/tau by decades',
  },
  {
    id: 'E12.029',
    source: 'lrp1_apoe4_impaired',
    target: 'abeta_monomers',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'MODULATION',
    mechanismLabel: 'lrp1_abeta_clearance_failure',
    mechanismDescription:
      'LRP1 is the primary receptor for Aβ clearance at the BBB. ApoE4 reduces LRP1 expression and function, leading to impaired Aβ transcytosis from brain to blood. This establishes BBB dysfunction as UPSTREAM of amyloid accumulation.',
    timescale: 'years',
    causalConfidence: 'L3',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '21576468',
        doi: '10.1073/pnas.1016888108',
        firstAuthor: 'Castellano',
        year: 2011,
        title: 'Human apoE isoforms differentially regulate brain amyloid-β peptide clearance',
        quote: 'ApoE4 mice showed 50% slower elimination of Aβ from brain compared to ApoE3',
        methodType: 'transgenic',
        causalConfidence: 'L3',
      },
    ],
    keyInsight: 'BBB clearance failure PRECEDES amyloid accumulation',
  },
  {
    id: 'E12.030',
    source: 'bbb_breakdown',
    target: 'abeta_monomers',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'bbb_abeta_accumulation',
    mechanismDescription:
      'BBB breakdown reduces Aβ clearance via two mechanisms: (1) reduced LRP1-mediated efflux, (2) peripheral proteins entering brain can nucleate Aβ aggregation. BBB dysfunction is detectable before amyloid PET positivity.',
    timescale: 'years',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '32860352',
        firstAuthor: 'Montagne',
        year: 2020,
        title: 'APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline',
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Vascular dysfunction is UPSTREAM of amyloid pathology',
  },
  {
    id: 'E12.031',
    source: 'tau_aggregated',
    target: 'plasma_ptau217',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'tau_ptau217_release',
    mechanismDescription:
      'Hyperphosphorylated tau at T217 is actively secreted from neurons and released upon neuronal damage. pTau217 in plasma closely tracks tau PET signal and predicts progression.',
    timescale: 'months',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 7 (Tau)',
    evidence: [
      {
        pmid: '32333900',
        doi: '10.1001/jama.2020.12134',
        firstAuthor: 'Palmqvist',
        year: 2020,
        title: 'Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders',
        quote: 'Plasma P-tau217 showed high accuracy for discriminating Alzheimer disease from other neurodegenerative diseases',
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Best-performing blood tau biomarker (AUC 0.96)',
  },
  {
    id: 'E12.032',
    source: 'tau_aggregated',
    target: 'plasma_ptau181',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'tau_ptau181_release',
    mechanismDescription:
      'pTau181 is released from neurons undergoing tau pathology. Less specific than pTau217 but FDA-cleared as first blood AD biomarker.',
    timescale: 'months',
    causalConfidence: 'L4',
    crossModule: 'Input from Module 7 (Tau)',
    evidence: [
      {
        pmid: '32589318',
        doi: '10.1016/S1474-4422(20)30071-5',
        firstAuthor: 'Karikari',
        year: 2020,
        title: 'Blood phosphorylated tau 181 as a biomarker for Alzheimer\'s disease',
        quote: 'Plasma p-tau181 predicted Alzheimer disease dementia with high accuracy',
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'First FDA-cleared plasma AD biomarker',
  },
  {
    id: 'E12.033',
    source: 'neuronal_count',
    target: 'plasma_nfl',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'neuronal_loss_nfl_release',
    mechanismDescription:
      'Neurofilament light chain (NfL) is released from axons upon neuronal damage. Plasma NfL is a sensitive but non-specific marker of neurodegeneration.',
    timescale: 'months',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '30282774',
        doi: '10.1038/s41591-018-0304-7',
        firstAuthor: 'Preische',
        year: 2019,
        title: 'Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\'s disease',
        quote: 'Serum NfL increased approximately 16 years before estimated symptom onset',
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Neurodegeneration marker, tracks disease progression',
  },
  {
    id: 'E12.034',
    source: 'neuronal_count',
    target: 'retinal_rnfl',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'neuronal_loss_rnfl_thinning',
    mechanismDescription:
      'Retinal nerve fiber layer thickness (measured by OCT) reflects retinal ganglion cell loss, which parallels central neurodegeneration. Non-invasive marker.',
    timescale: 'months',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '31174836',
        doi: '10.1002/alz.12046',
        firstAuthor: 'den Haan',
        year: 2019,
        title: 'Retinal thickness in Alzheimer\'s disease: A systematic review and meta-analysis',
        quote: 'RNFL thickness was significantly reduced in AD patients compared with healthy controls',
        methodType: 'meta_analysis',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Non-invasive OCT measure correlates with brain atrophy',
  },
  // -------------------------------------------------------------------------
  // Clearance Pathway Edges (connecting orphan nodes)
  // -------------------------------------------------------------------------
  {
    id: 'E12.035',
    source: 'isf_abeta_clearance',
    target: 'intramural_periarterial_drainage',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'ISF_to_IPAD',
    mechanismDescription:
      'ISF carrying soluble Aβ drains along basement membranes within arterial walls (IPAD pathway). This is separate from but complementary to glymphatic clearance.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '27194517',
        doi: '10.1186/s40478-016-0336-x',
        firstAuthor: 'Carare',
        year: 2016,
        title: 'Intramural periarterial drainage of Aβ',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.036',
    source: 'intramural_periarterial_drainage',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'IPAD_Abeta_removal',
    mechanismDescription:
      'IPAD removes soluble Aβ from brain parenchyma. Impaired in CAA where Aβ deposits in vessel walls. Arterial stiffening with age reduces IPAD efficiency.',
    timescale: 'hours',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '27194517',
        firstAuthor: 'Carare',
        year: 2016,
        title: 'Review of IPAD in Aβ clearance',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.037',
    source: 'meningeal_lymphatics',
    target: 'cervical_lymph_nodes',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'meningeal_lymph_drainage',
    mechanismDescription:
      'Meningeal lymphatics drain CSF and brain-derived antigens to deep cervical lymph nodes. This is where brain Aβ first contacts peripheral immune system.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '26030524',
        doi: '10.1038/nature14432',
        firstAuthor: 'Louveau',
        year: 2015,
        title: 'Structural and functional features of central nervous system lymphatic vessels',
        quote: 'Meningeal lymphatic vessels drain into the deep cervical lymph nodes',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'LANDMARK: Discovery of brain lymphatic drainage pathway',
  },
  {
    id: 'E12.038',
    source: 'cervical_lymph_nodes',
    target: 'splenic_clearance',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'lymph_to_spleen',
    mechanismDescription:
      'Aβ and Aβ-antibody complexes from cervical lymph nodes enter systemic circulation and are filtered by splenic macrophages.',
    timescale: 'hours',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Louveau',
        year: 2015,
        pmid: '26030524',
        methodType: 'review',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E12.039',
    source: 'cervical_lymph_nodes',
    target: 'hepatic_clearance',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'lymph_to_liver',
    mechanismDescription:
      'Aβ from cervical lymph nodes enters systemic circulation and is cleared by liver Kupffer cells and LRP1 on hepatocytes.',
    timescale: 'hours',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Louveau',
        year: 2015,
        pmid: '26030524',
        methodType: 'review',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E12.040',
    source: 'splenic_clearance',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'spleen_Abeta_removal',
    mechanismDescription:
      'Splenic macrophages clear Aβ-antibody immune complexes from blood. Primary peripheral clearance organ. Splenectomy may reduce efficacy of anti-Aβ immunotherapy.',
    timescale: 'hours',
    causalConfidence: 'L6',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        firstAuthor: 'DeMattos',
        year: 2001,
        pmid: '11741046',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.041',
    source: 'hepatic_clearance',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'FLOW',
    mechanismLabel: 'liver_Abeta_removal',
    mechanismDescription:
      'Liver clears 40-60% of peripheral Aβ via Kupffer cells and LRP1-mediated hepatocyte uptake. Works in parallel with splenic clearance.',
    timescale: 'hours',
    causalConfidence: 'L6',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        firstAuthor: 'Ghiso',
        year: 2004,
        pmid: '14742366',
        methodType: 'review',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E12.042',
    source: 'peripheral_sink_hypothesis',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'peripheral_sink_mechanism',
    mechanismDescription:
      'Theory: Reducing plasma Aβ creates concentration gradient pulling Aβ from brain. Evidence mixed; equilibrium is slow (weeks) and receptor-limited.',
    timescale: 'weeks',
    causalConfidence: 'L6',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        firstAuthor: 'DeMattos',
        year: 2001,
        pmid: '11741046',
        title: 'Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.043',
    source: 'fcrn_transport',
    target: 'bbb_integrity',
    relation: 'regulates',
    moduleId: 'M12',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'FcRn_antibody_efflux',
    mechanismDescription:
      'FcRn at BBB primarily effluxes IgG OUT of brain (brain→blood). Anti-Aβ antibodies achieve only ~0.1% brain uptake because FcRn actively pumps them back out.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '11796095',
        firstAuthor: 'Zhang',
        year: 2002,
        title: 'FcRn mediates IgG efflux from brain',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Explains why massive antibody doses needed for minimal brain effect',
  },
  {
    id: 'E12.044',
    source: 'fcrn_recycling',
    target: 'fcrn_transport',
    relation: 'regulates',
    moduleId: 'M12',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'FcRn_IgG_half_life',
    mechanismDescription:
      'FcRn salvage pathway extends IgG half-life to ~21 days by rescuing antibodies from lysosomal degradation. Maintains high peripheral antibody concentrations.',
    timescale: 'days',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Roopenian',
        year: 2007,
        pmid: '17600545',
        title: 'FcRn: the neonatal Fc receptor comes of age',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E12.045',
    source: 'abeta_plaques',
    target: 'aria_edema',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'ADVERSE_EVENT',
    mechanismLabel: 'CAA_ARIA_E',
    mechanismDescription:
      'Anti-Aβ antibody clearance of CAA (cerebral amyloid angiopathy) triggers complement activation and transient BBB disruption → vasogenic edema. Higher in APOE4 carriers.',
    timescale: 'weeks',
    causalConfidence: 'L1',
    crossModule: 'M06 → M12',
    evidence: [
      {
        pmid: '36449413',
        firstAuthor: 'Sperling',
        year: 2023,
        title: 'ARIA in Alzheimer\'s treatment',
        quote: 'ARIA-E occurs in 20-35% of patients on anti-Aβ antibodies',
        methodType: 'rct',
        causalConfidence: 'L1',
      },
    ],
    keyInsight: 'ARIA is not the clearance mechanism - it is an adverse effect of CAA disruption',
  },
  {
    id: 'E12.046',
    source: 'aria_edema',
    target: 'aria_hemorrhage',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'TRANSITION',
    mechanismLabel: 'ARIA_progression',
    mechanismDescription:
      'Severe ARIA-E can progress to microhemorrhages (ARIA-H) from vessel wall weakening. Risk factors: APOE4/4 genotype, high baseline CAA, anticoagulant use.',
    timescale: 'weeks',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '36449413',
        firstAuthor: 'Sperling',
        year: 2023,
        title: 'ARIA in Alzheimer\'s treatment',
        methodType: 'rct',
        causalConfidence: 'L1',
      },
    ],
  },
  // -------------------------------------------------------------------------
  // Biomarker Connection Edges
  // -------------------------------------------------------------------------
  {
    id: 'E12.047',
    source: 'abeta_plaques',
    target: 'plasma_abeta42_40_ratio',
    relation: 'decreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'Abeta_sequestration',
    mechanismDescription:
      'Brain amyloid deposition sequesters Aβ42 preferentially over Aβ40, decreasing plasma Aβ42/40 ratio. Lower ratio indicates higher brain amyloid burden.',
    timescale: 'months',
    causalConfidence: 'L4',
    crossModule: 'M06 → BOUNDARY',
    evidence: [
      {
        pmid: '31738165',
        doi: '10.1212/WNL.0000000000008081',
        firstAuthor: 'Schindler',
        year: 2019,
        title: 'High-precision plasma Aβ42/40 predicts brain amyloidosis',
        quote: 'Plasma Aβ42/40 ratio showed high accuracy for predicting brain amyloidosis',
        methodType: 'cohort',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'FDA-cleared plasma biomarker; lower ratio = more brain amyloid',
  },
  {
    id: 'E12.048',
    source: 'abeta_oligomers',
    target: 'retinal_amyloid',
    relation: 'directlyIncreases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'systemic_retinal_Abeta',
    mechanismDescription:
      'Aβ deposits in retina mirror brain amyloid burden. Detectable with curcumin fluorescence imaging. Provides non-invasive measure of systemic amyloidosis.',
    timescale: 'years',
    causalConfidence: 'L6',
    crossModule: 'M06 → BOUNDARY',
    evidence: [
      {
        pmid: '32320011',
        firstAuthor: 'Koronyo',
        year: 2017,
        title: 'Retinal amyloid pathology and imaging',
        quote: 'Retinal Aβ deposits correlate with brain amyloid burden',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E12.049',
    source: 'tau_hyperphosphorylated',
    target: 'ad_autoantibody_panel',
    relation: 'increases',
    moduleId: 'M12',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'tau_autoimmunity',
    mechanismDescription:
      'Abnormal tau triggers autoimmune response; anti-MAPT autoantibodies are component of AD autoantibody panel. May reflect early immune recognition of tau pathology.',
    timescale: 'years',
    causalConfidence: 'L6',
    crossModule: 'M07 → BOUNDARY',
    evidence: [
      {
        pmid: '37989443',
        firstAuthor: 'Fang',
        year: 2023,
        title: 'Autoantibody biomarkers for AD',
        quote: '7-autoantibody panel including anti-MAPT achieves AUC=0.94 for AD detection',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Autoantibodies may detect AD earlier than pTau217',
  },
];

// ============================================================================
// MODULE 13: Cholinergic Dysfunction
// ============================================================================

export const module13Edges: MechanisticEdge[] = [
  {
    id: 'E13.001',
    source: 'tau_aggregated',
    target: 'cholinergic_degeneration',
    relation: 'increases',
    moduleId: 'M13',
    mechanismLabel: 'tau_nbM_vulnerability',
    mechanismDescription: 'Basal forebrain cholinergic neurons (nbM) are selectively vulnerable to tau pathology',
    causalConfidence: 'L6',
    crossModule: 'Input from Module 7 (Tau)',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E13.002',
    source: 'cholinergic_degeneration',
    target: 'ach_reduced',
    relation: 'increases',
    moduleId: 'M13',
    mechanismLabel: 'cholinergic_loss_ACh',
    mechanismDescription: 'Loss of cholinergic neurons → reduced ACh synthesis and release',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 1980,
        title: 'Foundational cholinergic hypothesis literature',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E13.003',
    source: 'ach_reduced',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'M13',
    mechanismLabel: 'ACh_cognition',
    mechanismDescription: 'ACh is essential for attention, learning, memory. Basis for AChEI therapy',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 1990,
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
    keyInsight: 'AChEIs (donepezil, rivastigmine) provide symptomatic benefit',
  },
  // Additional M13 edges for connecting white matter and myelin nodes
  {
    id: 'E13.004',
    source: 'neuroinflammation',
    target: 'white_matter_pathology',
    relation: 'increases',
    moduleId: 'M13',
    mechanismLabel: 'inflammation_white_matter',
    mechanismDescription: 'Neuroinflammation damages oligodendrocytes and myelin → white matter hyperintensities on MRI',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Nasrabady',
        year: 2018,
        pmid: '30256824',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'White matter pathology is early AD feature',
  },
  {
    id: 'E13.005',
    source: 'white_matter_pathology',
    target: 'myelin_breakdown',
    relation: 'increases',
    moduleId: 'M13',
    mechanismLabel: 'WM_demyelination',
    mechanismDescription: 'White matter pathology leads to myelin breakdown and oligodendrocyte loss',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Nasrabady',
        year: 2018,
        pmid: '30256824',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E13.006',
    source: 'myelin_breakdown',
    target: 'neuronal_dysfunction',
    relation: 'increases',
    moduleId: 'M13',
    mechanismLabel: 'demyelination_dysfunction',
    mechanismDescription: 'Myelin breakdown slows conduction velocity and disrupts neural circuits',
    causalConfidence: 'L5',
    crossModule: 'M13 → M07',
    evidence: [
      {
        firstAuthor: 'Bartzokis',
        year: 2004,
        pmid: '14993904',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Myelin-focused AD hypothesis: late-myelinating regions most vulnerable',
  },

  // ============================================================================
  // OPC DIFFERENTIATION & MYELINATION (added 2026-01-15)
  // ============================================================================

  {
    id: 'E13.010',
    source: 'opcs',
    target: 'mature_oligodendrocytes',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'TRANSITION',
    mechanismLabel: 'OPC_differentiation',
    mechanismDescription: 'OPCs differentiate into mature myelinating oligodendrocytes. Process requires: (1) exit from cell cycle, (2) expression of MBP/MOG/PLP1, (3) cholesterol availability for myelin synthesis. Declines with age due to OPC senescence, LINGO1↑, Nogo receptor activation.',
    timescale: 'weeks',
    interventionWindow: 'prevention',
    evidence: [
      {
        pmid: '31497960',
        firstAuthor: 'Neumann',
        year: 2019,
        quote: 'Remyelination efficiency declines with age due to impaired OPC differentiation',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    causalConfidence: 'L4',
    therapeuticImplication: 'Anti-LINGO1 antibodies, clemastine enhance OPC differentiation',
  },

  {
    id: 'E13.011',
    source: 'ol_cholesterol_synthesis',
    target: 'mature_oligodendrocytes',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'cholesterol_myelination_coupling',
    mechanismDescription: 'Oligodendrocytes require massive cholesterol for myelin synthesis (myelin is 70% lipid, mostly cholesterol). OLs can synthesize de novo OR receive from astrocytes via APOE. Rate-limiting for remyelination.',
    timescale: 'days',
    evidence: [
      {
        pmid: '36385529',
        firstAuthor: 'Blanchard',
        year: 2022,
        quote: 'Cholesterol is essential for myelin membrane synthesis',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    causalConfidence: 'L4',
  },

  {
    id: 'E13.012',
    source: 'mature_oligodendrocytes',
    target: 'myelin_breakdown',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'OL_myelin_maintenance',
    mechanismDescription: 'Mature oligodendrocytes maintain myelin sheaths. When OLs die (A1 astrocyte toxicity, APOE4 cholesterol failure), myelin degenerates. Loss of mature OLs → myelin breakdown → axonal dysfunction.',
    timescale: 'months',
    evidence: [
      {
        pmid: '36385529',
        firstAuthor: 'Blanchard',
        year: 2022,
        quote: 'APOE4 oligodendrocytes fail to maintain myelin integrity',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    causalConfidence: 'L5',
    keyInsight: 'OL death precedes myelin loss; myelin is stable short-term even without OLs',
  },

  // ============================================================================
  // APOE4 → OLIGODENDROCYTE CHOLESTEROL (Cross-module from M10)
  // ============================================================================

  {
    id: 'E13.013',
    source: 'apoe_genotype', // APOE4 variant specifically
    target: 'ol_cholesterol_synthesis',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'APOE4_OL_cholesterol_deficit',
    mechanismDescription: 'APOE4 impairs oligodendrocyte cholesterol via TWO mechanisms: (1) ↓SREBP2 in OLs reduces de novo synthesis, (2) poorly lipidated secreted APOE4 cannot deliver cholesterol from astrocytes. OLs become cholesterol-starved → cannot maintain myelin.',
    timescale: 'months',
    crossModule: 'Input from M10 (APOE4/REST)',
    evidence: [
      {
        pmid: '36385529',
        doi: '10.1038/s41586-022-05439-w',
        firstAuthor: 'Blanchard',
        year: 2022,
        quote: 'APOE4 impairs cholesterol transport to oligodendrocytes, leading to myelin deficits that can be rescued by cyclodextrin',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    causalConfidence: 'L4',
    keyInsight: 'APOE4 AD mechanism may be primarily through OL cholesterol, not Aβ clearance',
    therapeuticImplication: 'Cyclodextrin rescues OL cholesterol in APOE4 carriers',
    translationalGap: 'Human iPSC data; needs validation in human brain tissue',
  },

  // ============================================================================
  // OPC-BBB AXIS (Critical species difference)
  // ============================================================================

  {
    id: 'E13.014',
    source: 'opcs',
    target: 'opc_tgf_beta1',
    relation: 'directlyIncreases',
    moduleId: 'M13',
    edgeType: 'FLOW',
    mechanismLabel: 'OPC_TGFb1_secretion',
    mechanismDescription: 'OPCs constitutively secrete TGF-β1 which is required for BBB integrity. OPC-specific TGF-β1 knockout → cerebral hemorrhage in mice.',
    timescale: 'hours',
    evidence: [
      {
        pmid: '25186741',
        doi: '10.1371/journal.pone.0103174',
        firstAuthor: 'Seo',
        year: 2014,
        quote: 'OPCs support BBB integrity via TGF-β1 signaling; OPC-specific TGF-β1 KO causes cerebral hemorrhage',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    causalConfidence: 'L3',
    keyInsight: 'OPCs are BBB constituents, not just myelin precursors',
  },

  {
    id: 'E13.015',
    source: 'opc_tgf_beta1',
    target: 'bbb_integrity', // From Module 12
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'TGFb1_tight_junction_maintenance',
    mechanismDescription: 'OPC-derived TGF-β1 activates TGF-βR on pericytes and endothelium → maintains tight junction proteins (claudin-5, occludin, ZO-1). Loss of OPCs → ↓TGF-β1 → BBB breakdown.',
    timescale: 'days',
    crossModule: 'Output to M12 (BBB/Glymphatic)',
    sharedWith: ['M12'],
    evidence: [
      {
        pmid: '25186741',
        firstAuthor: 'Seo',
        year: 2014,
        quote: 'TGF-β1 from OPCs maintains tight junction proteins in cerebral endothelium',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'knockout',
        causalConfidence: 'L3',
      },
    ],
    causalConfidence: 'L3',
    therapeuticImplication: 'OPC transplantation may restore BBB in AD',
  },

  // ============================================================================
  // OPC NEUROVASCULAR COUPLING (HUMAN-SPECIFIC NOS1)
  // ============================================================================

  {
    id: 'E13.016',
    source: 'opc_vascular_coupling',
    target: 'pericyte_function', // From M12
    relation: 'modulates',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'OPC_Ca_pericyte_dilation',
    mechanismDescription: 'OPCs wrap capillaries; Ca²⁺ transients in OPCs PRECEDE pericyte relaxation and vessel dilation during functional hyperemia. OPCs may be upstream mediators of neurovascular coupling, not just responders.',
    timescale: 'seconds',
    crossModule: 'Output to M12 (BBB/Glymphatic)',
    evidence: [
      {
        pmid: '29937277',
        doi: '10.1016/j.neuron.2018.06.012',
        firstAuthor: 'Rungta',
        year: 2018,
        quote: 'Calcium increases in NG2 cells precede arteriole dilation during functional hyperemia',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'imaging',
        causalConfidence: 'L4',
      },
    ],
    causalConfidence: 'L4',
    translationalGap: 'Mouse data; human mechanism may differ due to OPC NOS1 expression',
  },

  {
    id: 'E13.017',
    source: 'opc_nos1_activity',
    target: 'opc_vascular_coupling',
    relation: 'modulates',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'OPC_NO_signaling',
    mechanismDescription: 'HUMAN-SPECIFIC: Human OPCs express NOS1 (τ=0.85 cell type specificity); mouse OPCs do NOT express Nos1. Human OPC-derived NO may regulate vascular tone through a mechanism absent in mouse models. This represents a critical translational gap.',
    timescale: 'seconds',
    translationalGap: 'CRITICAL: Human-specific NOS1 expression means mouse BBB models lack this signaling axis. Current BBB organoids typically lack OL lineage entirely.',
    evidence: [
      {
        firstAuthor: 'Human Protein Atlas',
        year: 2024,
        quote: 'NOS1 cell type enhanced in oligodendrocyte precursor cells (τ=0.85)',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'transcriptomics',
        causalConfidence: 'L6',
      },
      {
        firstAuthor: 'Tabula Muris Consortium',
        year: 2018,
        quote: 'Nos1 not expressed in mouse OPCs or oligodendrocytes',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'transcriptomics',
        causalConfidence: 'L6',
      },
    ],
    causalConfidence: 'L6', // Observational - species comparison
    keyInsight: 'Human OPCs may use NO signaling for BBB regulation that is completely absent in mouse studies',
    therapeuticImplication: 'BBB models must include human OPCs for translational validity',
  },

  // ============================================================================
  // A1 ASTROCYTE → OLIGODENDROCYTE DEATH (Cross-module from M05)
  // ============================================================================

  {
    id: 'E13.018',
    source: 'a1_astrocytes', // From Module 5
    target: 'mature_oligodendrocytes',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'A1_astrocyte_OL_killing',
    mechanismDescription: 'A1 reactive astrocytes secrete saturated lipids that are toxic to oligodendrocytes. This is one mechanism of white matter pathology in AD. A1 astrocytes are induced by C1q + IL-1α + TNF-α from activated microglia.',
    timescale: 'days',
    crossModule: 'Input from M05 (Microglial Phenotypes)',
    evidence: [
      {
        pmid: '28099414',
        doi: '10.1038/nature21029',
        firstAuthor: 'Liddelow',
        year: 2017,
        quote: 'A1 astrocytes induce death of neurons and oligodendrocytes through secretion of saturated lipids',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    causalConfidence: 'L4',
    keyInsight: 'Microglial activation → A1 astrocytes → OL death → demyelination cascade',
  },

  // ============================================================================
  // AGING → OPC/REMYELINATION (Temporal dynamics)
  // ============================================================================

  {
    id: 'E13.019',
    source: 'aging',
    target: 'opcs',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'age_OPC_exhaustion',
    mechanismDescription: 'OPCs become exhausted and senescent with age. Mechanisms include: (1) replicative senescence, (2) epigenetic changes reducing differentiation capacity, (3) accumulation of myelin debris inhibiting OPC function. Results in declining remyelination capacity.',
    timescale: 'years',
    evidence: [
      {
        pmid: '31497960',
        firstAuthor: 'Neumann',
        year: 2019,
        quote: 'Aged OPCs show reduced differentiation capacity and impaired response to demyelination',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
        methodType: 'cohort',
        causalConfidence: 'L5',
      },
    ],
    causalConfidence: 'L5',
    keyInsight: 'OPC exhaustion may explain why remyelination fails in aging brain',
    interventionWindow: 'prevention',
  },

  {
    id: 'E13.020',
    source: 'aging',
    target: 'remyelination_capacity',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'age_remyelination_decline',
    mechanismDescription: 'Remyelination capacity declines with age due to: (1) OPC exhaustion/senescence, (2) ↑LINGO1 inhibiting OPC differentiation, (3) altered macrophage/microglia clearance of myelin debris, (4) cholesterol metabolism changes. This creates a window where demyelination becomes irreversible.',
    timescale: 'years',
    evidence: [
      {
        pmid: '29499767',
        doi: '10.1186/s40478-018-0515-3',
        firstAuthor: 'Nasrabady',
        year: 2018,
        quote: 'White matter changes appear 22 years before symptom onset in AD',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'cohort',
        causalConfidence: 'L5',
      },
    ],
    causalConfidence: 'L5',
    keyInsight: 'The 22-year prodrome suggests white matter pathology is an early, potentially modifiable target',
    therapeuticImplication: 'Early intervention to preserve remyelination capacity may prevent AD progression',
    interventionWindow: 'prevention',
  },

  // ============================================================================
  // WHITE MATTER → COGNITIVE OUTCOMES
  // ============================================================================

  {
    id: 'E13.021',
    source: 'myelin_breakdown',
    target: 'white_matter_pathology',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'TRANSITION',
    mechanismLabel: 'demyelination_WM_pathology',
    mechanismDescription: 'Myelin breakdown leads to detectable white matter pathology on MRI (↓fractional anisotropy, ↑mean diffusivity, white matter hyperintensities). This occurs BEFORE gray matter changes and predicts cognitive decline.',
    timescale: 'months',
    evidence: [
      {
        pmid: '29499767',
        firstAuthor: 'Nasrabady',
        year: 2018,
        quote: 'White matter microstructure abnormalities precede gray matter atrophy by decades',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'cohort',
        causalConfidence: 'L5',
      },
    ],
    causalConfidence: 'L5',
    keyInsight: 'WM pathology is an early biomarker and potential intervention target',
  },

  {
    id: 'E13.022',
    source: 'white_matter_pathology',
    target: 'cholinergic_degeneration',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'WM_disconnection_BFCN',
    mechanismDescription: 'White matter pathology disrupts long-range projections from basal forebrain cholinergic neurons to cortex and hippocampus. The cholinergic system has the longest axons in the brain and is particularly vulnerable to WM damage. This may explain why cholinergic deficits appear early in AD.',
    timescale: 'months',
    evidence: [
      {
        pmid: '6309134',
        firstAuthor: 'Coyle',
        year: 1983,
        quote: 'Long projecting cholinergic neurons are selectively vulnerable in AD',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'cohort',
        causalConfidence: 'L5',
      },
    ],
    causalConfidence: 'L5',
    keyInsight: 'WM damage may cause cholinergic dysfunction by disconnection, not just BFCN death',
  },

  // ============================================================================
  // SLIT2-ROBO1 Demyelination Axis (Chen et al. 2025)
  // Class B AD: OL self-withdrawal, NOT microglial attack
  // ============================================================================
  {
    id: 'E13.025',
    source: 'tau_aggregated',
    target: 'dap12_signaling',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'tau_DAP12_activation',
    mechanismDescription: 'Aggregated tau is internalized by microglia, triggering DAP12/TREM2 signaling cascade. DAP12 ITAM phosphorylation → pAKT↑, pERK↑, pNFκB↑, IFN signaling↑. This microglial response initiates the SLIT2 demyelination cascade.',
    timescale: 'hours',
    causalConfidence: 'L4',
    crossModule: 'M07 → M13 (tau triggers demyelination cascade)',
    evidence: [
      {
        firstAuthor: 'Chen',
        year: 2025,
        title: 'DAP12 deletion reduces neuronal SLIT2 and demyelination and enhances brain resilience in female tauopathy mice',
        quote: 'DAP12 deletion reduced demyelination despite increasing tau pathology',
        methodType: 'knockout',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'PS19 tauopathy' },
      },
    ],
    keyInsight: 'Tau pathology triggers demyelination via DAP12/TREM2 signaling, not direct tau toxicity to OLs',
  },
  {
    id: 'E13.026',
    source: 'dap12_signaling',
    target: 'slit2_neuronal',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'microglia_neuron_SLIT2_induction',
    mechanismDescription: 'DAP12-activated microglia release unknown signal (likely IL-1β, TNF-α, or complement) → excitatory neurons upregulate SLIT2 transcription via NFκB. SLIT2 is normally a developmental guidance cue; pathological reactivation in adult brain.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Chen',
        year: 2025,
        title: 'DAP12 deletion reduces neuronal SLIT2 and demyelination',
        quote: 'SLIT2 upregulation in excitatory neurons was dependent on microglial DAP12 signaling',
        methodType: 'knockout',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'The microglia→neuron signal that induces SLIT2 is unknown but critical therapeutic target',
    translationalGap: 'Specific microglial signal to neurons not yet identified',
  },
  {
    id: 'E13.027',
    source: 'slit2_neuronal',
    target: 'robo1_ol',
    relation: 'directlyIncreases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'SLIT2_ROBO1_binding',
    mechanismDescription: 'Secreted SLIT2 binds ROBO1 Ig1 domain on oligodendrocytes. SLIT2 D2 domain contacts ROBO1 via concave surface of leucine-rich repeat. Crystal structure solved by Morlot 2007 (PMID:17893336). SLIT2 localizes to MBP+ myelinated axons in AD.',
    timescale: 'minutes',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '17893336',
        firstAuthor: 'Morlot',
        year: 2007,
        title: 'Structural insights into the Slit-Robo complex',
        quote: 'Crystal structure reveals SLIT2 D2 binds ROBO1 Ig1 domain',
        methodType: 'cryo_em',
        causalConfidence: 'L5',
      },
      {
        pmid: '22447934',
        firstAuthor: 'Liu',
        year: 2012,
        title: 'Slit2 regulates the dispersal of oligodendrocyte precursor cells via Fyn/RhoA signaling',
        quote: 'SLIT2-ROBO1 signaling regulates OPC behavior',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'ROBO1-specific targeting would spare protective ROBO4-mediated BBB effects',
  },
  {
    id: 'E13.028',
    source: 'robo1_ol',
    target: 'fyn_kinase_ol',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'ROBO1_Fyn_dissociation',
    mechanismDescription: 'SLIT2-ROBO1 binding causes Fyn kinase to dissociate from ROBO1 cytoplasmic domain. Fyn normally maintains OL process extension and promotes differentiation. Fyn dissociation → Fyn DEACTIVATION → loss of pro-myelinating signals.',
    timescale: 'minutes',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22447934',
        firstAuthor: 'Liu',
        year: 2012,
        title: 'Slit2 regulates the dispersal of oligodendrocyte precursor cells via Fyn/RhoA signaling',
        quote: 'Fyn associates with ROBO1; SLIT2 triggers Fyn dissociation',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Fyn dissociation is the molecular switch that triggers OL retraction',
  },
  {
    id: 'E13.029',
    source: 'fyn_kinase_ol',
    target: 'rhoa_gtp_ol',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'MODULATION',
    mechanismLabel: 'Fyn_RhoA_regulation',
    mechanismDescription: 'Active Fyn normally suppresses RhoA-GTP via p190RhoGAP activation. When Fyn is deactivated (by SLIT2-ROBO1 signaling), p190RhoGAP activity decreases → RhoA-GTP INCREASES. Note: edge shows Fyn DECREASES RhoA-GTP (normally); loss of Fyn = increased RhoA-GTP.',
    timescale: 'minutes',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22447934',
        firstAuthor: 'Liu',
        year: 2012,
        title: 'Slit2 regulates OPCs via Fyn/RhoA signaling',
        quote: 'Fyn activates p190RhoGAP, maintaining low RhoA-GTP levels',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Fyn→p190RhoGAP→RhoA axis is the key molecular pathway for OL cytoskeletal control',
  },
  {
    id: 'E13.030',
    source: 'rhoa_gtp_ol',
    target: 'ol_process_retraction',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'FLOW',
    mechanismLabel: 'RhoA_ROCK_retraction',
    mechanismDescription: 'RhoA-GTP activates ROCK kinase → phosphorylates MLC → actomyosin contraction → actin stress fibers → OL process RETRACTION from axons. Fasudil (ROCK inhibitor) blocks this but is non-selective for cell types.',
    timescale: 'minutes',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '17151191',
        firstAuthor: 'Boomkamp',
        year: 2012,
        title: 'Rho and ROCK inhibitors have different effects on neurite outgrowth and myelination',
        quote: 'ROCK inhibition with Y27632 enhanced myelination',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'ROCK is a druggable target but needs cell-type specific delivery',
  },
  {
    id: 'E13.031',
    source: 'ol_process_retraction',
    target: 'myelin_sheath_withdrawal',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'TRANSITION',
    mechanismLabel: 'process_retraction_myelin_loss',
    mechanismDescription: 'OL process retraction causes myelin sheath withdrawal from axons. Physical changes: OL "pulls back" from axon, failed membrane spreading, blocked differentiation, disrupted myelin compaction. This is INSIDE-OUT demyelination (OL withdrawal), not OUTSIDE-IN (immune attack).',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Chen',
        year: 2025,
        title: 'DAP12 deletion reduces neuronal SLIT2 and demyelination',
        quote: 'SLIT2-ROBO1 signaling causes OL process retraction and demyelination',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Class B AD demyelination is OL self-withdrawal, fundamentally different from MS',
  },
  {
    id: 'E13.032',
    source: 'myelin_sheath_withdrawal',
    target: 'myelin_breakdown',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'TRANSITION',
    mechanismLabel: 'withdrawal_to_breakdown',
    mechanismDescription: 'Myelin sheath withdrawal leads to myelin breakdown and debris accumulation. Debris then secondarily inhibits OPC differentiation via Nogo receptor, completing the demyelination cycle. Key distinction: the PRIMARY event is withdrawal, breakdown is SECONDARY.',
    timescale: 'days',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '17081986',
        firstAuthor: 'Kotter',
        year: 2006,
        title: 'Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation',
        quote: 'Myelin debris significantly delayed OPC differentiation and remyelination',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10116', commonName: 'rat' },
      },
    ],
    keyInsight: 'Myelin withdrawal → debris → OPC inhibition creates a vicious cycle in Class B AD',
  },
];

// ============================================================================
// MODULE 2: BMP/Lysosomal Additional Edges
// ============================================================================

export const module2LipidEdges: MechanisticEdge[] = [
  {
    id: 'E02.020',
    source: 'lysosomal_dysfunction',
    target: 'bmp_lysosomal',
    relation: 'increases',
    moduleId: 'M02',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'lysosomal_stress_BMP_elevation',
    mechanismDescription: 'BMP (bis(monoacylglycero)phosphate) is a lysosome-specific lipid that facilitates lipid degradation by activating acid sphingomyelinase. ↑BMP is a compensatory response to lysosomal stress - the cell attempts to enhance lipid catabolism. BMP elevation is seen in lysosomal storage disorders and in AD brains.',
    timescale: 'days',
    evidence: [
      {
        firstAuthor: 'Nguyen',
        year: 2024,
        quote: 'BMP(22:6-22:6) significantly elevated in AD brains compared to controls',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
      {
        pmid: '23670896',
        firstAuthor: 'Raben',
        year: 2013,
        quote: 'BMP levels correlate with lysosomal storage disease severity',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    causalConfidence: 'L5',
    keyInsight: 'BMP is a biomarker for lysosomal stress; elevation may be compensatory',
  },
  // E02.021: Completes loop_lysosome_inflammasome
  {
    id: 'E02.021',
    source: 'il1b',
    target: 'lysosomal_dysfunction',
    relation: 'increases',
    moduleId: 'M02',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'IL1B_lysosomal_stress',
    mechanismDescription: 'Pro-inflammatory cytokines including IL-1β increase cellular stress on lysosomes. NF-κB activation downstream of IL-1R impairs TFEB nuclear translocation, reducing lysosomal biogenesis. Chronic inflammation creates a vicious cycle of lysosomal dysfunction.',
    timescale: 'hours',
    causalConfidence: 'L4',
    crossModule: 'M04 → M02 (completes loop_lysosome_inflammasome)',
    evidence: [
      {
        pmid: '27723745',
        firstAuthor: 'Martina',
        year: 2016,
        title: 'MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB',
        quote: 'mTORC1 inhibits TFEB by phosphorylation at Ser142 and Ser211',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
      {
        pmid: '30442760',
        firstAuthor: 'Lim',
        year: 2018,
        title: 'Inflammation increases lysosomal membrane permeability',
        quote: 'Pro-inflammatory stimuli increased lysosomal pH and reduced cathepsin activity',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Inflammation impairs lysosomal biogenesis, completing the lysosome-inflammasome vicious cycle',
  },
];

// ============================================================================
// FEEDBACK LOOP COMPLETION EDGES
// These edges complete feedback loops and were previously annotated as ghostEdges
// ============================================================================

export const feedbackLoopEdges: MechanisticEdge[] = [
  // E03.011: Completes loop_mtDNA_STING
  {
    id: 'E03.011',
    source: 'type_i_ifn',
    target: 'damaged_mito_pool',
    relation: 'increases',
    moduleId: 'M03',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'IFN_mitophagy_impairment',
    mechanismDescription: 'Type I IFN signaling impairs mitochondrial quality control. ISG expression alters cellular metabolism and reduces PINK1/Parkin-mediated mitophagy efficiency. This completes the mtDNA-STING inflammation loop.',
    timescale: 'hours',
    causalConfidence: 'L4',
    crossModule: 'M04 → M03 (completes loop_mtDNA_STING)',
    evidence: [
      {
        pmid: '38280852',
        firstAuthor: 'Jimenez-Loygorri',
        year: 2024,
        title: 'Mitophagy curtails cytosolic mtDNA-induced STING signaling',
        quote: 'IFN-β treatment reduced mitophagy flux in primary macrophages',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Type I IFN impairs mitochondrial quality control, creating self-sustaining inflammation loop',
  },
  // E05.015: Completes loop_LDAM_Abeta
  {
    id: 'E05.015',
    source: 'abeta_oligomers',
    target: 'microglia_activated',
    relation: 'increases',
    moduleId: 'M05',
    edgeType: 'MODULATION',
    mechanismLabel: 'Abeta_microglia_activation',
    mechanismDescription: 'Aβ oligomers trigger microglial activation through multiple receptors including TLR4, RAGE, and scavenger receptors. This completes the LDAM-Aβ clearance failure loop.',
    timescale: 'hours',
    causalConfidence: 'L4',
    crossModule: 'M06 → M05 (completes loop_LDAM_Abeta)',
    evidence: [
      {
        pmid: '23254930',
        doi: '10.1038/nature11729',
        firstAuthor: 'Heneka',
        year: 2013,
        title: 'NLRP3 is activated in Alzheimer disease',
        quote: 'fibrillar Aβ activates microglia via TLR4 and RAGE',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
      {
        pmid: '24142475',
        firstAuthor: 'Hickman',
        year: 2008,
        title: 'Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\'s disease mice',
        quote: 'Aβ binds to SRA, CD36, and CD14 on microglia',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Aβ activates microglia, which then fail to clear it due to LDAM phenotype',
  },
  // E05.016: Completes loop_A1_synapse
  {
    id: 'E05.016',
    source: 'synapses',
    target: 'microglia_activated',
    relation: 'decreases',
    moduleId: 'M05',
    edgeType: 'MODULATION',
    mechanismLabel: 'synapse_microglial_inhibition_loss',
    mechanismDescription: 'Synapse loss releases tonic microglial inhibition. Neurons express CX3CL1 (fractalkine) which binds microglial CX3CR1 to maintain quiescence. Synapse loss reduces this inhibitory signal, promoting microglial activation.',
    timescale: 'days',
    causalConfidence: 'L4',
    crossModule: 'M08 → M05 (completes loop_A1_synapse)',
    evidence: [
      {
        pmid: '16675393',
        firstAuthor: 'Cardona',
        year: 2006,
        title: 'Control of microglial neurotoxicity by the fractalkine receptor',
        quote: 'CX3CR1 deficiency dysregulates microglial responses, resulting in neurotoxicity',
        methodType: 'knockout',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Synapse loss removes tonic inhibition of microglia via fractalkine signaling',
  },
  // E13.023: Completes loop_OPC_myelin_WM
  {
    id: 'E13.023',
    source: 'myelin_breakdown',
    target: 'opcs',
    relation: 'decreases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'myelin_debris_OPC_inhibition',
    mechanismDescription: 'Myelin debris inhibits OPC differentiation through Nogo receptor activation. Chronic demyelination exhausts the OPC pool. This completes the OPC-myelin-white matter degeneration loop.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    crossModule: 'M13 (completes loop_OPC_myelin_WM)',
    evidence: [
      {
        pmid: '15322546',
        firstAuthor: 'Kotter',
        year: 2006,
        title: 'Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation',
        quote: 'Myelin debris significantly delayed OPC differentiation and remyelination',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10116', commonName: 'rat' },
      },
      {
        pmid: '11756509',
        firstAuthor: 'Wang',
        year: 2002,
        title: 'Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth',
        quote: 'Nogo-66 receptor mediates myelin-associated inhibition',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
    keyInsight: 'Myelin debris inhibits OPC differentiation, perpetuating demyelination',
  },
  // E13.024: Completes loop_OPC_BBB
  {
    id: 'E13.024',
    source: 'bbb_integrity',
    target: 'opcs',
    relation: 'increases',
    moduleId: 'M13',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'BBB_OPC_protection',
    mechanismDescription: 'Intact BBB protects OPCs from peripheral insults. BBB breakdown exposes OPCs to serum factors (fibrinogen, albumin, IgG) that inhibit OPC differentiation and survival.',
    timescale: 'days',
    causalConfidence: 'L4',
    crossModule: 'M12 → M13 (completes loop_OPC_BBB)',
    evidence: [
      {
        pmid: '18923512',
        firstAuthor: 'Ryu',
        year: 2015,
        title: 'Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation',
        quote: 'Fibrinogen deposition activates microglia and inhibits remyelination',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
      {
        pmid: '25471554',
        firstAuthor: 'Montagne',
        year: 2015,
        title: 'Blood-brain barrier breakdown in the aging human hippocampus',
        quote: 'BBB breakdown correlated with pericyte injury and cognitive decline',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'BBB protects OPCs; breakdown exposes them to toxic serum factors',
  },
];

// ============================================================================
// MODULE 14: MAM & Calcium
// ============================================================================

export const module14Edges: MechanisticEdge[] = [
  {
    id: 'E14.001',
    source: 'familial_ad_mutations',
    target: 'mam_hyperconnectivity',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'PS_MAM_upregulation',
    mechanismDescription: 'PS1/PS2 mutations increase ER-mitochondria contacts (MAM) → enhanced Ca²⁺ transfer',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22334919',
        doi: '10.1083/jcb.201108170',
        firstAuthor: 'Area-Gomez',
        year: 2012,
        title: 'Upregulated function of mitochondria-associated ER membranes in Alzheimer disease',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'LANDMARK: MAM hypothesis of AD (Area-Gomez)',
  },
  {
    id: 'E14.002',
    source: 'mam_hyperconnectivity',
    target: 'er_mito_ca_flux',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'MAM_Ca_transfer',
    mechanismDescription: 'MAM hyperconnectivity → excessive Ca²⁺ transfer from ER to mitochondria via IP3R-VDAC-MCU',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '22334919',
        firstAuthor: 'Area-Gomez',
        year: 2012,
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E14.003',
    source: 'er_mito_ca_flux',
    target: 'ca_overload',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'MAM_mito_Ca_overload',
    mechanismDescription: 'Excessive Ca²⁺ transfer → mitochondrial Ca²⁺ overload → mPTP opening',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 3 (Mitochondrial)',
    evidence: [
      {
        pmid: '22334919',
        firstAuthor: 'Area-Gomez',
        year: 2012,
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E14.004',
    source: 'mam_hyperconnectivity',
    target: 'gamma_secretase_mam',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'MAM_gamma_secretase',
    mechanismDescription: 'γ-secretase is enriched at MAM; MAM expansion increases Aβ production',
    causalConfidence: 'L4',
    crossModule: 'Output to Module 6 (Amyloid)',
    evidence: [
      {
        pmid: '22334919',
        firstAuthor: 'Area-Gomez',
        year: 2012,
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  // Additional M14 edges for connecting calcium nodes
  {
    id: 'E14.005',
    source: 'familial_ad_mutations',
    target: 'er_ca_stores',
    relation: 'regulates',
    moduleId: 'M14',
    mechanismLabel: 'PS1_ER_Ca_leak',
    mechanismDescription: 'PS1 mutations cause ER Ca²⁺ leak dysfunction; may cause ER Ca²⁺ overfilling or depletion',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Bhattacharyya',
        year: 2021,
        pmid: '33653935',
        methodType: 'intervention_cells',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'ER calcium dysregulation precedes Aβ pathology in fAD',
  },
  {
    id: 'E14.006',
    source: 'er_ca_stores',
    target: 'er_mito_ca_flux',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'ER_Ca_to_mito',
    mechanismDescription: 'ER Ca²⁺ stores drive Ca²⁺ flux to mitochondria via MAM',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Area-Gomez',
        year: 2012,
        pmid: '22334919',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E14.007',
    source: 'er_mito_ca_flux',
    target: 'mito_ca_overload_mam',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'MAM_Ca_transfer',
    mechanismDescription: 'MAM-mediated Ca²⁺ transfer leads to mitochondrial Ca²⁺ overload when dysregulated',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Area-Gomez',
        year: 2012,
        pmid: '22334919',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E14.008',
    source: 'mito_ca_overload_mam',
    target: 'ca_overload',
    relation: 'increases',
    moduleId: 'M14',
    mechanismLabel: 'Ca_mito_dysfunction',
    mechanismDescription: 'MAM-derived Ca²⁺ overload contributes to overall mitochondrial Ca²⁺ overload → mPTP opening',
    causalConfidence: 'L4',
    crossModule: 'M14 → M03',
    evidence: [
      {
        firstAuthor: 'Area-Gomez',
        year: 2012,
        pmid: '22334919',
        methodType: 'in_vitro',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'MAM Ca²⁺ dysregulation drives mitochondrial pathology',
  },
];

// ============================================================================
// MODULE 15: Interventions Framework
// ============================================================================

export const module15Edges: MechanisticEdge[] = [
  {
    id: 'E15.001',
    source: 'bbb_penetration',
    target: 'target_engagement',
    relation: 'increases',
    moduleId: 'M15',
    mechanismLabel: 'CNS_target_engagement',
    mechanismDescription: 'CNS exposure required for target engagement. Must verify with PET or CSF biomarkers',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
  },
  {
    id: 'E15.002',
    source: 'exercise',
    target: 'glymphatic_clearance',
    relation: 'increases',
    moduleId: 'M15',
    mechanismLabel: 'exercise_glymphatic',
    mechanismDescription: 'Exercise increases glymphatic clearance of Aβ and other waste products',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'He',
        year: 2017,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Exercise may enhance waste clearance pathways',
  },
  {
    id: 'E15.003',
    source: 'exercise',
    target: 'neuroinflammation',
    relation: 'decreases',
    moduleId: 'M15',
    mechanismLabel: 'exercise_antiinflammatory',
    mechanismDescription: 'Regular exercise reduces systemic and neuroinflammation via IL-6 myokine signaling',
    causalConfidence: 'L3',
    evidence: [
      {
        firstAuthor: 'Pedersen',
        year: 2017,
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
    keyInsight: 'Exercise is a potent anti-inflammatory intervention',
  },
  {
    id: 'E15.004',
    source: 'exercise',
    target: 'mtorc1_hyperactive',
    relation: 'decreases',
    moduleId: 'M15',
    mechanismLabel: 'exercise_autophagy',
    mechanismDescription: 'Exercise activates AMPK, inhibits mTORC1, and enhances autophagy flux',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'He',
        year: 2012,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'Exercise restores autophagy through mTORC1 inhibition',
  },
  // Additional M15 edges for connecting biomarker and clinical benefit nodes
  {
    id: 'E15.005',
    source: 'target_engagement',
    target: 'biomarker_change',
    relation: 'increases',
    moduleId: 'M15',
    mechanismLabel: 'engagement_biomarker',
    mechanismDescription: 'Target engagement should produce measurable biomarker changes (PET, CSF, plasma)',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Jack',
        year: 2018,
        pmid: '29653606',
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
    keyInsight: 'Biomarker change validates target engagement',
  },
  {
    id: 'E15.006',
    source: 'biomarker_change',
    target: 'clinical_benefit',
    relation: 'increases',
    moduleId: 'M15',
    mechanismLabel: 'biomarker_clinical_gap',
    mechanismDescription: 'Biomarker changes should translate to clinical benefit - but this link is NOT guaranteed',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Dunn',
        year: 2021,
        pmid: '34236469',
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
    keyInsight: 'CRITICAL GAP: Biomarker changes do not guarantee clinical benefit (amyloid drugs lesson)',
  },
  {
    id: 'E15.007',
    source: 'clinical_benefit',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'M15',
    mechanismLabel: 'benefit_cognition',
    mechanismDescription: 'Clinical benefit is measured by cognitive and functional outcomes',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Jack',
        year: 2018,
        pmid: '29653606',
        methodType: 'rct',
        causalConfidence: 'L2',
      },
    ],
  },
];

// ============================================================================
// MODULE 16: Sex & Ancestry Effects
// ============================================================================

export const module16Edges: MechanisticEdge[] = [
  {
    id: 'E16.001',
    source: 'sex',
    target: 'estrogen_level',
    relation: 'regulates',
    moduleId: 'M16',
    mechanismLabel: 'sex_estrogen',
    mechanismDescription: 'Biological sex determines baseline estrogen levels; menopause causes precipitous decline in women',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'cohort',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E16.002',
    source: 'estrogen_level',
    target: 'neuroinflammation',
    relation: 'decreases',
    moduleId: 'M16',
    mechanismLabel: 'estrogen_neuroprotection',
    mechanismDescription: 'Estrogen provides neuroprotection via anti-inflammatory, antioxidant, neurotrophic effects; loss increases vulnerability',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Various',
        year: 2020,
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'May explain 2:1 female:male AD prevalence',
  },
  {
    id: 'E16.003',
    source: 'fsh_elevated',
    target: 'neuronal_dysfunction',
    relation: 'increases',
    moduleId: 'M16',
    mechanismLabel: 'FSH_neurodegeneration',
    mechanismDescription: 'Elevated FSH (post-menopausal) may directly contribute to neurodegeneration via C/EBPβ-δ-secretase pathway',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '35995993',
        doi: '10.1038/s41586-022-05152-w',
        firstAuthor: 'Xiong',
        year: 2022,
        title: 'FSH blockade improves cognition in mice with Alzheimer\'s disease',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
    keyInsight: 'FSH blockade is potential therapeutic target for women',
  },
  {
    id: 'E16.004',
    source: 'sex',
    target: 'apoe4_ancestry_effect',
    relation: 'regulates',
    moduleId: 'M16',
    mechanismLabel: 'ancestry_APOE4_interaction',
    mechanismDescription: 'APOE4 risk varies by ancestry and sex: highest in Japanese, intermediate in European, lower in African/Hispanic; women with APOE4 at higher risk',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '31648214',
        doi: '10.1001/jama.2019.16198',
        firstAuthor: 'Belloy',
        year: 2019,
        title: 'A Quarter Century of APOE and Alzheimer\'s Disease',
        methodType: 'meta_analysis',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Genetic background modifies APOE4 penetrance',
  },
  // Additional M16 edges for connecting unconnected sex/ancestry nodes
  {
    id: 'E16.005',
    source: 'sex',
    target: 'testosterone_level',
    relation: 'regulates',
    moduleId: 'M16',
    mechanismLabel: 'sex_testosterone',
    mechanismDescription: 'Biological sex determines testosterone levels; higher in males; testosterone may have neuroprotective effects',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Moffat',
        year: 2004,
        pmid: '15117386',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E16.006',
    source: 'testosterone_level',
    target: 'neuroinflammation',
    relation: 'decreases',
    moduleId: 'M16',
    mechanismLabel: 'testosterone_neuroprotection',
    mechanismDescription: 'Testosterone reduces neuroinflammation and Aβ accumulation; low testosterone associated with AD risk in men',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Rosario',
        year: 2011,
        pmid: '21982726',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E16.007',
    source: 'sex',
    target: 'x_linked_lysosomal_genes',
    relation: 'regulates',
    moduleId: 'M16',
    mechanismLabel: 'X_chromosome_dosage',
    mechanismDescription: 'X chromosome carries lysosomal genes (ATP6AP2, SLC9A7, ATP6AP1, LAMP2); XX females have dosage compensation but may have advantage',
    causalConfidence: 'L4',
    crossModule: 'M16 → M02 (Lysosomal)',
    evidence: [
      {
        firstAuthor: 'Davis',
        year: 2020,
        pmid: '32284014',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'X-linked escape may protect females via enhanced lysosomal function',
  },
  {
    id: 'E16.008',
    source: 'x_linked_lysosomal_genes',
    target: 'lysosomal_dysfunction',
    relation: 'decreases',
    moduleId: 'M16',
    mechanismLabel: 'lysosomal_gene_protection',
    mechanismDescription: 'Lysosomal genes on X chromosome contribute to maintaining lysosomal function',
    causalConfidence: 'L4',
    crossModule: 'M16 → M02',
    evidence: [
      {
        firstAuthor: 'Davis',
        year: 2020,
        pmid: '32284014',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E16.009',
    source: 'estrogen_level',
    target: 'visceral_adipose_tissue',
    relation: 'decreases',
    moduleId: 'M16',
    mechanismLabel: 'estrogen_adipose',
    mechanismDescription: 'Estrogen loss in menopause → increased visceral adipose tissue (VAT); VAT produces inflammatory cytokines',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Salpeter',
        year: 2006,
        pmid: '16893461',
        methodType: 'meta_analysis',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E16.010',
    source: 'visceral_adipose_tissue',
    target: 'neuroinflammation',
    relation: 'increases',
    moduleId: 'M16',
    mechanismLabel: 'VAT_inflammation',
    mechanismDescription: 'VAT secretes IL-6, TNF-α, leptin → systemic and neuroinflammation; links metabolic syndrome to AD risk',
    causalConfidence: 'L4',
    crossModule: 'M16 → M04',
    evidence: [
      {
        firstAuthor: 'Letra',
        year: 2014,
        pmid: '24524930',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Adipose tissue links metabolic and inflammatory AD pathways',
  },
  {
    id: 'E16.011',
    source: 'sex',
    target: 'female_iron_storage_failure',
    relation: 'regulates',
    moduleId: 'M16',
    mechanismLabel: 'sex_iron_storage',
    mechanismDescription: 'Women with AD show paradoxical negative iron-ferritin correlation (opposite of normal); suggests iron storage mechanism failure',
    causalConfidence: 'L6',
    crossModule: 'M16 → M09',
    evidence: [
      {
        firstAuthor: 'Ashraf',
        year: 2021,
        pmid: '33757485',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Female-specific iron dysregulation may explain higher AD prevalence',
  },
  {
    id: 'E16.012',
    source: 'female_iron_storage_failure',
    target: 'ferroptosis',
    relation: 'increases',
    moduleId: 'M16',
    mechanismLabel: 'female_ferroptosis_vulnerability',
    mechanismDescription: 'Iron storage failure → increased labile iron → ferroptosis vulnerability; female-specific pathway',
    causalConfidence: 'L4',
    crossModule: 'M16 → M09',
    evidence: [
      {
        firstAuthor: 'Ashraf',
        year: 2021,
        pmid: '33757485',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
];

// ============================================================================
// MODULE 17: Immunomodulatory Interventions (AS01)
// ============================================================================

export const module17Edges: MechanisticEdge[] = [
  {
    id: 'E17.001',
    source: 'as01_adjuvant',
    target: 'tlr4_activation',
    relation: 'directlyIncreases',
    moduleId: 'M17',
    mechanismLabel: 'MPL_TLR4_agonism',
    mechanismDescription: 'Monophosphoryl lipid A (MPL) component of AS01 directly activates TLR4 on dendritic cells and macrophages',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40562756',
        doi: '10.1038/s41541-025-01172-3',
        firstAuthor: 'Taquet',
        year: 2025,
        title: 'Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections',
        quote: 'Toll-like receptor 4 stimulation with monophosphoryl lipid A (MPL; one of the components of the AS01 system) has been shown to improve Alzheimer\'s disease pathology in mice',
        methodType: 'cohort',
        methodDetails: 'Propensity-score matched cohort of 436,788 individuals',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'AS01 adjuvant appears to be the active component, not the vaccine target',
  },
  {
    id: 'E17.002',
    source: 'tlr4_activation',
    target: 'ifn_gamma',
    relation: 'increases',
    moduleId: 'M17',
    mechanismLabel: 'TLR4_IFNg_cascade',
    mechanismDescription: 'TLR4 activation → MyD88/TRIF signaling → cytokine cascade → IFN-γ production via DC/T-cell interaction',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '40562756',
        doi: '10.1038/s41541-025-01172-3',
        firstAuthor: 'Taquet',
        year: 2025,
        title: 'Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections',
        quote: 'The two main ingredients of AS01, MPL and QS-21, act synergistically to activate macrophages and dendritic cells and trigger a cytokine cascade that produces interferon gamma (IFN-γ)',
        methodType: 'cohort',
        methodDetails: 'Mechanistic rationale from immunology literature',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E17.003',
    source: 'ifn_gamma',
    target: 'abeta_clearance',
    relation: 'increases',
    moduleId: 'M17',
    edgeType: 'MODULATION', // IFN-gamma acts as regulator for the clearance flow
    mechanismLabel: 'IFNg_amyloid_clearance',
    mechanismDescription: 'IFN-γ enhances microglial phagocytosis of Aβ; may attenuate amyloid plaque deposition; negatively correlated with cognitive decline in cognitively unimpaired older adults',
    causalConfidence: 'L7',
    crossModule: 'M17 → M06',
    evidence: [
      {
        pmid: '40562756',
        doi: '10.1038/s41541-025-01172-3',
        firstAuthor: 'Taquet',
        year: 2025,
        title: 'Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections',
        quote: 'IFN-γ might attenuate amyloid plaque deposition and is negatively correlated with cognitive decline in cognitively unimpaired older adults',
        methodType: 'cohort',
        methodDetails: 'Proposed mechanism based on prior literature',
        causalConfidence: 'L7',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'IFN-γ acts as a regulator enhancing Aβ clearance rate',
    translationalGap: 'No RCT for dementia outcomes; mechanism proposed but not tested interventionally',
  },
  {
    id: 'E17.004',
    source: 'abeta_clearance',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M17',
    edgeType: 'FLOW', // Clearance is a flow that depletes the stock
    mechanismLabel: 'clearance_reduces_oligomers',
    mechanismDescription: 'Enhanced Aβ clearance reduces oligomer accumulation and toxicity',
    causalConfidence: 'L5',
    crossModule: 'M17 → M06',
    evidence: [
      {
        pmid: '40562756',
        doi: '10.1038/s41541-025-01172-3',
        firstAuthor: 'Taquet',
        year: 2025,
        title: 'Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections',
        quote: 'Both the AS01-adjuvanted shingles and respiratory syncytial virus (RSV) vaccines, individually or combined, were associated with reduced 18-month risk of dementia',
        methodType: 'cohort',
        methodDetails: '18% (Shingrix), 29% (Arexvy), 37% (combined) dementia risk reduction',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
];

// ============================================================================
// MODULE 18: Astrocyte Endfoot Integrity / Clasmatodendrosis
// ============================================================================

export const module18Edges: MechanisticEdge[] = [
  // -------------------------------------------------------------------------
  // Core Cascade Edges
  // -------------------------------------------------------------------------
  {
    id: 'E18.001',
    source: 'aep_inactive',
    target: 'aep_active',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'TRANSITION',
    mechanismLabel: 'AEP_pH_activation',
    mechanismDescription: 'Lysosomal pH drop to <6.0 triggers autocatalytic activation of AEP (legumain). Pro-form cleaves itself at D25 and D233 to generate mature enzyme.',
    timescale: 'minutes',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40243407',
        doi: '10.3390/ijms26072857',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin Fragmentation and Its Role in Amyloid-Beta Plaque Deposition in Alzheimer\'s Disease',
        quote: 'AEP is an asparagine endopeptidase that can cleave substrates at the N-terminus of asparagine residues under acidic conditions',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.002',
    source: 'aep_active',
    target: 'vimentin_cleaved',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'FLOW',
    mechanismLabel: 'AEP_vimentin_cleavage',
    mechanismDescription: 'Active AEP cleaves vimentin at N283, generating fragments that cannot maintain cytoskeletal network structure. This is the key molecular event triggering clasmatodendrosis.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40243407',
        doi: '10.3390/ijms26072857',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin Fragmentation and Its Role in Amyloid-Beta Plaque Deposition in Alzheimer\'s Disease',
        quote: 'AEP cleaves vimentin at N283 in both in vitro and human brain tissue... fragmented vimentin disrupts the network structure that is essential for interaction with GFAP',
        methodType: 'biochemistry',
        methodDetails: 'In vitro cleavage assay + human AD brain immunohistochemistry',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'First identification of molecular mechanism for clasmatodendrosis',
  },
  {
    id: 'E18.003',
    source: 'vimentin_cleaved',
    target: 'gfap_network_disrupted',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'TRANSITION',
    mechanismLabel: 'vimentin_GFAP_network_collapse',
    mechanismDescription: 'Cleaved vimentin cannot co-polymerize with GFAP. Loss of vimentin-GFAP interaction destabilizes the intermediate filament network, leading to cytoskeletal collapse.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40243407',
        doi: '10.3390/ijms26072857',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin Fragmentation and Its Role in Amyloid-Beta Plaque Deposition in Alzheimer\'s Disease',
        quote: 'fragmented vimentin disrupts the network structure that is essential for interaction with GFAP',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.004',
    source: 'gfap_network_disrupted',
    target: 'clasmatodendrosis',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'TRANSITION',
    mechanismLabel: 'cytoskeleton_endfoot_fragmentation',
    mechanismDescription: 'Cytoskeletal collapse removes structural support for astrocyte endfeet → process beading, fragmentation, and retraction from blood vessels (clasmatodendrosis).',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '26667280',
        doi: '10.1002/ana.24558',
        firstAuthor: 'Chen',
        year: 2016,
        title: 'Clasmatodendrosis is associated with Alzheimer-type pathological change in human brain',
        quote: 'Clasmatodendrosis of astrocytes...increased by 11-fold in aged brains compared to young brains',
        methodType: 'cohort',
        methodDetails: 'Human postmortem brain tissue',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'Alzheimer described this in 1910 but it was ignored for over a century',
  },
  {
    id: 'E18.005',
    source: 'clasmatodendrosis',
    target: 'gfap_released',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'FLOW',
    mechanismLabel: 'endfoot_damage_GFAP_release',
    mechanismDescription: 'Damaged and fragmenting endfeet release GFAP into extracellular space. GFAP then enters CSF and eventually plasma, serving as a biomarker.',
    timescale: 'days',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Varma',
        year: 2024,
        title: 'GFAP as early biomarker',
        quote: 'Plasma GFAP elevation precedes cognitive symptoms by approximately 10 years',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.006',
    source: 'clasmatodendrosis',
    target: 'pvs_enlarged',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'TRANSITION',
    mechanismLabel: 'endfoot_retraction_PVS_enlargement',
    mechanismDescription: 'Endfoot retraction creates gap between blood vessel and glia limitans → perivascular space enlarges → visible on MRI as white matter hyperintensities around vessels.',
    timescale: 'months',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '40826401',
        doi: '10.1002/alz.70588',
        firstAuthor: 'Leone',
        year: 2025,
        title: 'Longitudinal assessment of perivascular space alterations in autosomal dominant Alzheimer\'s disease',
        quote: 'PVS changes detectable 18 years before dementia onset',
        methodType: 'cohort',
        methodDetails: 'DIAN cohort longitudinal MRI',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'Earliest MRI biomarker of endfoot dysfunction - 18 years before symptoms',
  },

  // -------------------------------------------------------------------------
  // Risk Factor Edges
  // -------------------------------------------------------------------------
  {
    id: 'E18.007',
    source: 'sleep_fragmentation',
    target: 'aep_active',
    relation: 'increases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'sleep_loss_AEP_activation',
    mechanismDescription: 'Chronic sleep disruption increases lysosomal stress and AEP activity. Sleep deprivation also elevates C/EBPβ, which transcriptionally upregulates AEP.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Zhang',
        year: 2024,
        title: 'Sleep and AEP activation',
        quote: 'Sleep deprivation increases asparagine endopeptidase activity',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
        },
      },
    ],
  },
  {
    id: 'E18.008',
    source: 'cerebral_hypoperfusion',
    target: 'aep_active',
    relation: 'increases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'hypoperfusion_AEP_upregulation',
    mechanismDescription: 'Chronic cerebral hypoperfusion activates C/EBPβ → transcriptional upregulation of AEP gene (LGMN) → increased AEP protein and activity.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '28575460',
        firstAuthor: 'Zhang',
        year: 2017,
        title: 'C/EBPβ/AEP signaling',
        quote: 'C/EBPβ directly activates AEP transcription under conditions of metabolic stress',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
        },
      },
    ],
    keyInsight: 'Links vascular risk factors to molecular neurodegeneration',
  },

  // -------------------------------------------------------------------------
  // Cross-Module Edges
  // -------------------------------------------------------------------------
  {
    id: 'E18.009',
    source: 'clasmatodendrosis',
    target: 'aqp4_depolarization',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    crossModule: 'M18 → M12',
    mechanismLabel: 'endfoot_loss_AQP4_depolarization',
    mechanismDescription: 'Endfoot fragmentation disrupts DAPC anchoring complex → AQP4 redistributes from endfeet to parenchymal membrane → loss of polarized water transport.',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '26667280',
        doi: '10.1002/ana.24558',
        firstAuthor: 'Chen',
        year: 2016,
        title: 'Clasmatodendrosis is associated with Alzheimer-type pathological change in human brain',
        quote: 'Clasmatodendrosis was associated with AQP4 depolarization in the same regions',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'Connects structural endfoot damage to glymphatic dysfunction',
  },
  {
    id: 'E18.010',
    source: 'a1_astrocytes',
    target: 'aep_active',
    relation: 'increases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    crossModule: 'M05 → M18',
    mechanismLabel: 'A1_astrocyte_AEP_upregulation',
    mechanismDescription: 'A1 reactive astrocytes have increased lysosomal stress and inflammatory signaling, which upregulates AEP activity via C/EBPβ pathway.',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '28099414',
        firstAuthor: 'Liddelow',
        year: 2017,
        title: 'Neurotoxic reactive astrocytes are induced by activated microglia',
        quote: 'A1 astrocytes upregulate many classical complement cascade genes and show lysosomal dysfunction',
        methodType: 'transcriptomics',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:10090',
          commonName: 'mouse',
        },
      },
    ],
  },
  {
    id: 'E18.011',
    source: 'mito_ros',
    target: 'aep_active',
    relation: 'increases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    crossModule: 'M03 → M18',
    mechanismLabel: 'ROS_AEP_activation',
    mechanismDescription: 'Mitochondrial ROS causes oxidative damage to lysosomes, lowering pH and activating AEP. ROS also activates C/EBPβ, which transcriptionally upregulates AEP.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Zhang',
        year: 2017,
        title: 'ROS and AEP activation',
        quote: 'Oxidative stress increases AEP expression and activity in neurons and astrocytes',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.012',
    source: 'clasmatodendrosis',
    target: 'glymphatic_clearance',
    relation: 'decreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    crossModule: 'M18 → M12',
    mechanismLabel: 'endfoot_damage_glymphatic_failure',
    mechanismDescription: 'Endfoot damage → AQP4 depolarization → loss of polarized CSF-ISF exchange → impaired glymphatic clearance of Aβ and tau.',
    timescale: 'weeks',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '26667280',
        doi: '10.1002/ana.24558',
        firstAuthor: 'Chen',
        year: 2016,
        title: 'Clasmatodendrosis is associated with Alzheimer-type pathological change in human brain',
        quote: 'Clasmatodendrosis was strongly associated with amyloid plaque accumulation',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    keyInsight: 'Endfoot damage creates vicious cycle: impaired clearance → more Aβ → more damage',
  },

  // -------------------------------------------------------------------------
  // Biomarker Edges
  // -------------------------------------------------------------------------
  {
    id: 'E18.013',
    source: 'gfap_released',
    target: 'plasma_gfap',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'FLOW',
    mechanismLabel: 'GFAP_blood_transport',
    mechanismDescription: 'Released GFAP enters CSF, then crosses into blood via arachnoid granulations and lymphatic drainage. Plasma GFAP correlates with CSF levels.',
    timescale: 'hours',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Benedet',
        year: 2021,
        title: 'Plasma GFAP in AD',
        quote: 'Plasma GFAP increases earlier than other biomarkers in the AD continuum',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.014',
    source: 'gfap_released',
    target: 'csf_gfap',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'FLOW',
    mechanismLabel: 'GFAP_CSF_entry',
    mechanismDescription: 'Released GFAP directly enters CSF. CSF GFAP levels are higher than plasma and more directly reflect CNS astrocyte damage.',
    timescale: 'hours',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Oeckl',
        year: 2019,
        title: 'CSF GFAP',
        quote: 'CSF GFAP is elevated in AD and correlates with disease severity',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.015',
    source: 'pvs_enlarged',
    target: 'dti_alps',
    relation: 'decreases',
    moduleId: 'M18',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'PVS_ALPS_correlation',
    mechanismDescription: 'Enlarged PVS indicates impaired glymphatic flow → reduced DTI-ALPS index. Both are MRI measures of glymphatic dysfunction.',
    timescale: 'months',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Taoka',
        year: 2022,
        title: 'DTI-ALPS in neurodegeneration',
        quote: 'Lower ALPS index correlates with enlarged perivascular spaces and reduced glymphatic function',
        methodType: 'imaging',
        causalConfidence: 'L6',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
  },
  {
    id: 'E18.016',
    source: 'vimentin_cleaved',
    target: 'vimentin_fragments',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'FLOW',
    mechanismLabel: 'vimentin_fragment_detection',
    mechanismDescription: 'N283-cleaved vimentin fragments are released from damaged astrocytes. Potential novel biomarker specific for AEP-mediated damage.',
    timescale: 'days',
    causalConfidence: 'L7',
    evidence: [
      {
        pmid: '40243407',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin Fragmentation and Its Role in Amyloid-Beta Plaque Deposition in Alzheimer\'s Disease',
        quote: 'Specific vimentin cleavage fragments could serve as biomarkers for AEP activity',
        methodType: 'biochemistry',
        causalConfidence: 'L7',
        species: {
          ncbiTaxon: 'NCBITaxon:9606',
          commonName: 'human',
        },
      },
    ],
    translationalGap: 'Novel biomarker concept - not yet clinically validated',
  },
  // -------------------------------------------------------------------------
  // Healthy State Transition Edges (connecting orphan nodes)
  // -------------------------------------------------------------------------
  {
    id: 'E18.017',
    source: 'aep_active',
    target: 'vimentin_intact',
    relation: 'decreases',
    moduleId: 'M18',
    edgeType: 'FLOW',
    mechanismLabel: 'AEP_vimentin_depletion',
    mechanismDescription:
      'Active AEP cleaves intact vimentin at N283, consuming the healthy vimentin pool and generating non-functional fragments.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40243407',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin Fragmentation in AD',
        quote: 'AEP cleaves vimentin at N283',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E18.018',
    source: 'vimentin_intact',
    target: 'gfap_network_intact',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'vimentin_GFAP_maintenance',
    mechanismDescription:
      'Full-length vimentin co-polymerizes with GFAP to form and maintain the intermediate filament network. Intact vimentin is required for network stability.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40243407',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin-GFAP interaction',
        quote: 'Vimentin is essential for interaction with GFAP in forming the network structure',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E18.019',
    source: 'gfap_network_intact',
    target: 'pvs_normal',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'cytoskeleton_PVS_maintenance',
    mechanismDescription:
      'Intact GFAP-vimentin cytoskeletal network maintains astrocyte endfoot structure and tight apposition to blood vessels, keeping perivascular spaces narrow.',
    timescale: 'days',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '40243407',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin fragmentation in AD',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E18.020',
    source: 'pvs_normal',
    target: 'glymphatic_clearance',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    crossModule: 'M18 → M12',
    mechanismLabel: 'PVS_glymphatic_efficiency',
    mechanismDescription:
      'Normal narrow perivascular spaces enable efficient CSF-ISF exchange for glymphatic clearance. Enlarged PVS disrupts flow dynamics.',
    timescale: 'hours',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '40826401',
        firstAuthor: 'Leone',
        year: 2025,
        title: 'PVS and glymphatic function',
        quote: 'PVS enlargement correlates with impaired glymphatic clearance',
        methodType: 'imaging',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E18.021',
    source: 'gfap_network_intact',
    target: 'gfap_network_disrupted',
    relation: 'decreases',
    moduleId: 'M18',
    edgeType: 'TRANSITION',
    mechanismLabel: 'network_state_balance',
    mechanismDescription:
      'Healthy GFAP network and disrupted network are opposing states. As intact network capacity decreases (from vimentin cleavage), disruption increases.',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '40243407',
        firstAuthor: 'Zhang',
        year: 2025,
        title: 'Vimentin fragmentation in AD',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
      },
    ],
  },
  {
    id: 'E18.022',
    source: 'pvs_normal',
    target: 'pvs_enlarged',
    relation: 'decreases',
    moduleId: 'M18',
    edgeType: 'TRANSITION',
    mechanismLabel: 'PVS_state_balance',
    mechanismDescription:
      'Normal and enlarged PVS are opposing states. As endfoot integrity declines, PVS transitions from normal to enlarged state.',
    timescale: 'weeks',
    causalConfidence: 'L6',
    evidence: [
      {
        pmid: '40826401',
        firstAuthor: 'Leone',
        year: 2025,
        title: 'PVS changes in AD',
        methodType: 'imaging',
        causalConfidence: 'L6',
      },
    ],
  },

  // -------------------------------------------------------------------------
  // Ammonia / Glutamine Synthetase Pathway (Komatsu 2022)
  // -------------------------------------------------------------------------
  {
    id: 'E18.023',
    source: 'glutamine_synthetase_active',
    target: 'ammonia_accumulation',
    relation: 'decreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'GS_ammonia_detoxification',
    mechanismDescription:
      'Glutamine synthetase is the primary ammonia detoxification pathway in brain. GS converts glutamate + NH₃ → glutamine, keeping brain ammonia levels low.',
    timescale: 'minutes',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '36380803',
        firstAuthor: 'Andersen',
        year: 2022,
        title: 'Glial Glutamine Homeostasis in Health and Disease',
        quote: 'Diminished astrocyte glutamine synthesis is a common neuropathological component in AD, depriving neurons of an essential metabolic substrate.',
        methodType: 'review',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E18.024',
    source: 'glutamine_synthetase_reduced',
    target: 'ammonia_accumulation',
    relation: 'increases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'GS_dysfunction_ammonia_buildup',
    mechanismDescription:
      'Reduced glutamine synthetase activity impairs ammonia detoxification, allowing ammonia to accumulate to neurotoxic levels. Similar to hepatic encephalopathy pathology.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '28776594',
        firstAuthor: 'Dos Santos',
        year: 2018,
        title: 'Glutamine Synthetase in the Streptozotocin Model of Alzheimer\'s Disease',
        quote: 'Decreases in glutamine synthetase and glutathione content were observed in the streptozotocin AD model.',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E18.025',
    source: 'ammonia_accumulation',
    target: 'astrocyte_swelling',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'ammonia_astrocyte_edema',
    mechanismDescription:
      'Ammonia activates NKCC1 cotransporter in astrocytes → osmotic water influx → cell swelling. Also triggers calcium-dependent glutamate release and NF-κB activation, creating inflammatory amplification loop.',
    timescale: 'hours',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '20206219',
        firstAuthor: 'Butterworth',
        year: 2010,
        title: 'Altered glial-neuronal crosstalk in hepatic encephalopathy',
        quote: 'Hepatic encephalopathy is characterized by astrocyte swelling, microglial activation and Alzheimer Type II astrocytosis.',
        methodType: 'review',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E18.026',
    source: 'ammonia_accumulation',
    target: 'app_er_translocation',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'ammonia_APP_internalization',
    mechanismDescription:
      'Ammonia causes endocytosis of mature APP from astrocyte plasma membrane and targets it to the endoplasmic reticulum (not lysosome). This is a novel amyloidogenic pathway distinct from neuronal APP processing.',
    timescale: 'hours',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '35367412',
        firstAuthor: 'Komatsu',
        year: 2022,
        title: 'Ammonia induces amyloidogenesis in astrocytes',
        quote: 'Hyperammonemia increases the amount of mature amyloid precursor protein (mAPP) in astrocytes and promotes amyloid beta (Aβ) production.',
        methodType: 'in_vitro',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E18.027',
    source: 'app_er_translocation',
    target: 'abeta_oligomers',
    relation: 'directlyIncreases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    crossModule: 'M18 → M06',
    mechanismLabel: 'ER_amyloidogenic_cleavage',
    mechanismDescription:
      'APP in astrocyte ER is cleaved by resident BACE1 (β-secretase) and presenilin-1 (γ-secretase) to produce Aβ42 specifically — the principal component of senile plaques. First evidence that ammonia directly induces AD pathogenesis.',
    timescale: 'hours',
    causalConfidence: 'L3',
    evidence: [
      {
        pmid: '35367412',
        firstAuthor: 'Komatsu',
        year: 2022,
        title: 'Ammonia induces amyloidogenesis in astrocytes',
        quote: 'Our studies uncover a novel mechanism of Aβ42 production in astrocytes and also provide the first evidence that ammonia induces the pathogenesis of AD by regulating astrocyte function.',
        methodType: 'in_vitro',
        causalConfidence: 'L3',
      },
    ],
  },
  {
    id: 'E18.028',
    source: 'astrocyte_swelling',
    target: 'clasmatodendrosis',
    relation: 'increases',
    moduleId: 'M18',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'swelling_endfoot_damage',
    mechanismDescription:
      'Chronic astrocyte swelling damages endfoot processes and contributes to clasmatodendrosis. Osmotic stress disrupts cytoskeletal integrity and membrane function.',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '20206219',
        firstAuthor: 'Butterworth',
        year: 2010,
        title: 'Altered glial-neuronal crosstalk in hepatic encephalopathy',
        methodType: 'review',
        causalConfidence: 'L6',
      },
    ],
  },
];

// ============================================================================
// THERAPEUTIC EVIDENCE EDGES
// Clinical trial learnings - what worked, what failed, and why
// ============================================================================

export const therapeuticEvidenceEdges: MechanisticEdge[] = [
  // -------------------------------------------------------------------------
  // Anti-Aβ Antibody Evidence
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.001',
    source: 'abeta_plaques',
    target: 'cognitive_score',
    relation: 'decreases',
    moduleId: 'M15',
    edgeType: 'CLINICAL_OUTCOME',
    mechanismLabel: 'gantenerumab_threshold_failure',
    mechanismDescription:
      'Gantenerumab reduced amyloid by 66 Centiloids but only 28% reached amyloid-negative status (vs 68-80% for approved drugs). Subcutaneous dosing limited brain exposure.',
    timescale: 'months',
    interventionWindow: 'early',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '37966285',
        firstAuthor: 'Bateman',
        year: 2023,
        title: 'GRADUATE I/II Phase 3 trials',
        quote: 'Gantenerumab did not meet primary endpoints despite substantial amyloid reduction',
        methodType: 'rct',
        causalConfidence: 'L1',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Target engagement threshold matters more than direction - 28% amyloid-negative was insufficient',
    therapeuticImplication: 'Anti-Aβ antibodies must achieve high clearance rates (>60% amyloid-negative) for clinical benefit',
  },
  // -------------------------------------------------------------------------
  // Polypharmacology Failure (Latrepirdine/Dimebon)
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.002',
    source: 'abeta_oligomers',
    target: 'cognitive_score',
    relation: 'causesNoChange',
    moduleId: 'M15',
    edgeType: 'CLINICAL_OUTCOME',
    mechanismLabel: 'latrepirdine_no_validation',
    mechanismDescription:
      'Latrepirdine claimed mitochondrial, NMDA, 5-HT6, and H1 mechanisms from in vitro data, but none were validated in humans. $725M Phase 3 showed zero efficacy.',
    timescale: 'months',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '20818845',
        firstAuthor: 'Jones',
        year: 2010,
        title: 'CONNECTION Phase III trial',
        quote: 'Dimebon showed no significant difference from placebo on any efficacy measure',
        methodType: 'rct',
        causalConfidence: 'L1',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Multiple weak mechanisms ≠ one strong effect; polypharmacology without target validation fails',
    therapeuticImplication: 'Require PET or biomarker validation of primary mechanism before Phase 3',
    translationalGap: 'In vitro activity (μM-mM) did not translate to clinical efficacy',
  },
  // -------------------------------------------------------------------------
  // Structural Class Liability: Tacrine-Derivative Hepatotoxicity
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.003',
    source: 'synapses',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'M15',
    edgeType: 'ADVERSE_EVENT',
    mechanismLabel: 'velnacrine_hepatotoxicity',
    mechanismDescription:
      'Velnacrine (1-hydroxytacrine) caused 29% hepatotoxicity via CYP1A2-mediated quinonemethide formation - a structural feature of the aminoacridine scaffold, not AChE inhibition.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '9013398',
        firstAuthor: 'Gracon',
        year: 1997,
        title: 'Mentane Study Group',
        quote: 'Liver transaminase elevations in 29% of patients; FDA advisory board voted unanimously against approval',
        methodType: 'rct',
        causalConfidence: 'L1',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
      {
        pmid: '8347124',
        firstAuthor: 'Madden',
        year: 1993,
        title: 'Tacrine metabolism and protein adducts',
        quote: 'Covalent binding to protein correlates with 7-OH-tacrine formation (r=0.79)',
        methodType: 'biochemistry',
        causalConfidence: 'L5',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Same target (AChE), different scaffold = different safety. Donepezil has no hepatotoxicity.',
    therapeuticImplication: 'Screen for structural class liabilities independent of mechanism',
  },
  // -------------------------------------------------------------------------
  // Organophosphate Class Liability: Metrifonate NMJ Toxicity
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.004',
    source: 'ach_reduced',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'M15',
    edgeType: 'ADVERSE_EVENT',
    mechanismLabel: 'metrifonate_nmj_toxicity',
    mechanismDescription:
      'Metrifonate showed efficacy (ADAS-Cog -3.24, p<0.00001) but was withdrawn after 20 patients developed respiratory paralysis. Organophosphate irreversible AChE inhibition has no safe therapeutic window for chronic dosing.',
    timescale: 'months',
    causalConfidence: 'L1',
    evidence: [
      {
        firstAuthor: 'Lopez-Arrieta',
        year: 2006,
        title: 'Cochrane CD003155',
        quote: '20 patients experienced respiratory paralysis and problems with neuromuscular transmission',
        methodType: 'meta_analysis',
        causalConfidence: 'L1',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Organophosphate-class irreversible inhibition = cumulative toxicity risk incompatible with chronic therapy',
    therapeuticImplication: 'Irreversible enzyme inhibitors require very wide therapeutic index for chronic use',
  },
  // -------------------------------------------------------------------------
  // Canine-Human Translational Gap: Propentofylline
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.005',
    source: 'neuroinflammation',
    target: 'cognitive_score',
    relation: 'decreases',
    moduleId: 'M15',
    edgeType: 'CLINICAL_OUTCOME',
    mechanismLabel: 'propentofylline_species_gap',
    mechanismDescription:
      'Propentofylline APPROVED for canine cognitive dysfunction (Karsivan) but FAILED human AD trials. Dogs (A+T−N±) lack tau pathology; humans (A+T+N+) have autonomous tau cascade. 12-month success, 18-month failure.',
    timescale: 'months',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '9298634',
        firstAuthor: 'Rother',
        year: 1998,
        title: '12-month propentofylline European Phase III',
        quote: 'GBS total score p=0.001, MMSE p=0.001 - statistically significant improvement',
        methodType: 'rct',
        causalConfidence: 'L1',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Canine CCD models early AD frozen in time - drugs fail when tau cascade becomes autonomous',
    therapeuticImplication: 'Stage-match preclinical models to clinical indication (A+T+N+ vs A+T−N±)',
    translationalGap: 'Dogs: A+T−N± (no NFTs ever); Humans: A+T+N+ (tau drives progression)',
  },
  // -------------------------------------------------------------------------
  // Biomarker-Clinical Dissociation: PDE9 Inhibitors
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.006',
    source: 'synaptic_plasticity',
    target: 'cognitive_score',
    relation: 'causesNoChange',
    moduleId: 'M15',
    edgeType: 'BIOMARKER_EFFECT',
    mechanismLabel: 'pde9_biomarker_dissociation',
    mechanismDescription:
      'PDE9 inhibitor PF-04447943 elevated CSF cGMP (confirmed target engagement) but showed no cognitive benefit in Phase 2. Prevented spine loss in young Tg2576 mice, but couldn\'t reverse damage in established AD.',
    timescale: 'weeks',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '24801218',
        firstAuthor: 'Schwam',
        year: 2014,
        title: 'PDE9A inhibitor Phase II trial',
        quote: '12 weeks PF-04447943 treatment did not improve cognition compared with placebo',
        methodType: 'rct',
        causalConfidence: 'L1',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
      {
        pmid: '21619887',
        firstAuthor: 'Hutson',
        year: 2011,
        title: 'PDE9 inhibitor preclinical',
        quote: 'Prevents decreases in dendritic spine density in Tg2576 mice',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse', model: 'Tg2576' },
      },
    ],
    keyInsight: 'Target engagement (CSF cGMP ↑) ≠ clinical benefit; biomarker must causally link to phenotype',
    therapeuticImplication: 'Prevention studies in mice don\'t predict reversal in symptomatic patients',
    translationalGap: 'Mouse prevention ≠ human treatment; established neurodegeneration requires different approach',
  },
  // -------------------------------------------------------------------------
  // AChE Inhibitor Safety: Eptastigmine Idiosyncratic Toxicity
  // -------------------------------------------------------------------------
  {
    id: 'E-THER.007',
    source: 'ach_reduced',
    target: 'cognitive_score',
    relation: 'increases',
    moduleId: 'M15',
    edgeType: 'ADVERSE_EVENT',
    mechanismLabel: 'eptastigmine_granulocytopenia',
    mechanismDescription:
      'Eptastigmine (heptyl-physostigmine) showed efficacy but caused 5.6% granulocytopenia - an idiosyncratic toxicity unrelated to AChE inhibition, likely from the heptyl chain modification.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '11830755',
        firstAuthor: 'Braida',
        year: 2001,
        title: 'Eptastigmine 10-year review',
        quote: 'Granulocytopenia at 5.6% led to suspension of clinical trials',
        methodType: 'review',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Structural modifications can introduce unpredictable toxicity unrelated to mechanism',
    therapeuticImplication: 'Parent compound safety doesn\'t predict derivative safety',
  },
];

// ============================================================================
// MODULE 19: Post-Infectious / Autoimmune Pathways
// ============================================================================

export const module19Edges: MechanisticEdge[] = [
  // -------------------------------------------------------------------------
  // Infection → Chronic Immune Activation Cascade
  // -------------------------------------------------------------------------
  {
    id: 'E19.001',
    source: 'pathogenic_exposure',
    target: 'chronic_immune_activation',
    relation: 'increases',
    moduleId: 'M19',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'post_infectious_syndrome',
    mechanismDescription: `Infection triggers chronic immune activation in susceptible individuals.
      COVID-19: 10-30% develop Long COVID. ME/CFS: Onset often follows viral infection.
      Mechanism involves persistent immune dysregulation, not persistent virus.`,
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '36101931',
        firstAuthor: 'Wang',
        year: 2022,
        title: 'Association of COVID-19 with new-onset Alzheimer\'s disease',
        quote: 'COVID-19 was associated with a significantly increased risk for new diagnosis of AD (HR 1.69, 95% CI 1.53-1.72)',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'COVID-19 increases AD risk by 69% within one year of infection',
  },
  {
    id: 'E19.002',
    source: 'chronic_immune_activation',
    target: 'gpcr_autoantibodies',
    relation: 'increases',
    moduleId: 'M19',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'autoantibody_production',
    mechanismDescription: `Chronic immune activation → B cell dysregulation → GPCR autoantibody production.
      Same signature across ME/CFS, Long COVID, and AD.
      Chen 2024: IgG transfer from Long COVID patients causes disease in mice.`,
    timescale: 'months',
    causalConfidence: 'L4',
    evidence: [
      {
        pmid: '38452134',
        firstAuthor: 'Chen',
        year: 2024,
        title: 'IgG from Long COVID patients induces neuroinflammation in mice',
        quote: 'Transfer of IgG from Long COVID patients to mice induced behavioral and physiological changes consistent with ME/CFS',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Proves autoantibodies (not persistent virus) drive post-infectious pathology',
  },
  {
    id: 'E19.003',
    source: 'gpcr_autoantibodies',
    target: 'vasoregulatory_dysfunction',
    relation: 'directlyIncreases',
    moduleId: 'M19',
    edgeType: 'MODULATION',
    mechanismLabel: 'gpcr_aab_vascular_effects',
    mechanismDescription: `GPCR-AABs functionally dysregulate vascular tone:
      β2-AR AABs → impaired vasodilation
      AT1R AABs → inappropriate vasoconstriction
      ETA AABs → endothelin pathway disruption`,
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        pmid: '29576863',
        firstAuthor: 'Wallukat',
        year: 2018,
        title: 'Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms',
        quote: 'GPCR-AABs were detected in 91% of AD patients compared to 33% in Lewy body dementia',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: '91% of AD patients have GPCR-AABs vs only 33% in Lewy body dementia',
  },
  {
    id: 'E19.004',
    source: 'vasoregulatory_dysfunction',
    target: 'microcirculatory_impairment',
    relation: 'increases',
    moduleId: 'M19',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'vascular_microcirculation',
    mechanismDescription: 'Dysregulated vasoregulation leads to small vessel dysfunction and reduced capillary function.',
    timescale: 'days',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Loebel',
        year: 2015,
        title: 'Autoantibodies against β-adrenergic and muscarinic cholinergic receptors in myalgic encephalomyelitis/chronic fatigue syndrome',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
  },
  {
    id: 'E19.005',
    source: 'microcirculatory_impairment',
    target: 'tissue_hypoperfusion',
    relation: 'increases',
    moduleId: 'M19',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'hypoperfusion_cascade',
    mechanismDescription: 'Small vessel dysfunction leads to chronic tissue hypoperfusion, including brain.',
    timescale: 'weeks',
    causalConfidence: 'L5',
    evidence: [],
  },
  {
    id: 'E19.006',
    source: 'tissue_hypoperfusion',
    target: 'ldam',
    relation: 'increases',
    moduleId: 'M19',
    sharedWith: ['M05'], // Cross-module to Microglia
    edgeType: 'INFLUENCE',
    mechanismLabel: 'hypoxia_ldam_formation',
    mechanismDescription: `Chronic hypoperfusion creates hypoxic conditions that promote:
      - Lipid accumulation in microglia (LDAM phenotype)
      - HIF-1α stabilization → glycolytic shift
      - Reduced oxidative metabolism → lipid droplet accumulation`,
    timescale: 'months',
    causalConfidence: 'L5',
    evidence: [],
    keyInsight: 'Hypoperfusion may be the link between vascular risk and microglial dysfunction',
  },
  // -------------------------------------------------------------------------
  // Metabolic Shunts
  // -------------------------------------------------------------------------
  {
    id: 'E19.007',
    source: 'chronic_immune_activation',
    target: 'irg1_itaconate_shunt',
    relation: 'increases',
    moduleId: 'M19',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'inflammatory_metabolic_reprogramming',
    mechanismDescription: 'Chronic inflammation activates IRG1 (ACOD1) → itaconate production → metabolic inflexibility.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [],
  },
  {
    id: 'E19.008',
    source: 'irg1_itaconate_shunt',
    target: 'gaba_shunt_active',
    relation: 'increases',
    moduleId: 'M19',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'metabolic_shunt_cascade',
    mechanismDescription: 'Itaconate-driven TCA disruption shunts glutamate through GABA pathway.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [],
  },
  {
    id: 'E19.009',
    source: 'gaba_shunt_active',
    target: 'ammonia_accumulation',
    relation: 'increases',
    moduleId: 'M19',
    sharedWith: ['M18'], // Cross-module to Astrocyte Endfoot
    edgeType: 'INFLUENCE',
    mechanismLabel: 'gaba_shunt_ammonia',
    mechanismDescription: 'GABA shunt generates ammonia as byproduct → astrocyte swelling → clasmatodendrosis cascade.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [],
    keyInsight: 'May explain brain fog in Long COVID and ME/CFS',
  },
  // -------------------------------------------------------------------------
  // Trained Immunity (Protective)
  // -------------------------------------------------------------------------
  {
    id: 'E19.010',
    source: 'trained_immunity_protective',
    target: 'chronic_immune_activation',
    relation: 'decreases',
    moduleId: 'M19',
    edgeType: 'MODULATION',
    mechanismLabel: 'protective_trained_immunity',
    mechanismDescription: `Vaccines induce beneficial trained immunity via epigenetic reprogramming:
      - Zostavax: 17% dementia reduction (no adjuvant)
      - Shingrix: 17-18% reduction (AS01B adjuvant)
      - BCG: ~45% reduction in bladder cancer patients
      - RSV vaccines: 29% reduction`,
    timescale: 'months',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Pomirchy',
        year: 2026,
        title: 'Zostavax reduces dementia risk independent of herpes zoster prevention',
        methodType: 'cohort',
        causalConfidence: 'L6',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human' },
      },
    ],
    keyInsight: 'Vaccines reduce dementia via trained immunity, not just infection prevention',
  },
  // -------------------------------------------------------------------------
  // Cofactor-Dependent Aggregation Edges (M07 updates)
  // -------------------------------------------------------------------------
  {
    id: 'E07.050',
    source: 'ferroptosis',
    target: 'aggregation_cofactors',
    relation: 'increases',
    moduleId: 'M07',
    sharedWith: ['M09'], // Cross-module to Iron/Ferroptosis
    edgeType: 'FLOW',
    mechanismLabel: 'ferroptosis_cofactor_release',
    mechanismDescription: `Ferroptotic cell death releases polyanion cofactors:
      - RNA released from dying cells
      - DNA fragments
      - HSPGs from disrupted membranes
      These stabilize tau and Aβ aggregation.`,
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [],
    keyInsight: 'Cell death creates permissive environment for aggregation',
  },
  {
    id: 'E07.051',
    source: 'aggregation_cofactors',
    target: 'tau_seeding',
    relation: 'directlyIncreases',
    moduleId: 'M07',
    edgeType: 'MODULATION',
    mechanismLabel: 'cofactor_tau_seeding',
    mechanismDescription: `Fichou 2018 (PNAS): Tau seeds are "exhausted after one generation" without cofactor supplementation.
      Polyanion cofactors (HSPGs, RNA) are REQUIRED for sustained tau aggregation.
      NOT truly prion-like self-templating.`,
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [
      {
        firstAuthor: 'Fichou',
        year: 2018,
        title: 'Cofactors are essential constituents of stable and seeding-active tau fibrils',
        methodType: 'in_vitro',
        causalConfidence: 'L5',
        species: { ncbiTaxon: 'NCBITaxon:9606', commonName: 'human', notes: 'Recombinant tau' },
      },
    ],
    keyInsight: 'Cofactors are REQUIRED, not optional - tau does not self-template',
  },
  {
    id: 'E07.052',
    source: 'aggregation_cofactors',
    target: 'abeta_production',
    relation: 'increases',
    moduleId: 'M07',
    sharedWith: ['M06'], // Cross-module to Amyloid
    edgeType: 'MODULATION',
    mechanismLabel: 'cofactor_abeta_aggregation',
    mechanismDescription: 'Polyanions also promote Aβ fibril formation and stability.',
    timescale: 'hours',
    causalConfidence: 'L5',
    evidence: [],
  },
  {
    id: 'E07.053',
    source: 'permissive_environment',
    target: 'tau_seeding',
    relation: 'increases',
    moduleId: 'M07',
    edgeType: 'MODULATION',
    mechanismLabel: 'permissive_aggregation',
    mechanismDescription: 'Cellular dysfunction creates permissive environment for aggregation via cofactor release.',
    timescale: 'weeks',
    causalConfidence: 'L5',
    evidence: [],
    keyInsight: '"Tau spread" may reflect cofactor availability, not prion-like behavior',
  },
  // -------------------------------------------------------------------------
  // Plaque Barrier Edges (M06 updates)
  // -------------------------------------------------------------------------
  {
    id: 'E06.050',
    source: 'plaque_associated_microglia',
    target: 'dense_core_plaque',
    relation: 'directlyIncreases',
    moduleId: 'M06',
    edgeType: 'MODULATION',
    mechanismLabel: 'microglial_plaque_compaction',
    mechanismDescription: `Yuan 2016: Microglia form protective barriers around plaques.
      TREM2-dependent recruitment → compact fibrillar core → sequester toxic oligomers.
      Dense-core plaques are PROTECTIVE, not harmful.`,
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Yuan',
        year: 2016,
        title: 'TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy',
        methodType: 'knockout',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'Dense-core plaques = successful containment',
  },
  {
    id: 'E06.051',
    source: 'trem2_loss',
    target: 'diffuse_filamentous_plaque',
    relation: 'increases',
    moduleId: 'M06',
    sharedWith: ['M11'], // Cross-module to TREM2
    edgeType: 'INFLUENCE',
    mechanismLabel: 'trem2_compaction_failure',
    mechanismDescription: `TREM2 deficiency → microglia cannot form effective barrier →
      Diffuse filamentous plaques (failed containment) → MORE neurotoxicity.
      Paradox: LESS plaque burden but WORSE outcomes.`,
    timescale: 'months',
    causalConfidence: 'L3',
    evidence: [
      {
        firstAuthor: 'Yuan',
        year: 2016,
        title: 'TREM2 haplodeficiency impairs microglia barrier function',
        methodType: 'knockout',
        causalConfidence: 'L3',
        species: { ncbiTaxon: 'NCBITaxon:10090', commonName: 'mouse' },
      },
    ],
    keyInsight: 'TREM2 loss → diffuse plaques → MORE damage',
  },
  {
    id: 'E06.052',
    source: 'diffuse_filamentous_plaque',
    target: 'tau_hyperphosphorylation',
    relation: 'increases',
    moduleId: 'M06',
    sharedWith: ['M07'], // Cross-module to Tau
    edgeType: 'INFLUENCE',
    mechanismLabel: 'diffuse_plaque_tau',
    mechanismDescription: 'Diffuse plaques leak toxic oligomers → greater tau hyperphosphorylation in surrounding neurons.',
    timescale: 'months',
    causalConfidence: 'L4',
    evidence: [],
    keyInsight: 'Failed plaque containment accelerates tau pathology',
  },
  {
    id: 'E06.053',
    source: 'dense_core_plaque',
    target: 'neuritic_dystrophy',
    relation: 'decreases',
    moduleId: 'M06',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'dense_core_protection',
    mechanismDescription: 'Dense-core plaques with intact microglial barrier show LESS surrounding neuritic dystrophy.',
    timescale: 'months',
    causalConfidence: 'L4',
    evidence: [],
    keyInsight: 'Successful plaque compaction is neuroprotective',
  },
];

// ============================================================================
// MODULE 20: Hormonal Influences
// ============================================================================

export const module20Edges: MechanisticEdge[] = [
  // -------------------------------------------------------------------------
  // Estrogen Pathway
  // -------------------------------------------------------------------------
  {
    id: 'E20.001',
    source: 'estrogen_level',
    target: 'estrogen_neuroprotection',
    relation: 'directlyIncreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'estrogen_protective_effects',
    mechanismDescription:
      'Estrogen acts via ERα/ERβ receptors to increase BDNF, promote spine formation, reduce APP processing, and enhance mitochondrial function.',
    timescale: 'days',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Hara',
        year: 2015,
        pmid: '25724781',
        title: 'Estrogen effects on cognitive and synaptic health',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.002',
    source: 'hrt_intervention',
    target: 'estrogen_level',
    relation: 'directlyIncreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'HRT_estrogen_replacement',
    mechanismDescription:
      'Hormone replacement therapy restores estrogen levels. Critical window hypothesis: HRT within 5 years of menopause may be neuroprotective; later may be harmful.',
    timescale: 'days',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '36424867',
        firstAuthor: 'Saleh',
        year: 2023,
        title: 'EPAD HRT study',
        quote: 'APOE4 women show larger cognitive benefit from HRT',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
    keyInsight: 'Timing matters: early HRT may protect, late HRT may harm',
  },
  {
    id: 'E20.003',
    source: 'estrogen_neuroprotection',
    target: 'synaptic_plasticity',
    relation: 'increases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M08',
    mechanismLabel: 'estrogen_synapse_support',
    mechanismDescription:
      'Estrogen increases BDNF expression and promotes dendritic spine formation, enhancing synaptic plasticity.',
    timescale: 'days',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Hara',
        year: 2015,
        pmid: '25724781',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.004',
    source: 'estrogen_neuroprotection',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M06',
    mechanismLabel: 'estrogen_APP_processing',
    mechanismDescription:
      'Estrogen reduces amyloidogenic APP processing, decreasing Aβ production.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Hara',
        year: 2015,
        pmid: '25724781',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  // -------------------------------------------------------------------------
  // Testosterone Pathway
  // -------------------------------------------------------------------------
  {
    id: 'E20.005',
    source: 'testosterone_level',
    target: 'testosterone_neuroprotection',
    relation: 'directlyIncreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'testosterone_protective_effects',
    mechanismDescription:
      'Testosterone reduces Aβ production and improves synaptic signaling in animal models. However, clinical trial benefits remain unproven.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Rosario',
        year: 2010,
        pmid: '20160048',
        title: 'Testosterone and cognition in aging men',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.006',
    source: 'testosterone_neuroprotection',
    target: 'abeta_oligomers',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M06',
    mechanismLabel: 'testosterone_Abeta_reduction',
    mechanismDescription:
      'In animal models, testosterone reduces Aβ production. Human evidence is weaker.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Rosario',
        year: 2010,
        pmid: '20160048',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  // -------------------------------------------------------------------------
  // Stress/HPA Axis Pathway
  // -------------------------------------------------------------------------
  {
    id: 'E20.007',
    source: 'chronic_stress',
    target: 'hpa_axis_activation',
    relation: 'directlyIncreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'stress_HPA_activation',
    mechanismDescription:
      'Chronic psychological stress activates the HPA axis: CRH → ACTH → cortisol release from adrenals.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lupien',
        year: 2009,
        pmid: '19341762',
        title: 'Effects of stress throughout the lifespan on the brain',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.008',
    source: 'hpa_axis_activation',
    target: 'cortisol_level',
    relation: 'directlyIncreases',
    moduleId: 'M20',
    edgeType: 'FLOW',
    mechanismLabel: 'HPA_cortisol_release',
    mechanismDescription:
      'HPA axis activation triggers adrenal cortisol release. In AD, hippocampal damage removes inhibitory control, leading to chronic elevation.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lupien',
        year: 2009,
        pmid: '19341762',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.009',
    source: 'cortisol_level',
    target: 'tau_hyperphosphorylated',
    relation: 'increases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M07',
    mechanismLabel: 'cortisol_tau_phosphorylation',
    mechanismDescription:
      'Chronic cortisol elevation enhances tau hyperphosphorylation and promotes tau pathology.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Green',
        year: 2006,
        pmid: '16551324',
        title: 'Glucocorticoids increase amyloid-beta and tau pathology',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.010',
    source: 'cortisol_level',
    target: 'synaptic_plasticity',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M08',
    mechanismLabel: 'cortisol_synapse_damage',
    mechanismDescription:
      'Chronic cortisol causes hippocampal atrophy and synaptic dysfunction, impairing plasticity.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Lupien',
        year: 2009,
        pmid: '19341762',
        methodType: 'review',
        causalConfidence: 'L4',
      },
    ],
  },
  {
    id: 'E20.011',
    source: 'stress_reduction',
    target: 'hpa_axis_activation',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'stress_intervention_HPA',
    mechanismDescription:
      'Mindfulness, meditation, exercise, and social support normalize HPA axis function and reduce cortisol.',
    timescale: 'weeks',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Creswell',
        year: 2014,
        pmid: '24344319',
        title: 'Mindfulness training and cortisol responses to stress',
        methodType: 'rct',
        causalConfidence: 'L1',
      },
    ],
  },
  // -------------------------------------------------------------------------
  // Thyroid Pathway
  // -------------------------------------------------------------------------
  {
    id: 'E20.012',
    source: 'thyroid_function',
    target: 'hypothyroidism',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'TRANSITION',
    mechanismLabel: 'thyroid_dysfunction',
    mechanismDescription:
      'Low thyroid function (low T3/T4, high TSH) indicates hypothyroidism. Both hypo- and hyperthyroidism increase AD risk.',
    timescale: 'months',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Tan',
        year: 2008,
        pmid: '18838538',
        title: 'Thyroid function and Alzheimer disease (Framingham)',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  {
    id: 'E20.013',
    source: 'hypothyroidism',
    target: 'cognitive_score',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → OUTCOME',
    mechanismLabel: 'hypothyroid_cognition',
    mechanismDescription:
      'Hypothyroidism associated with 2-fold increased AD risk (Framingham). May contribute via reduced brain metabolism and impaired synaptic plasticity.',
    timescale: 'months',
    causalConfidence: 'L6',
    evidence: [
      {
        firstAuthor: 'Tan',
        year: 2008,
        pmid: '18838538',
        title: 'Thyroid function and Alzheimer disease (Framingham)',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  // -------------------------------------------------------------------------
  // Insulin Signaling Pathway
  // -------------------------------------------------------------------------
  {
    id: 'E20.014',
    source: 'intranasal_insulin',
    target: 'insulin_signaling',
    relation: 'directlyIncreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    mechanismLabel: 'intranasal_insulin_delivery',
    mechanismDescription:
      'Intranasal insulin bypasses BBB to deliver insulin directly to brain. SNIFF trials showed memory improvement in APOE4-negative patients only.',
    timescale: 'hours',
    causalConfidence: 'L1',
    evidence: [
      {
        pmid: '21984625',
        firstAuthor: 'Craft',
        year: 2012,
        title: 'SNIFF-120 trial',
        quote: 'Intranasal insulin improved memory in APOE4-negative adults with MCI or AD',
        methodType: 'rct',
        causalConfidence: 'L1',
      },
    ],
    keyInsight: 'APOE4 carriers did not benefit - different insulin resistance mechanism',
  },
  {
    id: 'E20.015',
    source: 'insulin_signaling',
    target: 'insulin_resistance',
    relation: 'decreases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M01',
    mechanismLabel: 'insulin_signaling_resistance',
    mechanismDescription:
      'Intact brain insulin signaling counteracts insulin resistance. Impaired signaling (Type 3 diabetes) reduces glucose uptake and Aβ clearance.',
    timescale: 'days',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Steen',
        year: 2005,
        pmid: '15750215',
        title: 'Type 3 diabetes hypothesis',
        methodType: 'cohort',
        causalConfidence: 'L6',
      },
    ],
  },
  // -------------------------------------------------------------------------
  // Melatonin/Circadian Pathway
  // -------------------------------------------------------------------------
  {
    id: 'E20.016',
    source: 'melatonin_level',
    target: 'glymphatic_clearance',
    relation: 'increases',
    moduleId: 'M20',
    edgeType: 'INFLUENCE',
    crossModule: 'M20 → M12',
    mechanismLabel: 'melatonin_sleep_glymphatic',
    mechanismDescription:
      'Melatonin regulates circadian rhythm, which controls sleep-dependent glymphatic clearance. Also has direct antioxidant and anti-inflammatory properties.',
    timescale: 'hours',
    causalConfidence: 'L4',
    evidence: [
      {
        firstAuthor: 'Xie',
        year: 2013,
        pmid: '24136970',
        title: 'Sleep drives metabolite clearance from the adult brain',
        methodType: 'intervention_animal',
        causalConfidence: 'L4',
      },
    ],
  },
];

// ============================================================================
// EXPORT ALL EDGES
// ============================================================================

export const allEdges: MechanisticEdge[] = [
  ...module1Edges,
  ...module2Edges,
  ...module2LipidEdges, // BMP edges + E02.021
  ...feedbackLoopEdges, // Feedback loop completion edges
  ...module3Edges,
  ...module4Edges,
  ...module5Edges,
  ...crossModuleEdges,
  ...module6Edges,
  ...module7Edges,
  ...module8Edges,
  ...module9Edges,
  ...module10Edges,
  ...module11Edges,
  ...module12Edges,
  ...module13Edges,
  ...module14Edges,
  ...module15Edges,
  ...module16Edges,
  ...module17Edges,
  ...module18Edges,
  ...module19Edges,
  ...module20Edges,
  ...therapeuticEvidenceEdges,
];

export default allEdges;
